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Summary 
In this thesis, we aimed to elucidate the functional effects of three rare 
nonsynonymous variants in ERCC4 on cell viability, DNA repair and localisation of 
the ERCC1-XPF repair complex. We also aimed to identify alleles that contribute to 
extreme adverse reactions to colorectal cancer (CRC) treatment. Previous work 
identified three rare nonsynonymous variants (Pro379Ser, Arg576Thr and 
Glu875Gly) in the ERCC4 gene of patients with severe peripheral neuropathy 
associated with oxaliplatin (PNAO). All variants were predicted to affect protein 
function, whilst two collectively contributed to the risk of the phenotype (11.11% of 
patients with PNAO vs. 4.88% of patients without PNAO; P = 0.03). 
We genotyped 480 EBV-transformed lymphoblastoid cell lines from healthy 
humans for ERCC1 and ERCC4 polymorphisms. From this data, we selected 
twelve cell lines for functional analysis (three wild type and three cell lines per 
ERCC4 variant). Following treatment with UV or oxaliplatin, we observed negligible 
differences in survival between wild type and variant cell lines. We identified 
negligible differences in localisation of the ERCC1-XPF repair complex between 
wild type and variant cell lines after oxaliplatin treatment. Using the haploid fission 
yeast, Schizosaccharomyces pombe, similarly we observed minimal differences in 
rad16 localisation between wild type and variant strains.  
We observed similar repair rates following oxaliplatin treatment in wild type 
and variant cell lines. However, following UV treatment, all cell lines carrying 
Pro379Ser exhibited retarded repair (defined as virtually no repair for the duration 
of the experiment) whilst all cell lines carrying Arg576Thr and Glu875Gly displayed 
delayed repair commencing 24 hours after damage. This suggested a functional 
defect of XPF in the repair of UV damage in cells carrying an ERCC4 variant.  
We used whole exome resequencing data from 10 patients with PNAO and 
45 patients without PNAO, to identify causal alleles for the phenotype. We validated 
one variant in PAPLN, suggesting that this gene may cause PNAO. We identified a 
high rate of false-positive indel calls (98.1%), of which 96.1% contained 
homopolymers or short tandem repeats (STRs) in their flanking regions. 
Additionally, we used five filtering strategies to identify causal variants and 
manually excluded indels that were likely false-positives. In addition to PAPLN, this 
identified a further seven genes (ASGR2, ANXA7, OR2T35, SLC17A5, SMOC2, 
SPERT and TAF1D) that may cause PNAO. 
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Chapter One – Introduction  
1.1 Pharmacogenetics of cancer 
Cancer is a leading cause of mortality and morbidity in the developed 
world, with failure to respond to drug therapy posing a life threatening risk. The 
emerging field of pharmacogenetics aims to understand how genetic variation 
between individuals affects drug efficacy and toxicity (Wheeler et al. 2013). For 
any drug used to treat a patient population, there is significant variability in 
response to that drug, resulting in ineffective treatment for a proportion of that 
population. This is disadvantageous for a number of reasons; firstly, there is a 
reduction in the patient’s quality of life resulting from treatment-related toxicity, 
which is only acceptable while the tumour is responding. Secondly, in cases 
where a patient’s tumour fails to respond to therapy, this allows more 
opportunity for the tumour to grow and potentially become harder to treat. In 
some cases, therapy with one drug can cause resistance, resulting in a tumour 
that is resistant to other lines of therapy (Dean et al. 2005). Finally, ineffective 
therapy incurs a financial cost. All of these issues provide a rationale for 
developing strategies to select optimal treatment options for patients on an 
individual basis (Hertz and McLeod, 2013).  
When devising a cancer treatment plan, there are two relevant genomes 
to consider: the tumour’s somatic genome and the patient’s germline genome. 
Tumour prognosis is at least partially dependent on variation in these genomes, 
which affect tumour behaviour irrespective of treatment. The somatic genome 
dictates tumour sensitivity to treatment, which can be useful for efficacy 
prediction, whilst the germline genome primarily dictates drug 
pharmacokinetics, which can indirectly affect efficacy and toxicity. Additionally, 
variants in the germline genome can directly influence patient sensitivity to a 
drug’s side effects (McLeod, 2013). A summary of pharmacogenetic predictive 
factors of cancer treatment outcomes is depicted in Figure 1.1.  
1.1.1 Germline genetics  
 The germline genome is responsible for encoding proteins involved in all 
functioning processes throughout the body; therefore, variation in this genome  
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(A) 
 
(B) 
Outcome 
Prediction 
Genome Genes Treatment 
Decision 
Example 
Prognosis Somatic/ 
Germline 
Oncogenes; tumour 
suppressors; DNA 
repair genes; 
metastasis genes 
Dose BRCA2 gene 
expression in breast 
and ovarian cancers 
Exposure Germline Transporter enzymes Dose UGT1A1 in irinotecan 
and SN-38 exposure 
Efficacy Somatic Drug targets; tumour 
drivers 
Dose BRAF V600E and 
TSC1 in vemurafenib 
and everolimus, 
respectively 
Toxicity Germline Drug targets; cellular 
response genes; 
genes that affect 
toxicity mechanisms 
Dose TUBB2A, FGD4 and 
FANCD2 in 
paclitaxel-induced 
peripheral neuropathy 
 
Figure 1.1 Pharmacogenetic predictors of cancer treatment outcomes. (A) 
Tumour prognosis is at least partially influenced by variation in the germline and 
somatic genomes, which control tumour behaviour independent of treatment. The 
somatic genome dictates tumour sensitivity to therapy and therefore allows prediction 
of efficacy, whilst the germline genome governs drug pharmacokinetics, which may 
indirectly influence efficacy and toxicity. (B) All outcomes are affected by the drug dose 
selected. Different gene groups have variable effects on outcomes; therefore mutations 
in genes encoding drug targets affect drug pharmacodynamics, resulting in changes in 
efficacy and toxicity. Alternatively, variants in oncogenes and tumour suppressor genes 
may adversely affect prognosis.  
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may have implications for any organ system. Inherited variants in genes 
responsible for maintenance of cellular or DNA replication can predispose a 
patient to specific cancer types (Li, 1995). Germline variants present in genes 
encoding enzymes or transporters can adversely affect a patient’s exposure to 
treatment or the severity of side effects they experience (McLeod and Evans, 
2001). A number of germline genetic variants have been identified across 
multiple cancer types through candidate gene and genome wide association 
studies (GWAS) (Table 1.1).  
1.1.1.1 Prognostic predictors 
 It is widely accepted that germline genetic variants can contribute to 
susceptibility for cancer (Theodoratou et al. 2012; Siddiq et al. 2012), although 
less is known about whether these variants have consequences for prognosis. 
The Cancer Genome Atlas (TCGA) is a coordinated project designed to compile 
information about somatic mutations, copy number, variant expression and 
epigenetic modification in specific tumour types. TCGA has also collected 
germline DNA and outcome data in an attempt to characterise the effects of 
germline variants on cancer prognosis (Collins and Barker, 2007).  
Initial results have been published using patient cohorts with 
glioblastoma, ovarian, breast, lung and colorectal cancers. These have shown a 
slightly higher survival rate in patients with colorectal tumours displaying high 
microsatellite instability (MSI), suggesting that mutation status of mismatch 
repair (MMR) genes could be useful in predicting prognosis (Cancer Genome 
Atlas Network, 2012). Interestingly, it was reported that patients with ovarian 
cancer that were carrying germline founder variants in either the BRCA1 or 
BRCA2 genes demonstrated superior survival than patients without variants in 
either gene (E23fs deletion and Q1756 insertion in BRCA1; S1982 deletion in 
BRCA2) (Cancer Genome Atlas Research Network, 2011). Further analysis of 
this data confirmed that patients carrying a S1982 deletion in the RAD51 
binding domain of BRCA2 had longer overall and progression-free survival 
(PFS) compared with other patients (Yang et al. 2011). Bolton et al. (2012) 
performed a large pooled analysis, which reported that patients with this BRCA2  
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Drug Mechanism of action Cancer 
type(s) 
Germline 
markers 
Variants (Nucleotide 
changes) 
Phenotype References 
Irinotecan Inhibition of 
topoisomerase I 
(involved in DNA 
replication and 
transcription) 
Colorectal, 
lung  
UGT1A1 rs8175347  
(UGT1A1*28 and 
3156G>A) 
Neutropenia, 
diarrhoea  
Innocenti et al. 
2004; Iyer et al. 
2002; Hoskins et 
al. 2007 
Tamoxifen Inhibition of the 
oestrogen receptor 
Hormone-
receptor-
positive breast 
CYP2D6 rs16947 (2850C>T) 
rs1065852 (100C>T) 
rs28371706 (1023C>T) 
rs28371725 (2988G>A) 
rs35742686 (2549delA) 
rs3892097 (1846G>A) 
rs5030655 (1707delT) 
rs5030656 (CYP2D6*9) 
rs59421388 (3183G>A) 
Tamoxifen 
metabolism, 
progression-free 
and overall 
survival 
Schroth et al. 
2007; Kiyotani et 
al. 2010; Schroth 
et al. 2009; Regan 
et al. 2012; Goetz 
et al. 2011; Nowell 
et al. 2005; 
Okishiro et al. 2009 
 
 
Mercaptopurine Inhibition of purine 
nucleotide synthesis 
(required for DNA 
replication) 
Paediatric 
acute 
lymphoblastic 
leukaemia 
TPMT rs1142345 (TPMT*2) 
rs1800460 (TPMT*3A) 
rs1800462 (TPMT*3C) 
Myelosuppresion Relling et al. 1999; 
Relling et al. 2011 
 
Methotrexate Inhibition of folic acid 
metabolism (required 
for DNA replication) 
Paediatric 
acute 
lymphoblastic 
leukaemia 
SLCO1B1 rs11045879 (3886C>T) Methotrexate 
clearance, GI 
toxicity 
Trevino et al. 2009; 
Lopez-Lopez et al. 
2011; Ramsey et 
al. 2012 
 
Table 1.1 A selection of germline genetic variants associated with cancer drug-induced phenotypes.
  
5 
variant showed superior 5-year survival (52%) compared with BRCA1 carriers 
(44%) and non-carriers (36%). 
Several studies have identified several germline genes that may affect 
metastatic potential in multiple breast cancer subtypes; SIPA1, BRD4 and 
RRP1B have all been implicated in breast cancer metastasis (Park et al. 2005; 
Crawford et al. 2006; Pei et al. 2013; Crawford et al. 2008; Hsieh et al. 2009) 
and are associated with regulation of the Rap GTPase-activating protein SPA-1. 
It has been hypothesised that these germline genetic variants could influence 
tumour growth and metastasis by affecting the tumour microenvironment 
(Shimizu et al. 2011), although the mechanism for this is currently unknown.  
1.1.1.2 Exposure predictors  
 Current clinical practice in chemotherapy treatment involves 
administration of a drug dose intended to maximise drug exposure with limited 
risk of toxicity to the patient, typically based on patient weight and body surface 
area (Felici et al. 2002). Most drugs demonstrate substantial interpatient 
pharmacokinetic variability, some of which is explained by patient size (McLeay 
et al. 2012); however the remaining variability is a consequence of variation in 
genes associated with absorption, distribution, metabolism, or excretion 
(ADME) of the drug and its intermediates.  
 All drugs require a series of metabolising enzymes and drug transporters 
to perform the ADME processes, which are encoded by germline genes. 
Variation in exons of these genes may affect protein function, whereas intronic 
germline variants are more likely to influence protein expression. Several 
pharmacogenetic studies have identified germline variants that affect patient 
exposure to anti-cancer drugs. Phase I enzymes including cytochrome P450 
(CYP) can directly activate or inactivate the administered drug (Bosch et al. 
2006). Genetic polymorphisms have been reported in CYP2C8, CYP2C9, 
CYP2C19, CYP2D6 and CYP3A4 isoforms, which are associated with 
metabolism of taxane drugs including tamoxifen for treatment of oestrogen 
receptor-positive breast cancer. Tamoxifen is metabolised by the CYP system 
to form the active metabolites N-desmethyltamoxifen, formed by CYP3A4, and 
4-hydroxytamoxifen and endoxifen, both formed by CYP2D6 (Scripture and 
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Figg, 2006). Stearns et al. (2002) assessed plasma endoxifen levels in patients 
with breast cancer that were prescribed tamoxifen as adjuvant therapy in 
addition to paroxetine, a selective serotonin reuptake inhibitor (SSRI) 
metabolised by CYP2D6 and prescribed for management of hot flushes. They 
reported lower plasma endoxifen concentrations in women treated with both 
drugs, and interestingly the endoxifen concentrations decreased more rapidly in 
patients that were wild-type for CYP2D6, compared with homozygous non-
functional genotype carriers (reduction of 64% and 24% respectively). This was 
confirmed by Jin et al. (2005), suggesting that tamoxifen metabolite 
concentrations are directly affected by SSRIs and polymorphisms in CYP2D6. 
Phase II enzymes including uridine diphosphate glucouronosyl-
transferases (UGTs) activate the active form of the drug or its metabolites via 
conjugation (Bosch et al. 2006). Variants in genes encoding various isoforms of 
UGTs have been implicated in varying drug exposures to irinotecan, a 
compound used for treatment of metastatic colorectal cancer (CRC). Irinotecan 
is metabolised to form SN-38, an active compound responsible for both efficacy 
and toxicity associated with the drug. SN-38 is inactivated via glucuronidation 
via the isoform UGT1A1 and excreted through biliary elimination. Transcription 
of UGT1A1 is variable in patients due to germline variation in the gene’s 
promoter region; typically six thymine-adenine (TA) repeats form in the TATA 
box, whilst in a proportion of patients a seventh TA forms, known as 
UGT1A1*28. This isoform has been shown to diminish glucuronidation (Iyer et 
al. 1999), resulting in increased SN-38 levels and slower clearance of the drug 
in patients carrying a homozygous *28 allele (Ando et al. 1998). Homozygous 
and heterozygous variants in genes encoding UGTs have been associated with 
greater toxicity levels resulting from prolonged exposure to SN-38 in patients 
with CRC in some clinical studies (Paoluzzi et al. 2004; Saito et al. 2009), 
although others have suggested the association is less clinically important 
(Toffoli et al. 2006). Irinotecan is discussed in more detail in section 1.3.2.  
The association between variants in pharmacokinetic genes and clinical 
outcome is an indirect one caused by a direct influence of the variant on drug 
exposure. Clinical interpretation of such pharmacokinetic studies would result in 
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reduction of dose, altered administration or discontinuation of the drug (Bosch 
et al. 2006). 
1.1.1.3 Toxicity predictors 
 Clinical factors such as drug interactions or impaired liver function can 
affect a patient’s likelihood of developing side effects by influencing drug 
exposure, similar to mechanisms outlined in section 1.1.1.2. A potent example 
is the increased toxicity seen in patients carrying polymorphisms in genes 
encoding proteins involved in transport and excretion undergoing taxane 
treatment for various cancers; reduced clearance of the drug arising from 
truncated excretion proteins results in drug retention and severe toxicity (Jabir 
et al. 2012). Alternatively, individuals receiving equivalent drug exposure can 
develop toxicities of variable severity due to several biological mechanisms; 
these include high endogenous expression of the drug’s target protein, 
compromised response to a drug’s cytotoxic mechanism or an underlying 
pathology (Hertz and McLeod, 2013).  
Cells exhibiting high expression of a drug target may be highly sensitive 
to the drug in question; β-tubulin, the drug target of paclitaxel, exists as several 
isoforms that are differentially expressed throughout the peripheral nervous 
system. A common side effect of paclitaxel treatment is peripheral neuropathy. 
An analysis of germline variants in the TUBB2A promoter, which encodes the β-
tubulin class IIa isoform located primarily in neurons, identified a single 
nucleotide polymorphism (SNP) in the promoter which was associated with 
increased gene transcription and reduced peripheral neuropathy (Leandro-
Garcia et al. 2012).  
Additionally, cells may carry germline polymorphisms that render them 
unable to respond to a stimulus, such as compromised DNA repair in response 
to a DNA damaging chemotherapeutic. Sucheston et al. (2011) reported a 
significant association between SNPs and haplotypes present in the DNA repair 
gene FANCD2 with neuropathy risk with paclitaxel treatment. 
Finally, where a patient has an underlying condition which presents with 
similar symptoms to the drug’s toxicity, this condition may be aggravated during 
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treatment. Charcot-Marie-Tooth syndrome, a familial hereditary peripheral 
neuropathy (PN) disorder, has many subtypes caused by different germline 
variants; Charcot-Marie-Tooth disease type 4H is caused by a variant in FGD4, 
encoding FGD1-related F-actin-binding protein (Delague et al. 2007). Patients 
carrying germline variants in FGD4, or other genes encoding proteins that 
interact with FGD4, are therefore at increased risk of suffering extreme 
sensitivity to drug-induced PN associated with paclitaxel. Baldwin et al. (2012) 
confirmed an association between a novel FGD4 polymorphism and increased 
incidence of sensory PN in patients with breast cancer during paclitaxel 
treatment. It is likely that variants in other genes associated with familial PN 
syndromes will give rise to enhanced sensitivity to chemotherapy-induced PN 
(Hertz and McLeod, 2013).  
1.1.2 Somatic genetics  
 During tumourigenesis, healthy cells develop genetic aberrations that 
result in an inability to regulate their replication. These malignant cells carry a 
somatic genome, which acquires additional genetic abnormalities through 
repeated cellular replication (Gerlinger et al. 2013). Some of these additional 
acquired variants may enhance the tumour’s pathogenic qualities, particularly 
variants found in genes that regulate DNA replication or control metastatic 
potential (Ganem and Pellman, 2012). Both initial and acquired variants affect 
primary tumour behaviour, including its sensitivity to certain drugs and its 
potential for metastasis. Therefore, an understanding of the tumour’s underlying 
somatic genetics may help to predict the tumour prognosis and response to 
therapy. A number of somatic variants have been identified that can influence 
prognosis and efficacy in multiple tumour types (Table 1.2).  
According to Knudson’s two-hit hypothesis of tumour suppressor genes, 
an initial inherited mutation increases the probability of disease due to an 
increased chance of loss of the second allele within somatic cells. Alternatively, 
sporadic disease of the same type requires a somatic mutation to occur on both 
alleles (Knudson, 1996; Figure 1.2). 
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Figure 1.2 Knudson’s ‘two-hit’ hypothesis of tumourigenesis in inherited (A) and 
sporadic (B) forms of cancer. (A) In inherited disease, a variant of one allele is 
inherited in every germline cell, whereas the second allele variant is acquired in a 
single cell. (B) In sporadic disease, two normal alleles are inherited in every cell. One 
allele becomes inactivated by sporadic mutation, followed by a second sporadic 
mutation in the second allele. Inactivation of tumour suppressor genes in this way can 
contribute to cellular growth advantages and tumourigenesis (Knudson, 1985). 
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Drug Drug target Cancer 
type(s) 
Somatic 
markers 
Variants (Amino acid 
changes) 
Phenotype 
Cetuximab EGFR Colorectal, 
head and 
neck 
EGFR and 
KRAS 
KRAS variants (Gly12Asp, 
Gly12Ala, Gly12Val, 
Gly13Asp) 
EGFR (EGFRvIII) 
KRAS mutations associated with resistance to 
cetuximab (Linardou et al. 2008); mutant EGFR 
contributes to increased tumour growth and drug 
resistance (Sok et al. 2006) 
Panitumumab EGFR Colorectal EGFR and 
KRAS 
KRAS variants (Gly12Asp, 
Gly12Ala, Gly12Val, Gly12Ser, 
Gly12Arg, Gly12Cys, 
Gly13Asp) 
Associated with panitumumab resistance and 
reduced overall survival (Amado et al. 2008) 
Lapatinib ERBB2/ 
HER2 
receptor 
Breast ERBB2/HER2 HER2 (L755S, P780insertion) Associated with lapatinib resistance in HER2-
negative breast cancer patients (Bose et al. 
2013) 
Trastuzumab 
(Herceptin®) 
ERBB2/ 
HER2 
receptor 
Breast, lung ERBB2/HER2 HER2; in-frame insertions in 
exon 20 (G776V) 
HER2 variants associated with increased risk of 
lung and breast cancer development in non 
smokers (Shigematsu et al. 2005) 
Gefitinib and 
Erlotinib 
EGFR Lung EGFR EGFR; exon 21 (L858R); 
present in the activation loop 
of the tyrosine kinase domain  
Increased response to gefitinib and erlotinib, 
followed by acquired resistance in the presence 
of this variant (Pao et al. 2005) 
Imatinib BCR-ABL, 
KIT and 
PDGFRα 
tyrosine 
kinases 
Chronic 
myeloid 
leukaemia, 
GI cancers 
Philadelphia 
chromosome, 
KIT and 
PDGFRA 
ABL (Thr315Ile) 
KIT (V654A, T670I, T670E, 
S709F) 
PDGFRA (Val561Asp) 
BCR-ABL variants associated with imatinib 
resistance and accelerated progression of 
disease (Roche-Lestienne et al. 2002); Activating 
mutations in KIT and PDGFRA increase 
progression of stromal GI tumours and cause 
secondary resistance (Hirota et al. 2003)  
 
Table 1.2 A selection of somatic mutations in cancer pharmacogenetics.
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1.1.2.1 Prognostic predictors 
 Although germline mutations may affect prognosis in certain cancer 
types (see section 1.1.1.1), the majority of genetic determination of tumour 
prognosis is dependent on the tumour genome. Prognosis depends on local 
tumour growth and distant tumour spread, which can be measured using the 
tumour, node and metastasis (TNM) grading system (Figure 1.3). Prognostic 
grading systems exist for numerous tumour types and are essential for selecting 
a therapy regimen in the clinic. However, somatic genetics have a large impact 
on the aggressiveness of a tumour irrespective of treatment choice, and 
therefore the addition of genetic prognostic determinants to these staging 
systems would be hugely beneficial to clinicians with regard to making 
appropriate treatment decisions for patients on an individual basis (Greene and 
Sobin, 2008).  
Somatic genetic screening for cancer is most commonly used in the 
treatment of breast cancer. Breast tumours are classified according to 
expression of several receptors with chemotherapeutics targeted at each 
receptor specifically; oestrogen (ER), progesterone (PR) and human epidermal 
growth factor receptor-2 (HER2)-positive tumours are typically treated with 
tamoxifen- and trastuzumab-based regimens, for ER/PR and HER2-positive 
tumours respectively (Arpino et al. 2005; Romond et al. 2005; Gianni et al. 
2010). Sorlie et al (2001) developed an alternative system that classifies 
tumours according to their ‘intrinsic subtype’ based on gene expression, which 
is largely concordant with receptor-based classification. The intrinsic subtypes 
have been shown to correlate with disease recurrence (Nielsen et al. 2010), but 
receptor-based classification remains the current clinical approach to treatment 
(Goldhirsch et al. 2009). 
Olivier et al. (2006) demonstrated an association between somatic TP53 
mutations in patients with primary breast cancer and higher incidence of breast 
cancer-related death, compared with patients without TP53 variants, 
irrespective of tumour size, node status or hormone receptor expression. They 
also reported that patients carrying the R248W variant in TP53 in the absence 
of the progesterone receptor demonstrated the poorest prognosis.  
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(A) 
 
(B) 
 TNM Staging  
Stage Tumour 
size (T) 
Lymph nodes 
(N) 
Metastasis 
(M) 
Description 
0 Tis N0 M0 (Tis) Cancer in situ – tumour confined 
to mucosa  
(N0) No nodes affected 
(M0) No metastasis 
I T1 
T2 
N0 
N0 
M0 
M0 
(T1) Tumour invades submucosa 
(T2) Tumour invades muscle layer 
II T3 
T4 
N0 
N0 
M0 
M0 
(T3) Tumour invades subserosa or 
beyond 
(T4) Tumour invades adjacent organs 
III T1-2 
T3-4 
Any 
N1 
N1 
N2 
M0 
M0 
M0 
(N1) Metastasis to 1-3 lymph nodes 
(T1-2) Tumour spread to either 
submucosa or muscle layer 
(T3-4) Tumour spread to either 
subserosa or adjacent organs 
(N2) Metastasis to 4 or more lymph 
nodes 
IV Any Any M1 (M1) Distant metastasis 
Figure 1.3 TNM Staging of cancer. (A) Schematic of a colonic tumour at each TNM 
stage. (B) Number stages and corresponding TNM staging of CRC with description of 
tumour growth at each stage (adapted from Greene and Sobin, 2008). Tis = Tumour in 
situ.  
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1.1.2.2 Efficacy predictors  
Tumours are particularly sensitive to drugs that specifically target the 
driver of tumour progression. As a result of advances in genetic screening 
technologies, researchers can now perform somatic gene profiling of tumours, 
which allows researchers and clinicians the opportunity to target deficiencies in 
the tumour’s growth or metastatic potential (Albertson et al. 2003). In order to 
develop this translational work, drugs need to be developed to target specific 
biomarkers that can be screened for in a tumour prior to commencing treatment. 
Personalised treatment using this approach is being piloted currently 
(Tsimberidou et al. 2012; Roychowdhury et al. 2011); however, prospective 
validation of this approach is challenging (Mandrekar and Sargent, 2009). This 
approach has the potential to transform cancer treatment, by identifying patients 
with a tumour carrying a biomarker that increases efficacy whilst sparing non-
responders from unnecessary treatment. 
There are two strategies required for increasing access to personalised 
cancer treatment; firstly, identification of genetic biomarkers related to tumour 
sensitivity to drugs currently in use, and secondly, the design of new drugs to 
target oncogenic mutations found in tumour types. Everolimus, an inhibitor of 
the mammalian target of rapamycin (mTOR), was approved for treatment of 
advanced kidney cancer in 2009, followed by approval for other tumour types in 
more recent years. The drug was originally approved for the treatment of 
tuberous sclerosis (TS), a disease characterised by formation of benign 
tumours throughout the body which is caused by a mutation in TSC1 (Meikle et 
al. 2008; Franz, 2011). Following complete response to everolimus lasting >2 
years in a single patient with metastatic bladder cancer, the tumour was 
genotyped and a deletion in TSC1 was detected. Based on this finding, Iyer et 
al (2012) genotyped a further 96 bladder tumours and identified six patients out 
of thirteen with deletions in TSC1 that demonstrated impressive time to 
response (4.1 vs. 1.8 months) and longer duration of treatment (7.7 vs. 2.0 
months). This is one case of an existing drug that has been shown to potentially 
target a biomarker present in bladder tumours, which now requires prospective 
validation and incorporation into clinical practice (Hertz and McLeod, 2013). 
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 1.1.2.3 Overlap between somatic and germline genetics 
 Variation in germline DNA may influence which somatic mutations a 
tumour is most likely to acquire; a study in squamous cell carcinomas (SCC) of 
the skin revealed that chromosomal aberrations in these tumours were more 
similar within than between individuals, consistent with the hypothesis that 
background variation influences the pattern of somatic mutations within an 
individual (Dworkin et al. 2010). As a result, recent studies have used somatic 
mutations as endophenotypes to investigate germline genetic variants that may 
confer risk for acquiring specific somatic mutations (Jonsson et al. 2005; 
Kiemeney et al. 2010; Kilpivaara et al. 2009). Such studies have associated 
germline variants in MC1R and EGFR (in particular exon 19 microdeletions) 
with increased likelihood of somatic variants that increase risk of BRAF-mutant 
melanoma and non-small cell lung carcinoma (NSCLC) development, 
respectively (Landi et al. 2006; Liu et al. 2011).  
1.2 Colorectal Cancer  
  CRC is the fourth most common cancer in the UK, accounting for 
approximately 13% of all new diagnoses. Over 40,000 new cases are 
diagnosed each year, with an overall lifetime risk of developing the disease 
estimated at 5%. Advances in treatment and early screening programmes for 
CRC have reduced mortality rates by approximately 50% in the last four 
decades; however, despite this improvement, there are currently 16,000 deaths 
due to CRC each year in the UK (Cancer Research UK, Bowel cancer statistics, 
2010). 
Age is an important risk factor governing CRC development; 85% of new 
cases are diagnosed in patients over the age of sixty (Cancer Research UK, 
Bowel cancer statistics, 2010). Other non-modifiable risks include a personal 
history of adenomatous polyps or inflammatory bowel disease, or a family 
history of CRC or adenomatous polyps, which are considered a precursor lesion 
of CRC (Haggar and Boushey, 2009). Deaths due to CRC development in 
patients with ulcerative colitis and Crohn’s disease account for one third of 
CRC-related deaths annually (Itzkowitz and Yio, 2004). 
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Environmental factors associated with CRC onset include poor diet, 
obesity, increased alcohol consumption and cigarette smoking; these lifestyle 
habits are often associated with Westernised cultures, which may account for 
the disproportionately high incidence of CRC in Westernised continents (Europe 
and North America) compared with Africa and Asia (>10-fold increase in CRC 
incidence in Westernised continents) (Ferrari et al. 2007; Jemal et al. 2010).  
1.2.1 Heritable colorectal cancer 
There is a strong heritable component associated with CRC, which is 
indicated by the identification of a number of hereditary syndromes in recent 
decades. Advances in genetics have allowed elucidation of the underlying 
molecular mechanism of CRC and provided better treatment options and 
screening programmes for both patients and their relatives (Lynch et al. 2007).  
Hereditary CRC is defined as a tumour caused by germline mutations 
that give rise to a CRC ‘syndrome’. With regard to CRC specifically, these 
‘syndromes’ are a collection of signs and symptoms that characterise tumour 
progression in the presence of high penetrance germline mutations in the 
mismatch repair (MMR) pathway or the APC gene (Lynch and De la Chapelle, 
2003). Alternatively, so-called ‘sporadic’ cases of CRC arise due to low 
penetrance germline variants and somatic mutations that are acquired over 
time, without the presence of a germline mutation or signs of a hereditary CRC 
syndrome (Valle, 2014).  
Approximately 75% of all CRC cases are sporadic in nature, while the 
remaining 25% are comprised of several heritable CRC syndromes (Amersi et 
al. 2005). Epidemiological studies have estimated that, of these inherited CRC 
cases, at least 15% occur in dominantly inherited patterns, of which the two 
most well defined types are familial adenomatous polyposis (FAP) and 
hereditary nonpolyposis colorectal cancer (HNPCC) (Kinzler and Vogelstein, 
1996).  
Of the 25% of all CRC cases that are inherited, the underlying genetic 
cause of tumour progression has been identified in approximately 12% cases, 
whilst the remaining 13% are considered ‘familial’ due to a strong family history 
(Amersi et al. 2005). The latter are cases where the tumour’s morphology and 
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patient’s symptoms are similar to those of hereditary CRC syndromes, but 
where no germline causal mutation has been identified. In these cases, there is 
typically evidence of a family history of CRC in previous generations; therefore it 
becomes difficult to ascertain whether familial occurrence is the result of 
predisposition or chance. Similarly, seemingly ‘sporadic’ cases may have a 
familial component that is not immediately apparent, either due to chance, an 
increased risk of CRC that is inherited, a small family or incomplete diagnostics, 
therefore making the distinction between sporadic and familial CRC cases 
blurred (De la Chappelle, 2004; Figure 1.4).  
1.2.1.1 High penetrance alleles 
An allele is attributed high penetrance if its presence dramatically 
increases the likelihood of a specific phenotype. These characteristics are 
usually highly heritable and therefore relatively easy to track and identify. 
Approximately 6% of all CRC cases are attributable to high penetrance 
mutations (Jasperson et al. 2010; Patel and Ahnen, 2012). A substantial 
proportion of high penetrance, heritable CRC syndromes are directly caused by 
inactivating mutations in tumour suppressor genes. Most loss of function 
mutations are recessive, therefore requiring loss of both alleles in order to allow 
a cell to become cancerous.  
1.2.1.2 HNPCC  
Hereditary non-polyposis colorectal cancer (HNPCC; OMIM #120435), or Lynch 
syndrome, is an autosomal dominant disease characterised by formation of 
CRC and an increased risk of several extra-colonic malignancies, including 
ovary, endometrium, stomach, hepatobiliary tract, urinary tract, brain and skin 
cancers (Aarnio et al. 2006). It is the most common hereditary CRC syndrome, 
accounting for 2-6% of all CRC cases (Lynch et al. 2006). CRC is the most 
common malignancy associated with HNPCC, with an 80% lifetime risk and an 
average age of onset of 45 years. The syndrome arises as a result of inherited 
defects in key genes in the mismatch repair (MMR) pathway, which have been 
implicated in HNPCC disease etiology; MLH1 and MSH2 germline mutations, 
MSH6 mutations and PMS2 mutations are reported to account for 90%, 7-10%
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Figure 1.4 Schematic of the continuum of familial and sporadic hereditary CRC (adapted from De La Chapelle, 2004). Highly penetrant 
causative mutations in FAP, HNPCC and hamartomatous polyposis syndromes account for a small proportion of hereditary CRC cases, with little 
environmental influence. However, several other low penetrance alleles contribute to hereditary CRC incidence in a cumulative way, due to 
environmental influences and interactions between genes. These alleles are also believed to contribute to sporadic CRC cases. Additionally, modifier 
genes are believed to affect the genetic and environmental factors that contribute to CRC; therefore, the distinction between familial and sporadic 
CRC cases and between genetic and environmental predisposition factors has become increasingly blurred. 
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and 5% of mutations in families with HNPCC, respectively (Miyaki et al. 1997; 
Berends et al. 2002; Peltomaki, 2003; Senter et al. 2008). Deficiencies in the 
MMR pathway result in an increased mutation rate and secondary somatic 
mutations that ultimately give rise to the cancer phenotype in HNPCC (Burt and 
Neklason, 2005; Kinzler and Vogelstein, 1996). 
1.2.1.3 MAP  
Mut-YH associated polyposis (MAP; OMIM #604933) is an autosomal 
recessive disease characterised by formation of tens to a few hundred colonic 
adenomatous polyps, which contributes to a significantly increased lifetime risk 
of CRC (Jasperson et al. 2010). MAP was identified by somatic analysis of APC 
in patients presenting with multiple CRAs without a germline APC mutation. 
This revealed a disproportionately high expression of G:C→T:A transversions, 
resulting in excessive truncation mutations in tumours resulting from acquisition 
of somatic variants (Jones et al. 2002). These transversion mutations are 
formed during oxidative damage to guanine bases, resulting in formation of 8-
oxo-7, 8dihydro-2’-deoxyguanosine (8-oxoG), a highly mutagenic lesion that 
results in G:C→T:A transversion during subsequent replication cycles 
(Shibutani et al. 1991). The 8-oxoG lesions are removed during base excision 
repair (BER), during which the DNA glycosylases OGG1 and MUTYH remove 
8-oxoG and the mispaired adenine, respectively (Shinmura et al. 2012). An 
additional common transversion of this type in the KRAS gene (c.34G>T in 
codon 12) is present in 64% of patients with MAP CRC, which has led to 
recommendations for somatic KRAS screening of CRC tumours to identify 
patients eligible for MUTYH germline molecular genetic testing (Lipton et al. 
2003; Nielsen et al. 2009). 
1.2.2 Low penetrance alleles 
The majority of inherited CRC cases occur without any identifiable 
genetic causes, prompting the hypothesis that the remaining heritable CRC 
component could be attributed to common or rare, low penetrance alleles 
(Fearnhead et al. 2005). An allele is considered low penetrance if its effect on 
phenotype is small, although it may contribute significantly to disease incidence 
due to its relative frequency within the population (Valle, 2014).  
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1.2.2.1 ‘Common disease, common variant’ hypothesis 
According to the ‘common disease, common variant’ hypothesis, an 
individual variant risk of contributing to disease onset is relatively small (Bodmer 
and Bonilla, 2008). However, the relatively common incidence of such alleles in 
the population, and their ability to interact with one another polygenically, 
significantly increase the likelihood that they will affect disease incidence. This 
hypothesis helps to explain the variation witnessed in complex diseases such 
as CRC. In recent years, a number of susceptibility variants for CRC have been 
identified using GWAS.   
1.2.2.2 GWAS of CRC variants 
  Several factors have allowed use of GWAS; firstly, the completion of the 
HapMap project has enabled knowledge of linkage disequilibrium (LD) that 
captures variation across the genome to be readily accessed (International 
HapMap Consortium, 2003). Secondly, the collection of large case and control 
cohorts have allowed sample numbers large enough to overcome statistical 
power issues often faced during statistical analyses of large populations. 
Finally, technological advances in platforms for high throughput genotyping 
have allowed screening of large numbers of variants across thousands of 
samples at a reasonable cost with rapid turnaround. 
  Several GWAS studies in Caucasian populations of European ancestry 
have been performed and identified >20 low penetrance susceptibility alleles for 
CRC risk. Although individually all variants show a modest contribution to 
overall risk, it is estimated that they could collectively account for approximately 
7% of CRC familial risk (Dunlop et al. 2012). 
Despite the impact of GWAS in advancing current knowledge of CRC 
risk, there are limitations in their ability to detect novel variants. These include 
difficulty in acquiring a large enough sample number to supply enough power 
for detection of modest effect sizes, as well as a high rate of false positive 
readings. This requires validation of variants, which can be costly and labour 
intensive. Additionally, the importance of ruling out other ethnic populations to 
avoid population stratification can further restrict the sample sizes for research.  
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1.2.2.3 ‘Common disease, rare variant’ hypothesis 
 Detection of rare variants usually involves candidate searches of genes 
associated with disease aetiology, and rare variants have been shown to 
contribute to the phenotype of complex diseases (Pritchard, 2001). The 
‘common disease, rare variant’ hypothesis proposes that inherited susceptibility 
may be an additive effect of low frequency dominantly and independently acting 
variants in various genes. In CRC, it is thought that 20-30% of cases are a 
result of multifactorial inherited susceptibility arising from rare, low penetrance 
alleles without a clear cut familial inheritance pattern (Bodmer and Bonilla, 
2008).  
 Research by Fearnhead et al. (2004) has collectively associated rare 
variants in the Wnt signalling genes AXIN1 and CTNNB1, in addition to MMR 
genes MLH1 and MSH2, with a slightly increased risk of colorectal adenoma 
(CRA) onset. Additionally, non-synonymous variants Ile1307Lys and 
Glu1317Gly in APC have been shown to predispose to CRCs and CRAs in a 
number of studies (Frayling et al. 1998; Lamlum et al. 2000; Azzopardi et al. 
2008). Additional rare variants in APC have also been reported, suggesting a 
potential low penetrance effect of these rare alleles (Azzopardi et al. 2008).  
1.3 Treatments for CRC  
Treatment for CRC may involve surgery, radiotherapy, chemotherapy or 
targeted therapies depending on the stage of disease at diagnosis (Carethers, 
2008). The most significant prognostic factor for CRC progression is tumour 
staging, and treatment options rely heavily on this (Section 1.1.2.1; Figure 1.2). 
The five year relative survival rates drop to approximately 11% and 12% for 
patients with stage IV colon and rectal cancers respectively, compared with 
92% and 87% respectively, when diagnosed with stage I cancer (National 
Cancer Institute SEER database, 2014). Approximately 80% of patients 
diagnosed with stage I-III CRC undergo surgical resection of the tumour, 
resulting in curative treatment. Additionally, adjuvant treatment with 
radiotherapy or chemotherapy is common (Winawer et al. 2003). However, as 
25% of patients present with metastatic CRC and approximately 50% progress 
to metastases, further treatments are necessary and treatment at this stage is 
  
21 
often challenging (Xu et al. 2011). Only 20% of patients with hepatic metastases 
are candidates for curative surgery, meaning that currently chemotherapy 
remains the treatment of choice for advanced CRC (aCRC) (Stangl et al. 1994).  
A number of drugs used for the treatment of aCRC have been identified 
and reported to improve survival and response via clinical trials (Table 1.3).  
1.3.1 Fluoropyrimidines 
The fluoropyrimidine class of drugs is widely used for aCRC treatment. 
Fluorouracil (5-FU, Efudex) has been administered for CRC treatment for more 
than fifty years. It is an analogue of uracil and therefore uses the same cellular 
transport systems to enter the cell following parenteral administration. 5-FU can 
be considered a ‘fraudulent’ nucleotide; upon cell entry, the drug is converted to 
several active metabolites including fluorodeoxyuridine monophosphate 
(fdUMP), fluorodeoxyuridine triphosphate (fdUTP) and fluorouridine 
triphosphate (FUTP). These metabolites firstly insert themselves into newly 
synthesised DNA strands, and secondly inhibit thymidylate synthetase (TS) 
activity in the production of deoxythymine monophosphate, resulting in inhibition 
of DNA synthesis (Longley et al. 2003). 5-FU is most commonly administered in 
addition to the folate supplement leucovorin (5’-formyltetrahydrofolate, folonic 
acid). Leucovorin is metabolised to the methyl donor 5,10-
methylenetetrahydrofolate (MTHF), which interacts with fdUMP. Leucovorin has 
been shown to increase cellular levels of the donor and to stabilise the TS-
fdUMP complex, which is essential for 5-FU metabolism (Radparvar et al. 
1989). Studies have revealed that administration of 5-FU alongside leucovorin 
results in clinical synergism and doubles the overall response rate in aCRC 
(Advanced Colorectal Cancer Meta-Analysis Project, 1992). 
Capecitabine (CPB, Xeloda) is an oral fluoropyrimidine drug that is 
absorbed via the gut wall (Lamont and Schilsky, 1999). Capecitabine is 
converted to 5’-deoxy-5-fluorouridine (DFUR) in the liver by the enzymes 
carboxylesterase and cytidine deaminase. DFUR is then transported to tumour 
cells and converted to 5-FU by thymidylate phosphorylase (TP). TP is 
expressed preferentially in tumour cells compared with normal tissue, which 
allows metabolism of 5-FU at a higher rate in tumour cells (Kosuri et al. 2010).  
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Regimen (Clinical Trial) Effects seen/Outcome of trial 
5-FU, leucovorin and oxaliplatin 
(FOLFOX); (National Cancer 
Institute trial; led by the North 
Central Cancer Treatment 
Group) 
Significantly improved response rate and 
median survival in patients with previously 
untreated aCRC (Goldberg et al. 2004) 
CPB and oxaliplatin (XELOX); 
(Large phase II, open label 
study; involved 13 centres in 
Europe, North America and 
Israel) 
Similar response rate and overall survival to 
FOLFOX regimen; additional advantage of 
reducing prolonged infusion times with 5-FU due 
to substitution of oral CPB (Cassidy et al. 2004) 
FOLFOX plus irinotecan 
(FOLFIRI); (Prospective phase 
II study at the Institute of 
Oncology Ljubljana, Slovenia) 
Significantly improved response to treatment 
(Patt et al. 2007) 
XELOX plus irinotecan 
(XELIRI); (Prospective phase II 
study at the Institute of 
Oncology Ljubljana, Slovenia) 
Increased efficacy, improved safety and 
improved convenience for patients with aCRC 
(Patt et al. 2007); more acceptable toxicity levels 
than FOLFIRI, although patients displayed 
similar overall survival and PFS compared with 
those treated with FOLFIRI (Skof et al. 2009) 
Irinotecan; (A series of phase II 
studies in Japan, North America 
and Europe) 
Efficacy in mCRC when used alone as first line 
treatment (Cunningham et al. 2001) and as 
second line treatment after 5-FU failure 
(Guglielmi and Sobrero, 2007) 
Irinotecan in combination with 
5-FU and leucovorin; (A series 
of phase II studies in Japan, 
North America and Europe) 
Improved overall survival, PFS and response 
rates when used as a first-line therapy for 
metastatic CRC (Saltz et al. 2000; Douillard et 
al. 2000) 
Cetuximab (monotherapy or in 
combination with irinotecan 
regimens); (Phase II, non-
randomised, multicentre trial) 
Improved prognosis in patients with aCRC with 
chemotherapy-refractory EGFR-expressing 
tumours (Saltz et al. 2004) 
Panitumumab; (Phase III, open 
label, multicentre trial; treatment 
regimens were stratified 
according to centres based in 
Western Europe, Canada and 
Australia vs. rest of world) 
Increased PFS as a first-line treatment 
alongside FOLFOX in mCRC patients (Douillard 
et al. 2010); panitumumab efficacy relies on wild 
type KRAS and BRAF status (Amado et al. 
2008; Di Nicolantonio et al. 2008) 
Bevacizumab; (Eastern 
Cooperative Oncology Group 
Study E2300; Phase III 
randomised, open label, multi-
institutional trial) 
Statistically significant and clinically meaningful 
improvement in overall survival and PFS in 
patients with mCRC, when used in combination 
with fluoropyrimidine based regimens 
(Kabbinavar et al. 2003; Hurwitz et al. 2004; 
Giantonio et al. 2007; Saltz et al. 2008) 
 
Table 1.3 Summary of clinical trials investigating treatments for CRC.  
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As a result, addition of capecitabine to fluorouracil regimens has been shown to 
reduce systemic exposure of 5-FU and therefore any associated toxicity (Van 
Cutsem et al. 2001). 5-FU is administered alongside leucovorin and oxaliplatin 
as part of the FOLFOX regimen, whilst CPB is given in combination with 
oxaliplatin as part of the XELOX regimen for either first or second line 
treatments for metastatic CRC (Rothenberg et al. 2008). Alternatively, the two 
regimens may be administered in addition to irinotecan as part of the FOLFIRI 
and XELIRI regimens, for use as first and second line treatments for aCRC, 
although not as adjuvant therapy (Patt et al. 2007).  
1.3.2 Irinotecan 
Irinotecan (Camptosar) is a plant alkaloid isolated from the Camptotheca 
acuminata tree, which functions as a topoisomerase I inhibitor. Topoisomerase I 
is a nuclear enzyme involved in relaxation of super-coiled DNA during 
replication (Saltz et al. 2000). The enzyme introduces a single transient nick into 
double-stranded DNA during repair and replication, allowing strand rotation and 
subsequent relief of the torsional strain created by supercoiling (Rivory et al. 
2002). Irinotecan is processed by intestinal and hepatic carboxylesterases to 
form the active metabolite SN38, which has been reported to demonstrate a 
1000-fold higher anti-tumour activity than irinotecan (Iyer et al. 1998). SN38 
functions to stabilise the topoisomerase-DNA complex, preventing reannealing 
of the DNA strand after nicking, which ultimately leads to replication fork stalling 
and apoptosis (Pommier, 2013; Rudolf et al. 2013).  
1.3.3 Oxaliplatin  
Oxaliplatin (Eloxatin) is a third generation platinum compound developed 
in 2002 and approved, in combination with 5-fluorouracil, for treatment of 
metastatic CRC. Oxaliplatin molecules consist of 1,2-diaminocyclohexane 
(DACH) carrier group and a bidentate oxalate group, which becomes displaced 
non-enzymatically following drug absorption, resulting in formation of DACH 
intermediates (Kidani et al. 1978). These active intermediates react with DNA, 
in particular with adenine and guanine bases, to form multiple crosslinks 
(Woynarowski et al. 2000). Oxaliplatin treatment results in formation of three 
types of lesions: DNA-intrastrand crosslinks, DNA-interstrand crosslinks and 
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DNA-protein crosslinks. Approximately 90% of lesions are intrastrand adducts 
between two adjacent guanine bases or, less commonly, between adjacent 
adenine and guanine bases (Chaney et al. 2005); the remaining 10% are made 
up of interstrand crosslinks and DNA-protein crosslinks (Woynarowski et al. 
2000).  
During intrastrand adduct formation, the DNA strand becomes distorted 
the DACH moiety bends approximately 30 degrees towards the major groove, 
resulting in DNA distortion. Formation of intrastrand crosslinks, in addition to 
secondary lesions that form due to an accumulation of damage, eventually 
result in cell cycle arrest, apoptosis and initiation of immunologic reactions 
(Springler et al. 2003; Woynarowski et al. 2000; Alcindor and Beauger, 2011). 
Prior to the development of oxaliplatin, CRC was thought to have intrinsic 
resistance to other platinum agents (Rixe et al. 1996). 
1.3.4 Targeted therapies 
 Stratified cancer treatment has led to the development of therapies to 
target specific weaknesses or advantages displayed by tumour cells. A number 
of monoclonal antibodies have been developed to seek out antigens present in 
cancer cells, in an attempt to increase efficacy and reduce the severe toxicity 
that arises as a result of chemotherapy. However, this treatment option is 
relatively expensive and these drugs also give rise to side effects, meaning that 
investigation of pharmacogenetic reasons to explain different responses 
between individuals could be crucial for effective use of these drugs.  
1.3.4.1 Cetuximab 
 Cetuximab (Erbitux) is a recombinant chimeric monoclonal antibody that 
was approved for CRC treatment in 2004 after it was shown to improve 
prognosis in aCRC either as a monotherapy or in combination with irinotecan in 
chemotherapy-refractory EGFR-expressing tumours (Van Cutsem et al. 2011; 
Cunningham et al. 2004). However, it was shown that cetuximab was ineffective 
in aCRC treatment when combined with oxaliplatin-based regimens (Maughan 
et al. 2011). 
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 The human epidermal growth factor receptor (EGFR) is involved in ligand 
binding and subsequent regulation of downstream cellular signalling cascades 
including the Ras/Raf/MEK/MAPK and PI3K-Akt pathways, which monitor cell 
survival and growth (Friday and Adjei, 2008). Overexpression of EGFR is 
correlated with poor prognosis in a number of cancers including CRC, non-small 
cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma and cervical 
carcinoma (Spano et al. 2005; Selvaggi et al. 2004; Ueda et al. 2004; 
Kersemaekers et al. 1999). Cetuximab targets the extracellular ligand-binding 
domain of the EGFR and blocks receptor activation by endogenous ligands, 
effectively preventing the receptor-dependent transduction pathway. This 
triggers a number of anti-tumour effects including cell cycle arrest in G1 leading 
to induction of apoptosis (Huang et al. 1999), in addition to inhibition of 
angiogenesis and metastasis (Bou-Assaly and Mukherji, 2010). There is also 
evidence that cetuximab, as an IgG1 antibody, stimulates antibody-dependent 
cell-mediated cytotoxicity (ADCC) in which the Fc region of the antibody is 
recognised as an antigen. This results in an immune reaction in which tumour 
cells expressing EGFR on their cell surface are targeted and destroyed, 
suggesting that this is an important mechanism of the drug’s action (Kimura et 
al. 2007).  
1.3.4.2 Panitumumab 
Similar to cetuximab, panitumumab (Vectibix) is another EGFR inhibitor 
that selectively targets the extracellular binding domain and blocks downstream 
signal transduction. Panitumumab is an entirely humanised monoclonal 
antibody that appears to act through a slightly different epitope, as shown by 
studies of cetuximab-resistant but panitumumab-sensitive cell lines (Montagut 
et al. 2012). The drug has been approved for treatment of aCRC since 2006 
and is frequently used alongside standard chemotherapy regimens (Van 
Cutsem et al. 2007).  
1.3.4.3 Bevacizumab  
 Bevacizumab (Avastin) is another humanised monoclonal antibody 
developed specifically to target the vascular endothelial growth factor (VEGF)-A 
ligand to prevent it binding to the VEGF receptor. The VEGF system is involved 
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primarily in promotion of angiogenesis and regulation of endothelial cell 
proliferation, both of which are crucial for tumour development. Where tumour 
vasculature forms to enhance tumour growth, often the vasculature structure 
becomes structurally and functionally imbalanced, resulting in elevated 
interstitial pressure and subsequent non-uniform perfusion throughout the 
tumour (Ellis, 2006). This can lead to hypoxia and upregulation of VEGF, which 
drives selection of highly aggressive tumour cells; therefore VEGF levels 
correlate not only with extent of angiogenesis but also with prognosis (Goel and 
Mercurio, 2013; Hockel, 2001; Dubois and Demetri, 2006).   
1.3.5 Toxicities associated with therapy  
Chemotherapeutic drugs and targeted treatments cause toxicities of 
varying degrees, with significant interpatient variation. Management of side 
effects is crucial for maintaining quality of life whilst maximising drug efficacy, 
and the spectrum of drug related toxicities can vary from mild to dose-limiting in 
nature, resulting in withdrawal from treatment in the most severe cases 
(Cassidy and Misset, 2002). In addition to general side effects resulting from 
destruction of rapidly dividing cells, toxicities may be more specific to a drug’s 
mechanism of action (Table 1.4).  
1.3.5.1 Fluoropyrimidines 
The main toxicities associated with 5-FU with leucovorin treatment are 
gastrointestinal (GI) epithelial damage resulting in diarrhoea, nausea, vomiting, 
stomatitis, neutropaenia and hand-foot syndrome (De Gramont et al. 2000). The 
severity of toxicity varies according to different regimens, although infusion of 5-
FU is typically tolerated better than bolus administration, due to fewer peaks in 
exposure to the drug with the latter option (Spicer et al. 1988). Similar side 
effects are experienced with CPB treatment, though at a reduced frequency 
(Cassidy et al. 2002). However, hand-foot syndrome occurs in 50% of patients 
receiving CPB, a considerably higher incidence than those receiving 5-FU with 
leucovorin. This is commonly characterised by dysthesia, erythema and, in 
more severe cases, ulceration and blistering of the skin, in particular the hands 
and feet (Gressett et al. 2006), which is believed to be the result of elevated 
levels of thymidine phosphorylase, the CPB metabolising enzyme, within the 
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Year Therapy Advance Toxicity 
1962 5-Fluorouracil FDA approved 5-FU for treatment of aCRC GI epithelial damage; hand foot syndrome; 
neutropenia 
1990 Adjuvant 
therapy 
Chemotherapy becomes most common treatment following surgery; improved 
survival after surgical resection by 40% 
Higher risk of infection; fatigue; anaemia; 
contusions; nausea; diarrhoea; alopecia 
1996-98 Irinotecan FDA and EMA approve use of irinotecan alongside 5-FU and leucovorin 
(FOLFIRI) in first line treatment and as second line monotherapy for aCRC 
Hyper-stimulation of cholinergic system; 
neutropenia 
1996-99 Oxaliplatin EMA approved use of oxaliplatin in combination with 5-FU and leucovorin 
(FOLFOX) for second line treatment of aCRC 
Acute and chronic peripheral neuropathy 
2001-4 Capecitabine FDA and EMA approved use of capecitabine in treatment of aCRC in 
combination with irinotecan and oxaliplatin in the XELIRI and XELOX 
regimens, respectively 
Anaemia; nausea; diarrhoea; fatigue 
2004-5 Bevacizumab FDA and EMA approved addition of bevacizumab to the FOLFIRI and XELIRI 
regimens for aCRC 
Hypertension 
2004 & 
2008 
Cetuximab FDA and EMA approved cetuximab use for aCRC as monotherapy or in 
combination with irinotecan (2004); mutations in codons 12 and 13 in the 
EGFR pathway gene KRAS found to result in ineffective treatment (2008) 
Acneiform skin rash; alopecia; trichomegaly 
(Karapetis et al. 2008) 
2006-7 Panitumumab FDA and EMA approved panitumumab use for aCRC as monotherapy, as first 
line treatment alongside FOLFOX and as second line treatment alongside 
FOLFIRI 
Acneiform skin rash; alopecia; trichomegaly 
2009-10 Cetuximab and 
Panitumumab 
FDA and EMA altered guidelines for use of EGFR inhibitors to account for 
mutations in codons 12 and 13 in KRAS, which result in ineffective therapy 
As above 
2012 Regorafenib FDA approved use of regorafenib for aCRC refractory to other 
chemotherapeutics 
Hand-foot syndrome; fatigue; diarrhoea; 
hypertension (Grothey et al. 2013) 
2013 Aflibercept EMA approved use of aflibercept for treatment of aCRC refractory to 
oxaliplatin-based regimens 
Higher risk of infection; anaemia; petechia; 
fatigue; diarrhoea; fistula development 
(Van Cutsem et al. 2012) 
Table 1.4 Major therapeutic advances in the treatment of aCRC and their respective toxicities. 
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epidermis (Milano et al. 2008). In severe cases, this side effect may lead to 
treatment discontinuation due to a reduced quality of life (Surjushe et al. 2008). 
1.3.5.2 Irinotecan 
Irinotecan causes acute dose-limiting toxicities associated with hyperstimulation 
of the cholinergic system, resulting in abdominal cramps, diarrhoea, emesis, 
hypotension and bradycardia (Blandizzi et al. 2001). Experiments using animal 
models have shown that irinotecan effectively inhibits acetycholinesterases and 
stimulates muscarinic receptors (Zambrowicz and Sands, 2003). Additional 
toxicities include delayed onset of diarrhoea resulting from circulation of high 
concentrations of SN38 in the intestine following hepatic elimination. This side 
effect is severe in approximately 40% of patients (Yamamoto et al. 2008). The 
anti-cholinergic drug, atropine, has been shown to alleviate the acute 
cholinergic symptoms effectively (Cheng et al. 2015), whilst the delayed onset 
diarrhoea responds well to high doses of loperamide (Takasuna et al. 2006).  
1.3.5.3 Oxaliplatin 
Peripheral neuropathy is the main dose limiting side effect associated 
with oxaliplatin treatment and as such presents a major problem for the 
treatment of CRC. It is more common for patients withdraw from therapy due to 
the onset of peripheral neuropathy associated with oxaliplatin (PNAO) than to 
die as a result of disease progression, and as PNAO is not correlated with drug 
response it is considered an avoidable toxicity (Whinney et al. 2009). There are 
currently no existing treatment options to reduce PNAO symptoms (Wolf et al. 
2008), although ongoing clinical trials are investigating whether vitamin D 
supplements during oxaliplatin-based therapy can alleviate side effects (Higa, 
2011).  
PNAO occurs in two forms; acute, transient neuropathy and chronic, 
cumulative sensory neuropathy. The acute, transient form occurs in most 
patients and has a rapid onset, occurring during or within hours of infusion. 
Patients may experience distal sensory and motor toxicities that are particularly 
aggravated by the cold. Sensory toxicity includes paresthesia and dysesthesia 
in the extremities and jaw. Additionally, 2% of patients report a transient cold-
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induced pharyngolaryngeal dysesthesia, resulting in a feeling of difficulty 
breathing. Occasionally patients will also develop transient motor toxicities such 
as involuntary muscle spasms, although the incidence of this is much less 
frequent than sensory neuropathy (Waisif Saif and Reardon, 2005).  
Chronic, cumulative sensory neuropathy is present in 10-15% of patients 
once a cumulative dose of 780-850mg/m2 has been reached (De Gramont et al. 
2000; Grothey et al. 2003). Symptoms consist of temperature-independent 
dysesthesia and paresthesia of extremities, similar to the acute form. However, 
symptoms occur in cycles and increase in intensity with cumulative doses, 
resulting in impaired sensation and coordination over time. Manifestation of 
chronic, cumulative neuropathy may be so severe that patients become unable 
to perform normal daily activities (Waisif Saif and Reardon, 2005). These 
symptoms are usually reversible; the majority of patients recover from Grade 3 
neurotoxicity to grade 1 or lower within 12 months of discontinuing therapy 
(Grothey, 2003).  
Acute PNAO has been associated with interference of voltage gated 
sodium channels indirectly via chelation of calcium ions by oxalate, an 
oxaliplatin metabolite (Grolleau et al. 2001), whilst the chronic form has been 
associated with accumulation of platinum in the dorsal root ganglia, resulting in 
direct toxicity to nerve cells (Argyriou et al. 2008; Ta et al. 2006). PNAO 
manifests as several separate symptoms and, as such, has been classified to 
allow oncologists to monitor dosage according to the type and severity of side 
effects experienced by patients (Wasif Saif and Reardon, 2005; Table 1.5).  
 Currently there is little knowledge of genes that confer predisposition to 
PNAO. An association between chronic PNAO and a coding variant in the 
GSTP1 gene, causing an isoleucine to valine substitution at codon 105, has 
been reported (Grothey et al. 2005; Ruzzo et al. 2007), although the impact of 
the risk allele has been questioned (Gamelin et al. 2007; Inada et al. 2010). 
Specific haplotypes of the AGXT gene have also been linked with predisposition 
to both acute and chronic PNAO (Gamelin et al. 2007; Table 1.6). 
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Peripheral 
neuropathy grade 
National Cancer Institute description of 
peripheral sensory neuropathy 
1 Mild paresthesia that does not interfere with 
function; Loss of deep tendon reflexes 
2 Moderate paresthesia affecting function but not daily 
activities 
3 Moderate paresthesia affecting daily activities 
4 Disability; Permanent sensory loss 
5 Death 
 
Table 1.5 Grading criteria of symptoms associated with PNAO, according to the 
National Cancer Institute guidelines. 
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Drug Polymorphism 
(Gene) 
Effect on response/toxicity 
5-FU Truncating splice 
variant IVS14+1G>A 
and 2846A>T in 60% 
of patients (DYPD) 
Reduced activity of the DPYD enzyme is 
highly correlated with greater severity and 
more rapid onset of 5-FU toxicity (Morel et al. 
2006) 
5-FU G>A point mutation in 
5’-splice recognition 
site of intron 14 leads 
to removal of entire 
exon 14 (DYPD) 
Greater severity of toxicity is associated with a 
splice site mutation resulting in a 165bp 
deletion (Wei et al. 1996); up to 25% of 
patients carrying at least one copy of this 
allele display Grade >3 toxicity, despite a low 
prevalence of the variant (MAF <1% in 
Caucasian population; Raida et al. 2001) 
5-FU Asp949Val in exon 22 
and intronic 
Ser534Asn associated 
with reduced enzyme 
activity (DYPD) 
Greater severity of toxicity associated with a 
rare nonsynonymous variant at position 949, 
causing a substitution of a valine for an 
aspartic acid residue (similar toxicity as that 
seen with the 165bp deletion; Morel et al. 
2006; Seck et al. 2005) 
5-FU Ala222Val and 
Glu429Ala (MTHFR) 
Two common polymorphisms associated with 
improved response to 5-FU treatment in 
patients carrying with aCRC (Toffoli and De 
Mattia, 2008) 
Irinotecan TA indel in promoter 
region and two exon 1 
variants; 211 G>A and 
686C>A (UGT1A1) 
Strong correlation between presence of 
variants and increased severity of irinotecan-
induced neutropaenia; most severe (Grade 4) 
toxicity associated with the TA indel genotype 
(Innocenti et al. 2004) 
Oxaliplatin Asp118Asn (C>T 
silent polymorphism) 
(ERCC1)  
Correlated with an increased rate of PNAO 
onset in a Japanese population (Oguri et al. 
2013) 
Oxaliplatin Asp118Asn (C>T 
silent polymorphism) 
(ERCC1) 
Associated with clinical outcome following 
oxaliplatin treatment; individuals homozygous 
for the C allele respond well (Park et al. 2003), 
whilst individuals carrying a heterozygous T 
allele exhibit increased mRNA levels and drug 
resistance (Ruzzo et al. 2007) 
Oxaliplatin 154C>T substitution 
on exon 1 and 
1142A>G substitution 
on exon 10 (AGXT) 
Minor allele haplotype associated with 
increased predisposition towards oxaliplatin-
induced toxicity (acute and chronic forms) 
(Gamelin et al. 2007) 
Oxaliplatin Ile105Val (GSTP1) Contributes to increased risk of chronic PNAO 
(Grothey et al. 2005; Ruzzo et al. 2007) 
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Drug Polymorphism 
(Gene) 
Effect on response/toxicity 
Oxaliplatin Leu1092Pro 
(SCN10A) and an 
intronic variant, 
rs2302237 (SNC4A) 
Associated with increased risk of acute 
PNAO, whilst also increasing severity of 
toxicity (Argyriou et al. 2013) 
Cetuximab 
and 
panitumumab 
Activating mutations in 
codons 12 and 13; 
rarer activating 
mutations in codons 
61 and 146 (KRAS) 
Significantly reduced response rates to 
cetuximab treatment; from 13% to 1.2% 
(Karapetis et al. 2008); Variants in codons 61 
and 146 associated with a similar lack of 
clinical response to treatment (Loupakis et al. 
2009) 
Cetuximab 
and 
panitumumab 
Mutations in exon 2 
(KRAS); population 
wild-type for KRAS 
carried mutations in 
exon 20 (PI3KCA) and 
multiple 
nonsynonymous 
variants in BRAF and 
NRAS  
Variants in KRAS associated with resistance 
to cetuximab (Karapetis et al. 2008; Lievre et 
al. 2006; Di Fiore et al. 2007); variants in 
BRAF, NRAS and PIK3CA exon 20 
associated with reduction in response rate in a 
KRAS- wild type population (De Roock et al. 
2010) 
Cetuximab 
and 
panitumumab 
V600E (BRAF) Associated with a reduction in drug efficacy; 
present in approx. 10% of all aCRC cases (Di 
Nicolantonio et al. 2008; Benvenuti et al. 
2007) 
Cetuximab 
and 
panitumumab 
Variants in codon 61 
(NRAS) 
Strongly correlated with reduced response 
rate (reduced by over 30% in carriers; Peeters 
et al. 2013) 
Cetuximab 
and 
panitumumab 
Oncogenic mutations 
and loss of expression 
(PI3KCA and PTEN, 
respectively) 
Strongly associated with EGFR inhibitor 
treatment failure (Frattini et al. 2007; Perrone 
et al. 2009; Loupakis et al. 2009); variants in 
both genes reported to co-occur with other 
variants in EGFR-related genes (Sartore-
Bianchi et al. 2009) 
 
Table 1.6 Summary of pharmacogenetic factors that affect response and toxicity 
in the treatment of CRC.  
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1.3.5.4 Cetuximab 
The most common dose-limiting toxicity associated with cetuximab is the 
development of an acneiform skin rash on the face and upper body resulting 
from keratinocyte alterations, in addition to hair follicle proliferation and 
maturation, which occurs in approximately 50% of patients receiving treatment 
(Agero et al. 2006). Clinical manifestation of the skin rash is similar to acne 
vulgaris although histological examination has revealed it more closely 
resembles infectious folliculitis (Lenz, 2006). The skin rash peaks in severity 
during the first two weeks of therapy and usually stabilises in subsequent weeks 
(Busam et al. 2001).The mechanism of rash formation remains poorly 
elucidated, although interference of follicular epidermal growth signalling is 
considered crucial (Lynch et al. 2007). The EGFR, located within the epidermis, 
stimulates epidermal growth, inhibits differentiation, protects against UV 
damage and inflammation, and accelerates wound healing (Jost et al. 2000). 
EGFR is ubiquitously expressed in epidermal keratinocytes, sebaceous and 
eccrine glands, and hair follicle epithelial cells (Nanney et al. 1990; Fox, 2006). 
Cetuximab-induced inhibition of EGFR alters keratinocyte differentiation, 
proliferation, migration and attachment, which most likely contributes to 
acneiform skin rash presentation (Peus et al. 1997; Woodworth et al. 2005).  
There is evidence to suggest that skin rash presentation correlates with 
cetuximab efficacy, indicated by increased survival in patients across multiple 
tumour types (Bruno et al. 2003; Saltz et al. 2003, Orditura et al. 2009). Given 
that the skin rash acts as a surrogate marker for efficacy, clinicians manage 
toxicity in patients using topical antibiotic and steroid treatments to prevent 
treatment discontinuation (Pinto et al. 2011). 
1.3.5.5 Panitumumab 
As an EGFR inhibitor, panitumumab causes similar toxicities to those 
seen with cetuximab, with dermatological side effects accounting for 90% of 
reported toxicity. Additionally, patients commonly experience fatigue, diarrhoea, 
nausea, neutropaenia and hypomagnesaemia (Van Cutsem et al. 2007).  
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1.3.5.6 Bevacizumab 
 The most common toxicity associated with bevacizumab therapy is 
severe hypertension; 23% of patients experience hypertension, with 8% of 
these considered severe cases (Scartozzi et al. 2009). Inhibition of vascular 
endothelial growth factor (VEGF) is believed to result in hypertension as a result 
of two mechanisms; firstly, a reduction in vasodilator production lowers normal 
physiological levels, causing vasoconstriction (Isenberg et al. 2009). Secondly, 
reduced nitric oxide levels cause a reduction in sodium excretion, leading to 
hypertension due to water retention in the bloodstream (Beevers et al. 2001). 
Additional toxicities include proteinuria, bleeding, increased risk of arterial and 
venous embolisms, and, in the most severe cases, poor wound healing and 
perforation of the GI wall (Scartozzi et al. 2009). 
 Hypertension can be treated with administration of anti-hypertensive 
drugs, including angiotensin-converting enzyme (ACE) inhibitors, calcium 
channel blockers or beta-blockers (Messerli, 1999). As with most drugs, a 
proportion of patients remain unresponsive to drugs to alleviate side effects, in 
which case dose modification can reduce severity of side effects (Scartozzi et 
al. 2009).   
1.3.6 Pharmacogenetics of CRC treatments  
 Multiple genetic variants have been associated with differing degrees of 
response to and side effects from drugs used in the treatment of CRC, as 
shown in Table 1.6.  
 1.3.6.1 Fluoropyrimidines 
Several genetic variants have been associated with varying response to 
the fluoropyrimidine class of drugs in CRC treatment. The primary mechanism 
of 5-FU metabolism is via dihydropyrimidine dehydrogenase (DPYD) activity; 
approximately 80% of administered drug is metabolised by the enzyme 
(Amstutz et al. 2011). At least 15 polymorphisms in the DPYD gene have been 
reported to alter enzyme activity, typically with reduced activity associated with 
greater severity and more rapid onset of 5-FU-induced toxicity (Schwab et al. 
2008; Morel et al. 2006; Ciccolini et al. 2010; Raida et al. 2001; Table 1.6). 
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Additional polymorphisms have been shown to influence response to the 
fluoropyrimidine drugs, including common polymorphisms in the gene encoding 
the methylenetetrahydrofolate reductase (MTHFR) enzyme. MTHFR is critical 
for reduced folate production, the presence of which is essential for the drug’s 
action (Etienne-Grimaldi et al. 2010). 
Variants in TS have also been correlated with altered protein expression, 
with increased expression typically inversely linked to clinical outcome. One 
particular variant consists of a 28 base pair repeat sequence in the 5’ 
untranslated region (5’UTR) of TS, with markedly increased expression of the 
protein when associated with three 5’UTR repeats as opposed to two (Lecomte 
et al. 2004). Alternatively, a six base pair deletion in the 3’UTR has been 
associated with significantly reduced mRNA stability, which subsequently 
affects protein expression (Mandola et al. 2004). 
1.3.6.2 Irinotecan 
As mentioned in section 1.1.1.2, polymorphisms in UGT1A1 have been 
associated with increased severity of irinotecan-induced toxicity, owing to the 
enzyme’s role in the deactivation of irinotecan’s active metabolite, SN38 (Iyer et 
al. 1999; Ando et al. 1998). Additionally, patients exhibiting elevated levels of 
bilirubin, another substrate of UGT1A1, or with an inherited deficiency in the 
enzyme such as Gilbert’s syndrome (OMIM #143500) have also been reported 
to have an increased risk of irinotecan-induced toxicity (Sai et al. 2004; 
Lankisch et al. 2008). 
 1.3.6.3 Oxaliplatin  
 The efficacy of oxaliplatin treatment for individuals with aCRC is typically 
affected by variants in genes involved in the pharmacokinetic and cellular 
response pathways. Modified expression of ERCC1, a gene essential for 
nucleotide excision repair (NER) of platinum adducts, has been reported to 
affect response to the drug; typically increased expression is associated with 
resistance to oxaliplatin (Kwon et al. 2007). Other DNA repair genes also have 
shown an association with clinical outcome of oxaliplatin treatment, including 
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the base excision repair (BER) gene XRCC1. Patients carrying an Arg399Gln 
variant in this gene typically respond better to treatment (Lv et al. 2013).  
Several variants have also been reported to affect oxaliplatin-induced 
toxicity. Certain haplotypes of alanine glycoxylate transferase (AGXT), required 
for oxalate metabolism, have been reported to increase predisposition towards 
the acute and chronic forms of peripheral neuropathy (Gamelin et al. 2007). 
Interestingly, the synonymous variant in ERCC1 encoding Asn118 was 
correlated with an increased rate of onset of peripheral neuropathy in a 
Japanese population following oxaliplatin treatment (Inada et al. 2010; Oguri et 
al. 2013). Oguri et al. also published an association between rs10486003 in 
tachykinin (TAC1) and rs17140129 in phenylalanyl-tRNA synthetase 2 (FARS2) 
with the rate of onset of peripheral neuropathy and its severity, respectively.  
 1.3.6.4 Cetuximab and panitumumab 
Variants in a downstream effector of the EGFR pathway, Kirsten rat 
sarcoma viral oncogene homolog (KRAS), have been reported to influence 
resistance to EGFR inhibitors. A lack of response has been reported in patients 
carrying KRAS mutations undergoing either monotherapy or combination 
therapies for both EGFR inhibitors (De Roock et al. 2008; Amado et al. 2008; 
Lievre et al. 2008; Bokemeyer et al. 2009). Tumours with inactivating mutations 
in KRAS at codons 12 and 13 demonstrated significantly reduced response to 
cetuximab therapy, down from 13% to 1.2% (Karapetis et al. 2008). Despite 
these findings, up to 60% of KRAS-wild type tumours display a lack of 
response, which prompted investigation of other components of the EGFR 
pathway for a role in lack of response to EGFR inhibitors (Linardou et al. 2008). 
In addition to KRAS mutations, variants in activating v-raf murine sarcoma viral 
oncogene homolog B1 (BRAF), neuroblastoma ras viral oncogene homolog 
(NRAS) and phosphatidylinositol-4,5-biphosphate 3-kinase (PI3KCA), as well as 
loss of expression of the PI3K pathway inhibitor and tumour suppressor, PTEN, 
are implicated in EGFR inhibitor treatment failure (Di Nicolantonio et al. 2008; 
De Roock et al. 2010; Laurent-Puig et al. 2009; Frattini et al. 2007; Perrone et 
al. 2009; Table 1.6).   
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1.4 Metabolism of oxaliplatin 
1.4.1 Pharmacokinetics 
Oxaliplatin is administered intravenously; first line treatment requires a 
dose of 85mg/m2 once every two weeks (De Gramont et al. 2000) and for 
second line treatment a dose of 130mg/m2 is given every three weeks when 
combined with fluoropyrimidines over 2-6 hours (Vyzula et al. 2006). 
1.4.2 Absorption and distribution 
Immediately after absorption, the initial oxaliplatin molecule is hydrolysed 
by displacement of the oxalate group, forming reactive intermediates that 
readily bind to amino groups in DNA, RNA and proteins (Desoize and Madoulet, 
2002). Additional interactions include binding of oxalate intermediates to sulphur 
atoms on cysteine and methionine residues (Raymond et al. 2002). After 2 
hours of drug infusion, at least 70% of these molecules bind reversibly to 
plasma proteins, facilitating distribution of the drug (Culy et al. 2000). From the 
plasma the DACH ligand of oxaliplatin is easily distributed throughout the body 
due to its highly lipophilic nature, a process that is further aided by its ability to 
bind to proteins, DNA and other large molecules (Graham et al. 2000).  
1.4.3 Metabolism and excretion 
Oxalate is the major metabolite of oxaliplatin produced following non-
enzymatic displacement of H2O and chlorine ions. Oxalate is metabolised in a 
similar manner to that of glycoxylate, a by-product of amino acid metabolism, 
which involves detoxification and metabolism by AGXT and glycoxylate 
reductase-hydroxypyruvate reductase (GRHPR), respectively (Holmes and 
Assimos, 1998). Since oxalate is a chelator of calcium ions, there is a high 
possibility that oxalate production may cause the acute neuropathy seen with 
oxaliplatin therapy (Grolleau et al. 2001).  
Renal elimination accounts for approximately 50% of unbound oxaliplatin 
molecules. This has been reported to occur at a rate of 121ml/min (Kern et al. 
1999), whilst the remaining oxaliplatin bound to erythrocytes is excreted at a 
rate in concordance with the cells’ half-life (Levi et al. 2000). 
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1.4.4 Cellular processing 
1.4.4.1 Cellular influx 
Although the primary uptake mechanism of oxaliplatin is passive 
diffusion, multiple drug transporters have also been implicated. These include 
the copper transporter protein 1 (CTR1) and both organic cation transporters 
(OCT1 and OCT2), which increase cellular levels of oxaliplatin (Holzer et al. 
2006; Zhang et al. 2006). Studies in mice have reported that OCT2 knockdown 
is associated with an elevated rate of oxaliplatin-induced neuropathy (Sprowl et 
al. 2013). 
1.4.4.2 Cellular localisation and trafficking 
Additional members of the copper transport system have been reported 
to control cellular localisation of platinum compounds by binding to platinum 
molecules and distributing these throughout the cell (Chen and Kuo, 2010). 
These include cytochrome C oxidase 17 (C0X17), copper chaperone for 
superoxide dismutase (CCS) and human antioxidant homologue 1 (HAH1), 
which are involved in trafficking of platinum compounds to the mitochondria for 
metabolism and to the Golgi apparatus, in preparation for efflux from the cell 
(Gupta and Lutsenko, 2010; Nejdl et al. 2015; Figure 1.5). 
1.4.4.3 Detoxification 
Detoxification of platinum compounds directly influences the amount of 
active circulating platinum that is free to interact with DNA. Biotransformation 
occurs when free platinum drug molecules form a complex with reducing agents 
rich in thiol groups, including L-methionine, L-glutathione and L-cysteine, which 
yields an unreactive species (Luo et al. 1999; Levi et al. 2000). Conjugation 
following detoxification causes efflux of platinum from cells, therefore protecting 
DNA from damage (Mackay et al. 2007). Glutathione conjugation is catalysed 
by glutathione S-transferase (GST), a metabolic enzyme of which multiple 
subclasses exist. However, only a few have been reported to mediate platinum 
detoxification, including GSTP1, GST-τ (GSTT1) and GST-µ (GSTM1) (Peklak-
Scott et al. 2008; Lecomte et al. 2006). 
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Figure 1.5 Cellular processing of oxaliplatin. Oxaliplatin enters the cell via passive or active transport using the copper transporter protein 1 
(CTR1) and both organic cation transporters (OCT1 and OCT2). Cytochrome C oxidase 17 (COX17) and copper chaperone for superoxide dismutase 
(CCS) facilitate trafficking of platinum compounds to the mitochondria and cytoplasmic superoxide dismutase (SOD), respectively (Chen and Kuo, 
2010). The human antioxidant homologue 1 (HAH1) escorts platinum compounds to the copper transporting P-type adenosine triphosphatase 7A and 
7B (ATP7A and ATP7B) located in the Golgi apparatus (Gupta and Lutsenko, 2010). Trafficking of these proteins to the plasma membrane is 
associated with a role in platinum efflux from the cell (Kim et al. 2009). GST = Glutathione S-transferase; GT = Glutathione; MT = Metallothionein. 
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Metallothioneins (MT), low molecular weight proteins rich in cysteine 
resides, also mediate platinum detoxification; MTs are thought to be important 
in the control of exposure to heavy metals and copper (Mejare and Bulow, 
2001). Tumours displaying high expression of MT1A and MT2A have been 
reported to show reduced response to platinum agents (Marsh et al. 2009).  
1.4.4.4 Cellular Efflux 
A key mechanism involved in cellular efflux of platinum agents is via the 
ATP7A and ATP7B copper transport proteins, although additional reports have 
implicated the ATP-binding cassette (ABC) family of proteins in platinum efflux, 
in particular subfamilies ABCB1, ABCC1, ABCC2, ABCC3, ABCC5 and ABCG2 
(Sprowl et al. 2013). Overexpression of several of these is reportedly 
associated with response to platinum therapy (Han et al. 2011; Tian et al. 2012; 
Marsh et al. 2007; Kim et al. 2009).  
1.4.5 Pharmacodynamics  
The major neoplastic property of platinum drugs is the ability to form 
platinum-DNA adducts (Figure 1.6). Crosslink formation results in stalled DNA 
synthesis (Raymond et al. 1998), which subsequently impairs replication and 
transcription, resulting in apoptosis (Faivre et al. 2003).  
Oxaliplatin and cisplatin demonstrate similar sequence-specific and 
regional localisation of DNA damage (Woynarowski et al. 1998), despite 
differing in other aspects. It is believed that oxaliplatin forms fewer lesions than 
cisplatin at an equimolar concentration, despite a higher efficiency of DNA chain 
elongation inhibition. This is partly due to the ability of the bulky DACH group to 
modify the helical structure of DNA (Woynarowski et al. 2000).   
1.5 DNA repair  
The cell’s ability to recognise and repair DNA damage is crucial for 
maintenance of genetic stability and ultimately survival. An individual cell is 
subjected to up to one million genotoxic events per day; some occur as a by-
product of normal cell metabolism whilst others are induced by radiation and 
environmental stressors (Jackson and Bartek, 2009; Ciccia and Elledge, 2010).  
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Figure 1.6 Oxaliplatin adduct formation. Following oxaliplatin treatment, initially 
monoadducts form, although these are considered non-toxic (Alcindor and Beauger, 
2011). The drug’s cytotoxic action is only apparent following formation of biadducts; of 
these lesions, approximately 60-65% constitute intrastrand crosslinks between 
adjacent guanine residues (A) and 20-25% constitute crosslinks between guanine and 
adenine residues (B). The remaining lesions include interstrand crosslinks (ICLs) 
between consecutive (C) and more distant guanine residues (D) (Woynarowski et al. 
2000) and DNA-protein interactions (E) (Raymond et al. 2002). Figure adapted from 
Boulikas, 2007.  
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Inability to repair damage can result in chromosomal instability and 
modifications to coding DNA, resulting in genomic aberrations that can trigger 
activation of oncogenes and inactivation of tumour suppressor genes, which 
promote tumour development (Hoeijmakers, 2001). 
Currently there are 168 proteins that are implicated in the various DNA 
repair pathways; each pathway contains numerous steps that are performed by 
specialised proteins required for repair of different forms of damage, although 
significant overlap of different pathways has been reported (Wood, 2005; 
Bernstein et al. 2002). An association between mutations in DNA repair genes 
and cancer-predisposing syndromes has been demonstrated in a number of 
studies (Muller and Fischel, 2002; Kinzler and Vogelstein, 1996).  
1.5.1 NER Pathway 
Nucleotide excision repair (NER) is responsible for the removal of bulky 
adducts that cause distortion of the DNA helix, resulting in impaired replication 
and transcription. It is primarily involved in the repair of ultraviolet (UV)-induced 
photoproducts, which consist of 6-4 photoproducts (6-4 PP) and cyclobutane 
pyrimidine dimers (CPD) (De Laat et al. 1999), although it can additionally 
repair other types of lesions resulting from exposure to a range of chemical and 
environmental stressors (Fousteri and Mullenders, 2008).  
The NER pathway consists of two distinct sub-pathways, which differ in 
their damage recognition processes. Transcription coupled (TC-NER) repair 
takes place when RNA polymerase II (RNA pol II) stalls at damaged DNA within 
a transcription site. Cockayne syndrome group A and B (CSA and CSB) are 
recruited to stalled RNA pol II and commence the damage recognition process 
(Svejstrup, 2002). Alternatively, where damage occurs at non-transcribed 
regions, global genomic (GG-NER) repair occurs via damage recognition by the 
xeroderma pigmentosum, group C (XPC) – HR23B complex and the DNA 
damage binding proteins, 1 and 2 (DDB1 and DDB2). The precise proteins 
involved depend on the extent of distortion of the DNA double helix and the 
specific lesions induced (Sugasawa et al. 2001; Kusumoto et al. 2001). CSB 
and XPC-HR23B are involved in the recruitment of the ten sub-unit basal 
transcription factor complex (TFIIH) to the damage site; TFIIH consists of two 
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helicases, XPB and XPD, which mediate DNA strand unwinding in the presence 
of ATP (Laine et al. 2006). This process enables binding of XPA, XPG and 
replication protein A (RPA). XPA confirms the site is damaged and then acts in 
combination with RPA to protect the undamaged single stranded DNA and 
recruits XPF and excision repair cross complementing, group 1 (ERCC1) 
complex. The 5’ ERCC1-XPF complex incises and releases the damaged 
strand, in conjunction with the 3’ incision by XPG (Tsodikov et al. 2007). This is 
followed by recruitment of repair machinery to facilitate repair and ligation using 
the undamaged strand as a template (Ogi et al. 2010; Figure 1.7). Multiple NER 
genes have been associated with disease, primarily disorders of NER and 
transcription (Table 1.7).  
1.5.2 Disorders of repair and transcription 
Xeroderma pigmentosum (XP) is an autosomal recessive disorder 
characterised by severe sensitivity to UV light and a 1000-fold increased 
incidence of skin cancers resulting from impaired NER and accumulation of UV-
induced lesions (Kraemar et al. 1994). There are currently eight 
complementation groups of XP, which all display similar phenotypes but with 
varying degrees of severity. Some complementation groups additionally exhibit 
neurological degenerative symptoms; approximately 20-30% of all XP patients 
present with neurological symptoms (De Boer and Hoeijmakers, 2000; Anttinen 
et al. 2008). 
Seven of the complementation groups of XP (XPA-G) arise due to 
function impairing mutations in NER pathways genes, whilst the eighth 
complementation group, XPV, is the result of variants in the replicative bypass 
polymerase η (POLH). Patients with XPV have fully functioning NER; however 
the cells’ inability to perform DNA replication past regions with UV lesions gives 
rise to the traditional XP phenotype (Masutani et al. 1999). 
Additional rare recessive disorders of repair and transcription include 
Cockayne syndrome (CS) and trichothiodystrophy (TTD). CS is characterised 
by cutaneous photosensitivity, despite no increased risk of skin cancer. Two 
known complementation groups exist, CSA and CSB, which arise due to 
functional mutations in ERCC8 and ERCC6, respectively (Wood, 1997). 
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Figure 1.7 The two sub-pathways of the NER pathway. The two branches of NER, 
showing A) DNA damage recognition, B) DNA unwinding, C) incision of the damaged 
strand and D) excision of damaged oligonucleotides followed by de novo synthesis. 
NER functions to remove helix distorting lesions. In coding regions of DNA, TC-NER is 
initiated via RNA pol II stalling, whilst lesions in non-transcribed DNA regions are 
repaired by GG-NER, whereby lesions are recognised by XPC-HR23B, DDB1 and 
DDB2. The damaged strand is excised and repair machinery is recruited, including 
POLD, POLE or polymerase K (POLK; Gillet and Scharer, 2006). Additionally XRCC1-
LIG1 or LIG3 may be recruited, depending on the stage of the cell cycle the cell in 
question is in (Moser et al. 2007).  
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Human Gene 
(Protein) 
Sub-
pathway 
Function in NER Disease phenotype 
CCNH (Cyclin H) Both CDK Activator Kinase 
(CAK) subunit 
None 
CDK7 (Cyclin 
Dependent 
Kinase (CDK) 7) 
Both CAK subunit Elevated protein expression in 
neurons associated with Alzheimer’s 
disease (Zhu et al. 2000) 
CETN2 (Centrin-
2) 
GG-NER Damage recognition, 
forms complex with 
XPC 
None 
DDB1 (DDB1) GG-NER Damage recognition; 
forms complex with 
DDB2 
Involved in pathogenesis of Best’s 
disease (Best’s vitelliform macular 
dystrophy; Stohr et al. 1998) 
DDB2 (DDB2) GG-NER Damage recognition; 
recruits XPC 
Absent DDB2 activity in patients with 
XPE, a hereditary photosensitive 
disease with high incidence of skin 
malignancy (Itoh et al. 2001) 
ERCC1 
(ERCC1) 
Both Incises on 3’ side of 
damage; forms a 
complex with XPF 
Certain polymorphisms associated 
with increased susceptibility to certain 
cancers; 19007 C allele (rs11615) 
contributes to skin cancer 
development; 17677 A>C and 19007 
T>C polymorphisms are low 
penetrance alleles for cancer 
susceptibility (Zhang et al. 2011) 
ERCC2 (XPD) Both ATPase and helicase 
activity; transcription 
factor II H (TFIIH) 
subunit 
 XPD characterised by a 1000-fold 
increased risk of cancer (Kraemer et 
al. 1994); ERCC2 variants also cause 
trichothiodystrophy (TTD), although 
TTD patients do not exhibit increased 
cancer risk (Stefanini, 2000); 
Lys751Gln homozygous variant 
associated with higher risk of head 
and neck cancer (Sturgis et al. 2000) 
ERCC3 (XPB) Both ATPase and helicase 
activity; transcription 
factor II H (TFIIH) 
subunit 
 XPB characterised by relatively mild 
XP symptoms, also causes an XP/CS 
phenotype with more severe 
symptoms and cancer predisposition 
(Oh et al. 2006); Variants in ERCC3 
cause a rarer TTD phenotype, which 
again is cancer-free (Stefanini, 2000) 
ERCC4 (XPF) Both Incises on 3’ side of 
damage; forms a 
complex with ERCC1 
 XPF characterised by acute sun 
sensitivity and neurologic symptoms 
and cancer predisposition (Sijbers et 
al. 1998); Fanconi anaemia caused 
by Leu238Pro and Arg689Ser 
(Bogliolo et al. 2013); variants in 
ERCC4 associated with increased 
cancer predisposition (e.g. 357A>C 
variant predicts risk and recurrence of 
bladder cancer; Wang et al. 2010b) 
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Human Gene 
(Protein) 
Sub-
pathway 
Function in NER Disease phenotype 
ERCC5 (XPG) Both Incises on 5’ side of 
damage; stabilises 
TFIIH 
 XPG characterised by mild to severe 
XP symptoms, occasionally coupled 
with symptoms of Cockayne 
syndrome (CS; O’Donovan et al. 
1994); variants increase risk of 
certain cancers (e.g. prostate cancer; 
Berhane et al. 2012) 
ERCC6 (CSB) TC-NER Transcription 
elongation factor; 
involved in 
transcription coupling 
and chromatin 
remodelling 
Cockayne syndrome; certain variants 
associated with significantly 
increased predisposition to lung 
cancer (rs2228526, rs4253160, 
rs12571445 and rs3793784; Ma et al. 
2009) 
ERCC8 (CSA) TC-NER Ubiquitin ligase 
complex; interacts with 
CSB and p44 of TFIIH 
Cockayne syndrome; predisposition 
to skin cancers (Laugel, 2013) 
LIG1 (DNA 
Ligase I) 
Both Final ligation Disruption of LIG1 led to a psoriasis 
phenotype in mice (Suzuki, 2002) 
MNAT1 
(MNAT1) 
Both Stabilises CAK 
complex 
None 
MMS19 
(MMS19) 
Both Interacts with XPD and 
XPB subunits of TFIIH 
helicases 
None 
RAD23A 
(RAD23A) 
GG-NER Damage recognition; 
forms complex with 
XPC 
None 
RAD23B 
(RAD23B) 
GG-NER Damage recognition; 
forms complex with 
XPC 
Ala249Val variant in RAD23B 
associated with significantly 
increased risk of laryngeal cancer 
(Abbasi et al. 2009) 
RPA1 (RPA1) Both Subunit of RFA 
complex 
None 
RPA2 (RPA2) Both Subunit of RFA 
complex 
None 
TFIIH 
(Transcription 
factor II H) 
Both Forms a complex 
around lesion prior to 
incision 
Variants in p44 gene, encoding a 
subunit of TFIIH, causes large-scale 
deletions that are implicated in 
Werdnig-Hoffmann disease (Burglen 
et al. 1997; Another subunit of TFIIH, 
GTF2H5, causes TTD group A 
(Giglia-Mari et al. 2004) 
XAB2 (XAB2) TC-NER Damage recognition; 
interacts with XPA, 
CSA and CSB 
None 
XPA (XPA) Both Damage recognition None 
XPC (XPC) GG-NER Damage recognition Increased predisposition to skin 
cancers demonstrated in mice (Sands 
et al. 1995) 
 
Table 1.7 Summary of NER genes with their protein functions and sub-pathways.  
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Alternatively, TTD consists of three known complementation groups, caused by 
mutations in genes encoding XPB, XPD and TTD-A, which cause up to a 70% 
reduction in cellular expression of TFIIH, regardless of zygosity (Botta et al. 
2002). As a result, TTD is characterised by short stature, immature sexual 
development and brittle hair (Kraemer et al. 2007). Unlike XP, all known 
complementation groups of CS and TTD display cancer-free phenotypes 
(Berneburg et al. 2000).  
In contrast to XP, CS is widely regarded a disorder of transcription, 
whereas TTD is considered a disorder of both repair and transcription. The 
similar clinical phenotypes exhibited by patients with these syndromes can be 
attributed to defects in common genes. This provides evidence for crosstalk 
between the NER and transcription pathways. For instance, overlap occurs 
between TTD and XP disorders as a result of shared mutations in XPB and 
XPD, both of which encode subunits of TFIIH responsible for unwinding the 
DNA helix prior to lesion removal. However, despite the similarities in the 
genetics between each disease, TTD patients do not exhibit a cancer-prone 
phenotype whilst XP sufferers exhibit massively increased predisposition to skin 
cancers (Nishiwaki et al. 2004; Berneburg et al. 2000). Additional overlap 
occurs due to mutations in CSA and CSB, both of which encode proteins 
involved in transcription coupled (TC)-NER, enabling removal of transcription-
blocking lesions from the transcribed strands of actively transcribed genes 
(Nardo et al. 2009). Similarly, mutations in ERCC5 encoding XPG, the 
endonuclease required for 3’ incision during NER, cause XP and, in rare cases, 
a phenotype that resembles that of CS. Cells from CS patients have 
demonstrated photosensitivity and an inability to recover from UV damage-
induced inhibition of RNA synthesis (Rockx et al. 2000). A summary of these 
overlapping disorders is given in Table 1.8. 
1.5.3 Mechanisms of peripheral neuropathy 
1.5.3.1 Inherited disorders of peripheral neuropathy 
Inherited peripheral neuropathy disorders are primarily caused by 
mutations in the peripheral myelin protein 22 (PMP22) gene. One of the most 
common PMP22-related neuropathies is Charcot-Marie-Tooth disease (CMT).  
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Disease Genes affected Phenotype Defect in repair 
or transcription 
Cockayne 
syndrome (CS) 
CSA, CSB Cancer-free multisystem 
disorder; photosensitivity; 
physical and mental 
retardation; severe early 
onset neurological 
degeneration; pigmentary 
retinopathy; cataracts 
Transcription 
Trichothiodystrophy 
(TTD) 
XPB, XPD, 
TTDA 
Cancer-free multisystem 
disorder; photosensitivity 
in TTD-A only; physical 
and mental retardation; 
sulphur-deficient brittle 
hair; ichthyosis; 
decreased fertility; short 
stature  
Both 
Xeroderma 
pigmentosum (XP) 
XPA, XPB, XPC, 
XPD, XPE, XPF, 
XPG, XPV 
Highly cancer-prone (skin 
cancer); photosensitivity; 
pigmentation 
abnormalities; 
progressive neurological 
degeneration; premature 
skin ageing; cataracts  
Repair 
XP/CS XPB, XPD Progressive neurological 
degeneration; impaired 
intellectual and sexual 
development 
Both 
XP/TTD XPB, XPD, XPG Features of TTD in 
addition to cancer 
predisposition seen in XP 
Both 
 
Table 1.8 Disorders of repair and transcription with their associated 
mutations and phenotype. 
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CMT encompasses a heterogeneous group of neuropathy disorders 
characterised by sensory loss, distal muscle weakness and atrophy. These are 
classified according to their genetic cause and neurophysiologic signs; the most 
common form, CMT type 1A (CMT1A) arises as a result of a 1.5 megabase 
(Mb) duplication on chromosome 17p11.2, resulting in three copies of the 
PMP22 gene (Van Paassen et al. 2014). The functional consequence of this is 
overproduction of PMP22 RNA and protein within Schwann cells, resulting in 
impaired neuron function. Although the exact mechanism for this is still under 
investigation, it is known that a defining factor of CMT1A is a motor conduction 
velocity (MCV) of less than 38 metres per second (m/s), compared with an MCV 
of up to 120m/s in physiologically normal peripheral neurons (Gasser and 
Erlanger, 1927; Manzano et al. 2008). CMT1A is a demyelinating neuropathy, 
meaning that the disease is due to degradation of either the protective myelin 
sheath that covers the long axons of neurons or the Schwann cells that produce 
and secrete myelin. Alternatively, CMT type 2A (CMT2A) is an axonal 
peripheral sensorimotor neuropathy, which means that the disease involves 
direct destruction of peripheral nervous system neurons. In particular, the axons 
that relay action potentials and transfer protein signals between adjacent 
neurons are degraded, resulting in a combination of sensory and motor 
symptoms. Unlike CMT1A, it is caused by autosomal dominant mutations in the 
mitofusin-2 (MFN2) gene, and is defined by a CMV of greater than 38m/s 
(Harding and Thomas, 1980). 
Rarer genetic disorders include leucodystrophy, a disorder of the white 
matter in which myelin may be decreased or absent, unstable and/or have an 
abnormal structure, resulting in symptoms of peripheral neuropathy. A number 
of leucodystrophy disorders exist with a number of various genetic causes, such 
as a deficiency of aryl sulphatase A, which causes metachromatic 
leucodystrophy (MCL). MCL exhibits symptoms of both peripheral and central 
nervous system neuropathy, of which the severity differs greatly between 
patients (Bindu et al. 2005).  
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1.5.3.2 Diabetic peripheral neuropathy 
Peripheral neuropathy has also been recognised as a common 
complication of diabetes mellitus and is associated with debilitating pain in 
these patients. Typically these complications arise in patients with a higher 
average hyperglycaemic index; however, aside from this observation, little is 
known about the aetiology of diabetic peripheral neuropathy. Using animal 
models, several studies have suggested that diabetic peripheral neuropathy 
(DPN) can be attributed to demyelination (removal of the protective sheath 
covering the axons, which communicate electrical action potentials between 
adjacent neurons) of neurons and axonal atrophy, although the association 
between these clinical signs and excess blood glucose has not yet been 
identified (Dyck and Giannini, 1996; Thomas, 1999). Additionally, patients with 
advanced DPN show evidence of axonal and glial degeneration, which supports 
the evidence in animal models (Britland et al. 1990). This could be due to an 
accumulation of injuries at various regions of an axon, resulting in impaired 
axonal protein transport and inefficient transfer of the action potential to its 
intended neuron (Thomas, 1999). Similarly, axonal injury may impair protein 
synthesis, in particular synthesis of neurotrophic proteins required to facilitate 
neuron survival and development. This would therefore contribute to reduced 
regeneration and recovery from damage (Zochodne, 1996). Further research is 
required to elucidate the molecular impact of excess blood glucose on the 
development and progression of DPN and myelin regeneration.  
1.5.3.3 Chemotherapy-induced peripheral neuropathy 
Peripheral neuropathy is a well-recognised toxicity of chemotherapy 
regimens using certain drugs, such as oxaliplatin, paclitaxel and bortezomib. 
Platinum drugs including cisplatin exert their cytotoxic effects via the formation 
of platinum-DNA lesions. It is believed that excess platinum molecules 
accumulate within the dorsal root ganglia (DRG), resulting in peripheral 
neuropathy as the primary associated toxicity (Dzagnidze et al. 2007; Ta et al. 
2006).  
Taxane drugs such as paclitaxel and docetexel for the treatment of 
breast cancer also cause peripheral neuropathy, primarily in the form of minor 
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or moderate axonal sensory polyneuropathy (Osmani et al. 2012). Taxane 
drugs promote microtubule formation within the cytoplasm of affected cells, 
which interferes with normal cell physiology and inhibits cell proliferation 
(Scripture et al. 2006). Microtubules perform vital maintenance and 
developmental functions for neurons; microtubule elongation facilitates the 
growth of precursor neurite cells during neuron development (Kobayashi and 
Mundel, 1998). Additionally, microtubules mediate axonal transport of proteins 
and provide structural support to the neuron as a whole (Osmani et al. 2012). In 
vitro studies and studies using animal models involving injection of the drug into 
the sciatic nerve demonstrated degeneration of the DRG, demyelination and 
reduced nerve conduction velocities following paclitaxel treatment (Cavaletti et 
al. 1995; Cliffer et al. 1998). Therefore, the ability of taxanes to disrupt 
microtubule assembly suggests that consequent structural and functional 
changes within neuron cells result in peripheral neuropathy as a result of drug 
treatment.  
Additionally, drugs such as bortezomib used in the treatment of multiple 
myeloma have been shown to trigger peripheral neuropathy. This is likely due to 
accumulation of unbound drug in the DRG, coupled with dysregulation of 
neurotrophic proteins in treated individuals, although the exact mechanism 
underlying peripheral neuropathy associated with bortezomib has not yet been 
elucidated (Argyriou et al. 2008).  
1.5.3.4 DNA repair defects and neurological disease 
 The nervous system is particularly sensitive to DNA damaging effects, 
compared with other non-replicating cell types. This is likely due to the brain’s 
ability to metabolise 20% of oxygen consumed by an individual, coupled with a 
lower capacity to neutralise reactive oxygen species (ROS) compared with 
other organ systems. Additionally, neurons are known to be highly susceptible 
to oxidative stress (Barzilai, 2007). The net result is a high oxygen load causing 
free radical generation, which increases DNA damage, in particular, the 
formation of single-stranded breaks (SSB), within mature neurons (Saxowsky 
and Doetsch, 2006; Cleaver, 2005; Ljungman and Lane, 2004). Defects in the 
repair of SSBs are associated with spinocerebellar ataxia with axonal 
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neuropathy (SCAN1) and ataxia with oculomotor apraxia 1 (AOA1). These are 
two neurodegenerative disorders that typically present with similar symptoms, 
including oculomotor apraxia (absence of control of voluntary eye movement), 
severe sensorimotor neuropathy, cognitive impairment and cerebellar atrophy in 
late childhood (Shawan et al. 2006; El-Khamisy and Caldecott, 2007). SCAN1 
and AOA1 are caused by mutations in the tyrosyl-DNA phosphodiesterase-1 
(TDP1) and aprataxin (APTX) genes, respectively. TDP1 repairs 3’ DNA ends 
that have been modified by oxidative damage, whilst APTX possesses AMP-
lysine hydrolase activity that is required for removal of 5’-AMP intermediates 
following unsuccessful DNA ligation (Rass et al. 2007; Ahel et al. 2006; Seidle 
et al. 2005).  
 Deficiencies in double-stranded break (DSB) repair processes also give 
rise to neurological disease; one of the earliest diagnosed DNA repair defects 
associated with neurodegeneration was ataxia-telangiectasia (AT), which 
develops during childhood and is characterised by severe sensitivity to ionising 
radiation and rapid neurodegeneration (Frappart and McKinnon, 2006; 
McKinnon, 2004; Perlman et al. 2003). AT is caused by mutations of the ataxia 
telangiectasia, mutated (ATM) gene, which encodes a protein kinase involved in 
the regulation of the DSB repair pathways (Shiloh, 2003; Helleday et al. 2007). 
The major DSB pathways are non-homologous end-joining (NHEJ) and 
homologous recombination (HR). Although HR is typically error-free, errors 
arise in NHEJ, which is primarily involved in DSB repair in non-replicating cell 
types including those of the nervous system (Lieber et al. 2003). During NHEJ, 
both ends of the DNA strand undergoing repair are modified to enable direct 
ligation by DNA ligase IV (LIG4). Mutations in LIG4 that result in attenuated 
LIG4 activity are associated with LIG4-syndrome, a disorder that presents with 
immunodeficiency, microcephaly and severe radio-sensitivity (Buck et al. 2006).  
 Mutations in several components within the NER pathway result in the 
human disorders XP, TTD and CS (Section 1.5.2). Although these are clinically 
distinct and have different aetiologies, there is overlap between the signs that 
patients present with. XP patients from most complementation groups (A-G) 
present with a range of neurological symptoms, with 30% of all XP patients 
showing signs of neurodegeneration and global brain atrophy (Kraemar et al. 
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2007; Mimaki et al. 1986). Additionally sensorineural hearing loss and 
progressive peripheral neuropathy develops in the second decade of disease 
(Anttinen et al. 2008; Robbins et al. 2002). Similarly, patients with CS show 
signs of progressive and severe neuropathology, including demyelination and 
calcification of the basal ganglia, although this is absent from XP (Brooks et al. 
2008; Itoh et al. 1999). TTD demonstrates similar neurological symptoms to CS, 
including demyelination and motor dysfunction (Brooks et al. 2008; Nance and 
Berry, 1992).  
 A number of other human disorders are caused by defects in DNA repair 
genes, including Fanconi anaemia (FA), Bloom syndrome (BLM), Werner 
syndrome (WS) and Rothmund Thomson syndrome (RTS). FA arises due to 
disruption of any one of many DNA repair proteins needed for removal of DNA 
crosslinks, including BRCA1 and its interaction partner, partner and localiser of 
BRCA1 (PALB1). Currently there are twelve known complementation groups of 
FA, many of which present with microcephaly and cognitive impairment, in 
addition to several non-neurological symptoms (Reid et al. 2007; Mirchandani 
and D’Andrea, 2006; D’Andrea and Grompe, 2003). Alternatively, BLM, WS and 
RTS are all associated with defects in the RecQ like helicase 4 (RECQ4) 
function (Hunter, 2008; Hickson, 2003; Harrigan and Bohr, 2003; Van Brabant 
et al. 2000). The RECQ4 helicase functions to unwind double-stranded DNA to 
facilitate repair of lesions on either strand (Sangrithi et al. 2005). Despite this 
essential role in DNA repair processes, the resulting neuropathology of these 
three syndromes has not been thoroughly characterised and remains poorly 
understood (McKinnon, 2009).  
1.6 Models of functional analysis  
 Model organisms have played a significant role in the history of research 
in the field of human genetic disease, both in terms of identifying causal genes 
and characterising normal and abnormal gene functions (Hedges, 2002). This 
has been particular important for drug discovery and development for targeting 
specific protein biomarkers (Rual et al. 2005). However, the emergence of high 
throughput technologies such as GWAS and genome sequencing has 
revolutionised this field, making discovery of disease genes in humans far 
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simpler and more accessible. Additionally, the genetic architecture identified via 
sequencing technologies is often complex, therefore making it challenging to 
replicate this variation using model organisms other than human cell lines 
(Aitman et al. 2011). This has led to the question of whether functional assays 
will be applicable to future avenues of human genetic research, owing to the 
limitations of certain organisms to replicate human cell physiology (Green et al. 
2011). A number of model organisms exist for investigation of genetic variants 
and their respective protein function, with different advantages and limitations 
(Table 1.9).  
1.7 Next generation sequencing (NGS)  
 Advances in next generation sequencing (NGS) in recent years have 
transformed our understanding of genomics, which can influence approaches to 
diagnosis and treatment in the clinic. Use of NGS in research has led to the 
identification of multiple causal alleles in different diseases, which would not 
have been possible using earlier technology (Schweiger et al. 2011; Table 
1.10). NGS employs the use of massively parallel sequencing to amplify and 
sequence the genome accurately and at a reasonable cost; sequencing of the 
first human genome on an NGS platform was considerably cheaper than 
preceding platforms (Sboner et al. 2011). 
1.7.1 General workflow 
 NGS protocols consist of three stages: initial sample preparation, 
massively parallel sequencing and imaging of sequence data, and data 
analysis. Several NGS platforms exist, each with their own variations in 
amplification methods and applications, and different advantages and 
disadvantages.  
 Approximately 85% of disease-causing variants are located within 
protein-encoding regions of genes, yet only 1% of an entire genome makes up 
the exome (Botstein and Risch, 2003). This, coupled with the considerably 
reduced cost of whole exome sequencing (WES) in comparison to whole 
genome sequencing (WGS), makes WES a promising alternative for identifying 
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Model (Species) Analysis Advantages Disadvantages Protein function assays 
Mammalian cell 
lines 
In vitro Representative of a multicellular organism; well-
studied; efficient recognition of signals for 
synthesis and secretion of proteins; relatively 
easy to genetically manipulate (although variation 
between cell lines/species) 
Expensive to culture over long periods; 
considerable variation in transfection rates; diploid 
genome which can it difficult to study effects of 
heterozygous mutations; some differences in 
pathways depending on species the cell line was 
isolated from 
Transfection of plasmids 
containing gene of interest 
with fluorescent tag, 
immunofluorescence, flow 
cytometry, ELISA, 
colorimetric assays, etc. 
Fission yeast 
(Schizo-
saccharomyces 
pombe; S. pombe)  
In vitro Easy to genetically manipulate; well-annotated 
genome; haploid organism which makes it useful 
for studying effects of recessive mutations; 
excises mammalian introns (unlike S. cerevisiae)  
Not a mammal; not representative of a multicellular 
organism; some differences in pathways compared 
with humans; additional pathway for repair of UV 
light 
Similar to mammalian cell 
line assays 
Budding yeast 
(Saccharomyces 
cerevisiae; S. 
cerevisiae) 
In vitro Easy to genetically manipulate; well-annotated 
genome; haploid organism which makes it useful 
for studying effects of recessive mutations; 
Not a mammal; not representative of a multicellular 
organism; some differences in pathways compared 
with humans 
Similar to mammalian cell 
line assays  
Bacteria 
(Escherichia coli; E. 
coli) 
In vitro Easy to genetically manipulate; cheap; well-
annotated genome 
Prokaryote; large differences in pathways 
compared with humans; not representative of a 
multicellular organism 
Transformation; 
transfection of plasmids 
with gene of interest; 
microarrays etc.  
Mice (Mus 
muscularis)  
In vivo Mammal; well-annotated genome; easy to 
genetically manipulate; high proportion of 
genome (>80%) is homologous with human 
genome 
Some differences in pathways compared with 
humans 
Similar to mammalian cell 
line assays; tissues 
isolated from animal after 
killing and processed for 
assay 
Fruit fly (Drosophila 
melanogaster) 
In vivo Well-annotated genome; easy and cheap for 
laboratory use; representative of a multicellular 
organism 
Not a mammal; some differences in pathways 
compared with humans 
Primarily behavioural 
assays; high throughput 
alternatives available 
Systems biology 
model  
 
In silico High-throughput nature; utilises DNA/RNA 
isolated from humans, allowing easy comparison 
of ‘control’ and ‘disease’ phenotypes; rapid 
Expensive to run depending on assay and platform 
used; expensive start-up costs for NGS/genome-
wide sequencing 
qPCR; genome-wide 
sequencing; NGS; ChIP-
chip; ChIP-seq, etc.   
Table 1.9 Summary of models used to assess protein or cell function after genetic manipulation. Model organisms used for assessment of cell 
function are listed with their respective advantages, limitations and potential assays.  
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Discovery using NGS technology Reference 
First genome sequenced by NGS Wheeler et al. 2008 
First cancer genome sequenced using WGS in a patient with 
acute myeloid leukaemia 
Ley et al. 2008 
Variants in IDH1 associated with glioblastoma multiforme 
(GBM) in younger patients; secondary somatic variants in the 
gene associated with increased overall survival 
Parsons et al. 2008 
First twelve human exomes sequenced using targeted capture 
sequencing technology; demonstrated a use for WES in 
identifying Mendelian disorders by investigating four individuals 
with Freeman-Sheldon syndrome (OMIM #193700) 
Ng et al. 2009 
WES used to identify somatic mutations in the intracellular 
kinase domain of bone morphogenetic protein receptor 1A 
(BMPR1A) gene associated with microsatellite-stable and -
instable colon cancers 
Timmermann et al. 
2010 
Inherited mutations in 21 genes including BRCA1 and BRCA2 
associated with predisposition to breast and ovarian cancers; 
associations confirmed via WGS  
Walsh et al. 2010 
Variants in POLD1 and POLE (OMIM #615083, #612591, 
respectively) associated with increased predisposition to 
numerous CRA and CRCs, identified via WES and linkage data  
Palles et al. 2013 
ERCC4 identified as a candidate gene for Fanconi anaemia 
(FA; OMIM #615272) in a single patient.  
Bogliolo et al. 2013 
NGS technology used to identify pathways and driver mutations 
implicated in oesophageal adenocarcinoma development 
Dulak et al. 2013 
Targeted NGS technology used to identify somatic mutations in 
BRAF, RAS, PIK3CA, PTEN, GNAS, CTNNB1 and RET 
associated with papillary and anaplastic thyroid carcinomas 
Nikiforova et al. 
2013 
NGS technology used to screen for mutational ‘hotspots’ in 46 
cancer-related genes; clinical validation performed to 
demonstrate the ease by which these genes could be routinely 
tested for at the point of diagnosis 
Singh et al. 2013 
 
Table 1.10 Summary of discoveries using NGS technology in recent years. 
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variants associated with a specific phenotype. During sample preparation for 
WES, an additional ‘target capture’ step is carried out to ensure only protein 
coding regions of DNA are selected. DNA is sheered to produce small 
fragments, followed by adapter ligation to fragment flanking regions and 
hybridisation assays to isolate coding sequences of DNA (Pruitt et al. 2009). 
Enrichment of DNA fragments is carried out using either microarray-based or 
solution-based assays (Albert et al. 2007; Porreca et al. 2007). 
 Massively parallel sequencing involves coupling of DNA synthesis and 
detection stages, followed by simultaneous sequencing of multiple reactions; for 
most NGS platforms the most common cause of sequencing errors and short 
reads is desynchronisation of reads during the sequencing and detection cycle 
(McNally et al. 2012). Following generation of sequencing reads, quality control 
is performed to remove errors that occur during sequencing. Reads are then 
aligned with a reference sequence using one of several available mapping 
algorithms; selection of the most appropriate mapping tool will depend on the 
sequencing platform used and the downstream applications required (Bao et al. 
2011; Ku et al. 2012). Annotation of variants can be aided by multiple available 
tools (McKenna et al. 2010; Wang et al. 2010; Yandell et al. 2011). 
1.8 Strategies for gene discovery  
NGS yields vast amounts of genomic data that is hugely challenging to 
sift through to identify disease-causing variants; approximately 20-50,000 
variants are identified in a single human exome (Gilissen et al. 2012). This 
number increases significantly when variation in the whole genome is included. 
Therefore, strategies are required to aid the identification of disease-causing 
alleles (Cooper and Shendure, 2011).  
1.8.1 Candidate gene and pathway analysis 
The vast majority of known Mendelian disease-causing mutations are 
located in protein coding regions; however, approximately 90% of coding 
variants are known polymorphisms (Robinson et al. 2011), suggesting that they 
are unlikely to contribute to disease. Until recent advances in NGS technology, 
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the traditional method of disease gene identification involved candidate pathway 
or gene analyses; this involved selection of genes associated with other 
diseases or where the predicted protein function was relevant to the disease 
physiology. Alternatively, a positional mapping approach such as karyotyping, 
linkage analysis or homozygosity mapping may have highlighted genes in 
specific genomic regions (Botstein and Risch, 2003; Kerem et al. 1989; Lander 
et al. 1987). Several limitations of the candidate approach exist, including 
difficulties in using genetic mapping technologies to predict whether a disease is 
caused by structural genetic variation or a single SNP. Additionally, these 
mapping approaches rarely reduce the number of candidate genes sufficiently 
to allow validation by Sanger sequencing, particularly when the disease locus is 
large (Tabor et al. 2002). Candidate approaches also cannot be used for rare 
genetic conditions caused by sporadic mutations, since neither a genetic 
mapping nor family-based data approach can be used (Gilissen et al. 2012). 
1.8.2 ‘No prior hypothesis’ approach  
Manipulation of NGS data using an approach with no prior hypothesis 
allows for selection of novel or rare variants that most likely would not be 
detected via a candidate gene or pathway approach. According to the ‘common 
disease, rare variant’ hypothesis (Section 1.2.2.3), rare variants could 
dramatically affect overall risk (Maniolo et al. 2009). However, rare variants are 
rarely included on large-scale genotyping arrays used for GWAS. Additionally, 
the low frequency of such variants means that often GWAS are not powerful 
enough to detect linkage with this variation (Wray et al. 2011), making NGS a 
more useful tool for rare causal variant discovery. Novelty and rarity status can 
be assessed using online databases, including dbSNP (NCBI Resource 
Coordinators, 2013), the 1000 Genome Project (1000 Genomes Project 
Consortium et al. 2010) and Ensembl (Flicek et al. 2013). Filtering for novelty 
status enables reduction of data output whilst maintaining sufficient power to 
detect causal variants (Mwenifumbo and Marra, 2013).  
An alternative filtering strategy is to investigate the likelihood of a 
variant’s effect on protein function, since it is often assumed that synonymous 
variants are unlikely to influence pathogenesis (Gilissen et al. 2012). Typically 
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missense variants including SNPs and indels are considered for analysis. Indels 
are the second most common form of genomic variant and the most common 
form of structural variant (Mullaney et al. 2010), accounting for approximately 
1.6 million collective indel polymorphisms within the human population (Mills et 
al. 2006). The presence of indels can cause disease when they adversely affect 
either amino acid coding sequences or regulatory functions of non-coding 
sequences (Barcena et al. 2014; Schutte et al. 2003; Zhang et al. 2014).  
Additional filtering strategies may be applied, depending on the nature of 
the disease in question. For instance, where a monogenic inherited disorder is 
being investigated, a linkage strategy may be employed whereby DNA from 
multiple affected family members is sequenced to identify common variation 
(Genin et al. 2008). Alternatively, in cases where a single patient is available 
without DNA from parents, and where the disease is suspected to be recessive 
in nature, a ‘double-hit’ strategy may be used. This involves exome sequencing 
of the patient’s DNA to identify homozygous or compound heterozygous 
variants, as private variants of this nature exist in relatively low abundance in 
unaffected individuals (Oetting, 2012). Investigation of highly heterogeneous 
disease is more complex, with a low likelihood of identifying mutations in the 
same gene in two affected individuals. For de novo variant identification, most 
commonly a family-based exome sequencing approach is required, whereby de 
novo candidate mutations can be targeted by filtering out all inherited variants 
present in the parents’ exomes. This results in a small yield of potentially 
pathogenic variants, since the average exome contains only 0-4 de novo 
variants (Vissers et al. 2010; Roach et al. 2010; Durbin et al. 2010). Multiple 
additional filtering strategies exist for sifting through vast amounts of NGS data 
with different criteria depending on the nature of the disease under investigation 
(Gilissen et al. 2012).  
1.9 Background to this project 
1.9.1 MRC COIN trial 
The Medical Research Council (MRC) COIN trial was a randomised trial 
investigating patient outcome with first-line oxaliplatin and fluoropyrimidine 
chemotherapy in 2,445 patients with advanced CRC. Participants were 
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randomly assigned to continuous oxaliplatin and fluoropyrimidine chemotherapy 
(Arm A), the same combination with the addition of cetuximab (Arm B), or 
intermittent chemotherapy (Arm C) (Maughan et al. 2011). The aim of the trial 
was to investigate response to therapy, survival and toxicity outcomes in 
patients with aCRC.   
The trial revealed excess toxicity in the oxaliplatin-, CPB-, cetuximab-
treated patients compared with continuous chemotherapy alone. This led to the 
conclusion that a CPB dose adjustment would be required to maintain safe 
toxicity levels during use of this regimen (Adams et al. 2009). Comparison of 
intermittent and continuous oxaliplatin-based chemotherapy plus cetuximab 
revealed comparable survival statistics with improved toxicity in patients 
undergoing intermittent therapy, suggesting that intermittent cetuximab-based 
chemotherapy could be promising for palliative care (Wasan et al. 2014).  
With regard to survival, the trial was unable to confirm whether addition 
of cetuximab to oxaliplatin-based chemotherapy was beneficial in terms of PFS 
or overall survival. Interestingly, response to chemotherapy was strongly 
correlated with somatic mutant KRAS or BRAF status, irrespective of treatment. 
Cetuximab increased response rate from 57% to 64%; however, this was 
coupled with increased severity of GI and skin-related toxicity, suggesting that 
addition of cetuximab for treatment of aCRC could not be recommended 
(Maughan et al. 2011). 
1.9.2 Patient selection 
The sequencing studies and sequencing data analysis outlined in 
sections 1.9.2 – 1.9.6 were organised and performed by Dr Hannah West. 
Where appropriate, data from experiments that were outsourced or performed 
by other staff are referenced in the relevant sections. Full details of this 
research, including outsourced data analyses, are outlined in Dr West’s PhD 
thesis (West, 2013).  
PNAO grade 3 or greater was recorded in 23% and 16% of patients 
undergoing fluorouracil-based and capecitabine-based regimens throughout the 
duration of the trial, respectively (Maughan et al. 2011). From commencement 
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of treatment, an assessment of PNAO was performed every six weeks by a 
consultant and clinical nurse using the Common Terminology Criteria for 
Adverse Effects v3.0 (CTCAE; Wasif Saif and Reardon, 2005). Patients with 
recorded PNAO grade 3 or greater carried out a Quality of life questionnaire 
(QLQ C30), which provided supporting evidence of severe PNAO. Following 
review of COIN toxicity data, a panel of ten patients with severe and dose 
limiting PNAO, requiring withdrawal from therapy within the first seven weeks, 
were selected for exome resequencing and analysis.  
Exome resequencing, read alignment and variant calling was carried out 
by Dr James Colley. Library fragments of exomic DNA from the 10 patients with 
severe PNAO were prepared using the Roche Nimblegen SeqCap EZ Exome 
Library v2.0 solution-based method. Massively parallel sequencing was carried 
out using the Illumina Genome Analyser at the University of North Carolina. 
Fastq files were resolved by a sequence analysis pipeline using the Burrows-
Wheeler Alignment (BWA) tool (Li and Durbin, 2009) for sequence alignment. 
Modules from the Broad Institute’s Genome analysis Toolkit (GATK) (McKenna 
et al. 2010) were used to ensure recalibration of quality scores and generation 
of GC metrics. Additionally, GATK modules were used to refine alignments 
around potential insertions and deletions (indels), remove duplicate reads, call 
indel and SNP genotypes and apply quality filters to the genotype calls. SNP 
calls were annotated using the ANNOVAR analysis package (Wang et al. 
2010).  
1.9.3 Exclusion of known neuropathies  
Exclusion of known neuropathies in the ten patients selected for exome 
resequencing was performed at Bristol Genetics Laboratory, using multiplex 
ligation-dependent probe amplification (MLPA) of PMP22, which encodes a 
peripheral nervous system protein called peripheral myelin protein 22, and all 
other genes associated with rare inherited neuropathies. No stop gain or 
truncating indel mutations were detected in any of these genes in the ten 
patients with PNAO. Several nonsynonymous variants were detected in 
IGHMBP2, which encodes DNA-binding protein SMUBP-2 helicase, although 
these were recorded in dbSNP at comparable frequencies, suggesting they are 
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benign polymorphisms. Therefore, all known neuropathies were excluded from 
the ten patients selected for exome resequencing (West, 2013).  
1.9.4 ERCC4 and Patient 8 
A novel stop gain (S613X) mutation in ERCC4 was identified in one 
patient with severe PNAO, which required withdrawal from treatment within 
seven weeks of commencement. This patient was a 79 year old female who 
was diagnosed with metastatic CRC in March 2006 after an ultrasound scan on 
her liver. The patient’s medical records showed no indication of xeroderma 
pigmentosum (XP). The second ERCC4 allele was assayed for biallelic 
mutation by Sanger sequencing using amplified sequences of the entire open 
reading frame (ORF) and flanking regions of ERCC4, which revealed no other 
coding variants. This indicated that the patient did not carry a second mutant 
allele (West, 2013). 
1.9.5 Variants identified in ERCC4 
Following identification of the novel stop gain in ERCC4 (patient 8), this 
gene was sequenced for other protein-coding variants in a panel of patients 
(n=63) with PNAO; 54 of these patients had severe and dose limiting PNAO, 
which meant they were withdrawn from treatment within the first twelve weeks, 
and 9 patients were withdrawn from therapy within seven weeks. DNA from one 
patient failed sequencing.  
Screening of the entire ORF, flanking regions and 5’UTR of ERCC4 in 
this panel identified five nonsynonymous variants in patients with PNAO. 
Pro379Ser was present in 3 patients (MAF=4.69%) and was previously 
documented in dbSNP (rs1799802); Arg576Thr in a single patient and in 
dbSNP (rs1800068); Glu875Gly in 4 patients (MAF=6.25%) and in dbSNP 
(rs1800124); Arg415Gln in 9 patients (MAF=14.1%) and in dbSNP (rs1800067) 
and His466Gln in a single patient and not in dbSNP (Table 1.11).  
All variants were assessed for their impact on protein function in Align-
GVGD, which revealed that Pro379Ser, Arg576Thr and Glu875Gly were likely 
to affect function, whereas Arg415Gln and His466Gln were predicted to have 
little or no effect on protein function. All non-synonymous variants were 
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sequenced in patients without PNAO and their incidences and minor allele 
frequencies were analysed statistically, with respect to their Align-GVGD score. 
Combined analysis of two variants (Pro379Ser and Glu875Gly) revealed that 
they were present in a significantly higher proportion of patients with PNAO than 
those without (p=0.037). This suggested that, while individually rare and 
predicted to be functionally damaging, they contribute to PNAO only when 
analysed collectively (Table 1.11). The Arg576Thr private variant was also 
predicted to interfere with protein function during in silico analysis, but could not 
be incorporated into the combined analysis of functional variants because it was 
only present in one patient (West, 2013).  
1.9.6 Selected variants for functional analysis 
Clustal Omega was used to carry out alignment of all mammalian 
sequences available on NCBI, which identified a high level of conservation of 
XPF across several species (West, 2013). This revealed conservation in all 
species (n=34) analysed for Pro379, Arg576, Glu875, Arg415 and Ser613. 
However, His466 was not well conserved. Since Pro379, Arg576 and Glu875 
were considered most likely to alter protein function and were well conserved in 
mammalian species, we therefore selected these variants for functional 
analyses in vitro (Table 1.11).  
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Variant 
 
rs number 
Frequency in patients (%)  
P + PNAO - PNAO 
Predicted 
to affect 
function 
Pro379Ser rs1799802 3/63 (4.76%) 27/1,763 (1.53%) 0.08 
Arg576Thr rs1800068 1/63 (1.59%) 4/1,763 (0.22%) 0.16 
Ser613X Novel 1/63 (1.59%) -  
Glu875Gly rs1800124 4/63 (6.35%) 60/1,763 (3.41%) 0.28 
Total (No. 
private 
variants) 
 7/63 
(11.11%) 
86/1,763 (4.88%) 0.03 
Less 
likely to 
affect 
function 
Arg415Gln rs1800067 9/63 (14.1%) 260/1,754 
(14.8%) 
0.91 
His466Gln Novel 1/63 (1.59%) 0/1,677 (0%) 0.04 
 
Table 1.11 Incidence and minor allele frequencies (MAF) of nonsynonymous and stop 
gain variants found in ERCC4 in germline DNA from patients with and without PNAO, 
analysed with respect to their likelihood of affecting function. Variants identified in more 
than one PNAO patient (shown in bold) were analysed using a combined analysis 
(total). The private variant in Arg576Thr was not included in the combined analysis due 
to its potential to skew the data, and Ser613X was not included since it was assayed 
for only in samples from patients with PNAO (West, 2013). Values in the total column 
represent the number of patients genotyped with respective p values (P). 
 
 
 
  
65 
 
 
 
1.10 Aims of this thesis 
 
1. To investigate the functional consequences of three variants in ERCC4 
associated with PNAO to provide evidence of a causal relationship, by 
studying their effects on: 
(i) Viability, assayed by Trypan blue exclusion (Chapter 3) 
(ii) Localisation of ERCC1-XPF, assayed by immunofluorescence 
(Chapter 4) 
(iii) Localisation of Rad16 in Schizosaccharomyces pombe, assayed by 
immunofluorescence (Chapter 4) 
(iv) Rate of DNA repair, assayed by ELISA (Chapter 5)  
 
2. To identify candidate genes that may cause PNAO for future sequencing 
studies (Chapter 6)  
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Chapter Two – Materials and Methods 
2.1 List of suppliers 
Materials and equipment were purchased from the following companies: 
Abcam (Cambridge UK) 
ABgene Ltd (Surrey, UK) 
Agilent Technologies (California, USA) 
Amersham Life Science (See GE Healthcare) 
Anachem Ltd (Bedfordshire, UK)  
Applied Biosystems (Cheshire, UK) 
BD Biosciences (New Jersey, USA) 
Beijing Genomics Institute (BGI; Shenzhen, China) 
Bibby Sterilin (see Thermo Fisher Scientific) 
Bioquell UK Ltd (Hampshire, UK)  
Bioquote (York, UK) 
Biorad (Hertfordshire, UK) 
Biotium (California, USA) 
Cambridge Biosciences (Cambridge, UK) 
Core Life Sciences (California, USA)  
Corning Incorporated (Flintshire, UK) 
DJB Labcare (Buckinghamshire, UK)  
Eurogentec (Hampshire, UK) 
Fisher Scientific (Leicestershire, UK) 
Formedium (Norfolk, UK) 
GE Healthcare (Buckinghamshire, UK) 
Helena Biosciences (Tyne & Wear, UK) 
Illumina (California, USA)  
Invitrogen/Life Technologies (Strathclyde, UK) 
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Jencon (West Sussex, UK) 
KBiosciences (Teddington, UK) 
Labtech International (Florida, USA) 
Leica Microsystems (Wetzlar, Germany) 
The Linde Group (Munich, Germany) 
Marienfield (Lauda-Konigshofen, Germany) 
Measuring and Scientific Equipment (London, UK)  
MJ Research (Massachusetts, USA) 
New England Biolabs (Hertfordshire, UK) 
Public Health England – HPA Culture Collection (Wiltshire, UK) 
Qiagen (West Sussex, UK) 
R&D Systems (Oxford, UK) 
Roche (West Sussex, UK) 
Sigma-Aldrich Ltd (Dorset, UK) 
Tecan (Reading, UK) 
Thermo Fisher Scientific (Massachusetts, USA) 
VWR International (Leicestershire, UK) 
  
2.2 Materials 
2.2.1 Chemicals  
Analytical grade chemicals were purchased from Sigma-Aldrich Ltd or 
Fisher Scientific unless otherwise mentioned. 
2.2.2 Mammalian tissue culture and reagents 
All mammalian cell lines were purchased from Public Health 
England/HPA Culture Collection.  
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 2.2.2.1 Cell culture  
 RPMI 1640 culture media supplemented with L-glutamine was purchased 
from VWR International. This was supplemented with foetal bovine serum (FBS) 
and penicillin/streptomycin purchased from Invitrogen/Life Technologies. 
Dimethyl sulfoxide (DMSO) for long-term storage was purchased from Sigma 
Aldrich.   
2.2.2.2 Measurement of cell viability 
Trypan blue for viability measurement was purchased from VWR 
International.  
2.2.2.3 Antibodies for immunofluorescence 
A primary rabbit polyclonal anti-ERCC1 antibody was purchased from 
Insight Biotechnology and a primary mouse monoclonal anti-XPF (3F2/3) 
antibody was purchased from Abcam. A secondary goat anti-rabbit Alexa 488 
antibody and a secondary donkey anti-mouse Alexa 546 antibody were both 
purchased from Life Technologies.  
An additional primary goat polyclonal XPF (M-16) antibody was 
purchased from Santa Cruz Biotechnology and an additional secondary donkey 
anti-goat Alexa 546 antibody was purchased from Life Technologies for the 
immunofluorescence assay with oxaliplatin treatment.  
2.2.2.4 Reagents for immunofluorescence  
 The following reagents were all purchased from Sigma Aldrich: 
Paraformaldehyde, Triton X-100, Bovine serum albumin (BSA), DAPI nuclear 
stain, Mowiol-488 and 1,4-diazabicyclo[2.2.2]octane (DABCO). Phosphate 
buffered saline (PBS) without magnesium and calcium was purchased from Life 
Technologies.  
2.2.2.5 Extraction of mammalian cell line genomic DNA  
The QIAmp DNA mini kit for genomic DNA extraction was purchased 
from Qiagen.  
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2.2.2.6 Fluorescence-activated cell sorting (FACS)  
FACS was carried out by Catherine Naseriyan in Central Biotechnology 
Services (CBS). Propidium iodide stain for permeation of non-viable cells was 
purchased from Sigma Aldrich. All other buffers were provided by CBS.  
2.2.2.7 Enzyme-linked immunosorbent assay (ELISA) 
The OxiSelect DNA Damage ELISA for detection of cyclobutane 
pyrimidine dimers (CPDs) was purchased from Cambridge Biosciences. A rat 
anti-cisplatin modified DNA antibody and a rabbit polyclonal anti-rat HRP-
conjugated secondary antibody were both purchased from Abcam.  
2.2.3 Schizosaccharomyces pombe (S. pombe) culture and reagents 
All solutions were made up using dH2O water and sterilised by 
autoclaving on the liquid cycle at 15Ib/sq.in at 121°C for 20 minutes.  
2.2.3.1 Yeast strains 
All S. pombe strains were kindly constructed and provided by Oliver 
Fleck (Bangor University).  
2.2.3.2 Yeast extract liquid (YEL) and Yeast extract agar (YEA) 
 To make YEL, 0.5% w/v yeast extract and 3% w/v glucose were made up 
to 1L in dH2O. This was supplemented with 100mg/L of adenine, histidine, 
uracil, lysine and arginine (Formedium). To make YEA, 1.6% w/v Bacto agar 
was added to YEL.  
2.2.3.3 Glycerol for long-term storage  
Glycerol was purchased from Applied Biosystems. A solution of 50% 
glycerol for long term storage of S. pombe cultures was made by diluting 100ml 
of 100% glycerol with 100ml dH2O.  
2.2.3.4 Antibodies for immunofluorescence 
A primary rat monoclonal anti-cisplatin modified DNA antibody was 
purchased from Abcam, which recognises the same epitope as that formed by 
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oxaliplatin adducts. A secondary goat anti-rat Alexa 488 antibody was 
purchased from Life Technologies.  
2.2.3.5 Reagents for immunofluorescence 
The following reagents were all purchased from Sigma Aldrich: 1,4-
Piperazinediethanesulfonic acid (PIPES), Ethylene-
bis(oxyethylenenitrilo)tetraacetic acid (EGTA), magnesium sulphate (MgSO4), 
sorbitol, Triton X-100, BSA and gelatin. PBS without magnesium and calcium 
was purchased from Life Technologies. Lysine was purchased from 
Formedium. 
2.2.4 Drugs for mammalian cell line and S. pombe treatment 
Oxaliplatin was purchased from R&D Systems and dissolved in H2O.  
2.2.5 Clinical material 
All blood samples from COIN (MRC Clinical Trials Unit [CTU] No. CR10) 
and COIN-B trial patients were obtained with patient consent and ethical 
approval for bowel cancer research.  
2.2.6 Polymerase chain reaction (PCR) 
AmpliTaq Gold DNA polymerase with appropriate buffer and MgCl2 were 
purchased from Applied Biosystems. Deoxyribonucleotide triphosphates 
(dNTPs) were purchased from GE Healthcare. All primers were purchased from 
Eurogentec. Dimethyl sulfoxide (DMSO) was purchased from Sigma Aldrich.  
2.2.7 PCR purification 
Exonuclease I (Exo) was purchased from New England Biolabs. Shrimp 
alkaline phosphatase (SAP) was purchased from GE Healthcare.  
2.2.8 Electrophoresis 
Agarose was purchased from Eurogentec. GelRed was supplied by 
Biotium. 100bp DNA ladder and 1kb Plus DNA ladder were purchased from 
New England Biolabs and Life Technologies, respectively.  
 
  
71 
2.2.9 Sanger sequencing 
BigDye Terminator cycle sequencing kit version 3.1 and POP6 polymer 
were purchased from Applied Biosystems. Capillary electrophoresis buffers 
were purchased from Sigma Aldrich.  
2.2.10 Sanger sequencing clean up 
Isopropanol was purchased from Fisher Scientific and HiDi formamide 
was purchased from Applied Biosystems.  
2.3 Equipment 
2.3.1 Plastics and glassware  
 Sterile pipette tips and tips for multi-channel pipettes were purchased 
from Anachem. Sterile stripettes were purchased from Corning Incorporated. 
Plastic Eppendorf tubes (0.65ml and 2ml) were purchased from Bioquote, 
whereas 1.5ml Eppendorf tubes were purchased from Sigma Aldrich. Sterile 
universal tubes were purchased from Bibby Sterilin. Thermo-Fast PCR reaction 
plates were supplied by Fisher Scientific, whilst 4titude adhesive PCR sealing 
sheets and 0.2ml plastic strip tubes were supplied by ABgene. Sterile falcons 
(15ml and 50ml) were purchased from Fisher Scientific. Sterile tissue culture 
flasks were purchased from Helena Biosciences. Sterile six-well multidishes 
were purchased from Fisher Scientific. Sterile 150mm dishes and 100mm 
dishes were purchased from Sigma Aldrich. Sterile cryovial tubes were supplied 
by Corning Inc. Glass flasks and beakers were supplied by Jencon or Fisher 
Scientific.  
2.3.2 Mammalian tissue culture 
Cell lines were cultured in a Microflow Peroxide Class II advanced 
biological safety cabinet (Bioquell Ltd). Flasks were incubated in a Heraeus 
HERAcell 150 incubator (DJB Labcare) connected to a CO2 cylinder (The Linde 
Group). 
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2.3.2.1 UV treatments  
Mammalian cells were treated with UV light using a UV-C lamp 
(Amersham Life Science) during optimisation and with a stratalinker (Amersham 
Life Science) during data acquisition.  
2.3.2.2 Calculating percentage viability of cells 
For measurement of cell viability, cells were counted using a 
haemocytometer (Marienfield). Viable cells were transparent upon viewing 
through a light microscope, whereas non-viable cells were stained blue.  
2.3.2.3 Immunofluorescence 
Microscope slides, Shandon filter cards and Shandon Cytofunnels were 
supplied by Fisher Scientific. Cytospinning was carried out using a Shandon 
Cytospin 4.0 cytocentrifuge (Thermo Scientific). Cells were visualised using a 
Leica SP5 confocal laser scanning microscope (Leica; Central Biotechnology 
Services).  
2.3.2.4 Preparation of cells for FACS  
For increasing cell density, cell lines were centrifuged using a Centurion 
Scientific C2000 bench top centrifuge (Core Life Sciences). Cells were sorted 
according to viability using a FACS Aria III (BD Biosciences).   
2.3.2.5 Extraction of genomic DNA from cell lines 
For extraction of DNA from cell lines, samples were centrifuged using a 
Micro Centaur Compact centrifuge (Measuring and Scientific Equipment). 
2.3.2.6 Quantification of nucleic acids 
For measurement of DNA concentration, a UV spectrophotometer 
(NanoDrop ND-800, Labtech International) with appropriate buffers was used.   
2.3.2.7 Quantification of ELISA absorbance 
 Absorbance of ELISA plates was quantified using a standard microplate 
reader (Tecan) at 450nm, with a reference wavelength of 620nm.  
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2.3.3 Thermocycling 
Thermocycling for PCR was carried out using an MJ Research DNA 
engine tetrad PTC-225.  
2.3.4 Electrophoresis 
Electrophoresis was carried out in an ABgene AB0708 100V gel tank 
attached to a BioRad 200/2.0 power pack. Visualisation of GelRed stained gels 
was carried out using a BioRad GelDoc XR transluminator.  
2.3.5 Sanger sequencing 
Sanger sequencing was achieved using an ABI 3100 Genetic Analyser 
(Applied Biosystems). All data was analysed using Sequencher v.5.3. 
Reference sequences were obtained from online databases including NCBI 
(http://www.ncbi.nlm.nih.gov/gene/) and Ensembl 
(http://www.ensembl.org/index.html).  
2.3.6 Whole exome sequencing 
 Whole exome sequencing was carried out on germline DNA samples 
from 50 COIN and COIN-B patients with advanced CRC. All DNA samples were 
processed at Beijing Genomics Institute (BGI). Thirty exomes were captured 
using a SureSelectAll Exon V2 enrichment kit (Agilent) and sequenced using a 
HiSeq 2000 (Illumina) to a depth of >30x coverage. A further ten exomes were 
captured using a SureSelectAll Exon 50Mb enrichment kit (Agilent) and 
sequenced using a HiSeq 2000 to >50x coverage. The remaining exomes were 
captured using a SeqCap EZ Exome capture kit V2 (Roche Nimblegen) and 
sequenced on a Genome Analyzer IIx (Illumina) to a depth of approximately 30x 
coverage.  
2.4 Imaging, statistical and bioinformatics software 
Images acquired by confocal microscopy were quantified using Leica 
LAS-AF Lite software, which was kindly provided by Dr. Christopher George 
(Cardiff University). Statistical analysis was carried out using SPSS v20.0. 
Microplate absorbance was read using XFluor software (supplied by Tecan).  
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Variant calling was carried out by Marc Naven using a bioinformatics 
pipeline that was established using BWA v.0.5.9 (Li and Durbin, 2009), 
SAMtools v.0.1.18 (Li et al. 2009), GATK v.1.3-145 (McKenna et al. 2010; 
DePristo et al. 2011) and SnpEff v.2.04 (Cingolani et al. 2012). A custom script 
written in Perl was established to analyse pipeline output. All software was run 
using the UNIX command line with default parameters. All bioinformatic analysis 
was carried out on a workstation running the Ubuntu operating system v.11.10. 
2.5 Methods 
2.5.1 General reagents 
10 x TAE buffer: 400mM Tris, 200mM Acetic acid, 10mM EDTA to pH 8.0 
PEM buffer: 100mM PIPES, 1mM EGTA, 1mM MgSO4, pH 6.9 
PEMS buffer: PEM supplemented with 1M sorbitol 
PEMST buffer: PEMS supplemented with 1% Triton X-100 
PEMBALG buffer: PEM pH 6.9 supplemented with 1% BSA, 100mM L-lysine, 
1% BSA and 1% gelatin 
 2.5.2 Genotyping 
Genotyping of Pro379Ser (rs1799802), Arg576Thr (rs1800068) and 
Glu875Gly (rs1800124) in ERCC4 in 480 human EBV-transformed 
lymphoblastoid cell lines was carried out by KBiosciences using their Kaspar 
technology. Genotyping of other known polymorphisms in ERCC4 and other 
NER genes in these cell lines was carried out by Illumina using their 
GoldenGate technology.  
 2.5.3 Mammalian tissue culture techniques 
2.5.3.1 Growth of mammalian cell lines  
Human EBV-transformed lymphoblastoid cell lines were maintained in 
RPMI-1640 with L-glutamine supplemented with 10% foetal bovine serum and 
penicillin/streptomycin and incubated at 37°C with 5.0% CO2.  
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2.5.3.2 Long-term storage of cell lines 
Cell lines were cooled gradually to -80°C in a solution of 90% FBS and 
10% DMSO at a density of 1 x 107 cells/ml for 24 hours, followed by transfer to 
liquid nitrogen for long term storage.  
2.5.3.3 Viability measurements 
Viability was measured by trypan blue exclusion, whereby cell 
suspension was mixed with trypan blue in a 1:1 ratio and examined visually. 
Viable, intact cells appeared clear whereas non-viable cells appeared blue, 
particularly in the cytoplasm. Percentage viability was calculated at each time 
point by calculating the ratio of viable cells to total cell number.  
 2.5.3.4 Immunofluorescence  
 Mammalian cells were cytospun onto glass microscope slides at 1,000 
RPM for four minutes at medium acceleration without prior serum starving 
(approx. 5 x 105 cells per slide). Cells were fixed in 4% paraformaldehyde, 
permeabilised in 0.2% Triton-X100, incubated in sodium borohydride (0.5mg/ml) 
to quench aldehyde groups and blocked in 1% bovine serum albumin (BSA). 
Cells were incubated with primary antibody overnight at 4°C and with secondary 
antibody for 1 hour at room temperature, with three wash steps in PBS in 
between. Cells were incubated with DAPI nuclear stain (0.1mg/ml) for 5 minutes 
at room temperature, prior to mounting microscope slides with Mowiol-488 
containing DABCO for anti-fade. Slide preparation for confocal imaging of 
untreated and oxaliplatin-treated cells was identical, with the exception of 
antibodies used.  
 2.5.3.5 FACS 
Aliquots of cell suspension were centrifuged at 1,200 RPM for five 
minutes and suspended at a density of 1 x 107 cells/ml in normal tissue culture 
media with FBS and antibiotics. Propidium iodide (PI; 50µg/ml) stain was added 
for permeation of non-viable cells, which were removed by FACS using a BD 
Aria III (BD Biosciences) via an 85 micron nozzle, to prevent masking of DNA 
repair due to the presence of non-viable cells. Cells were collected in normal 
tissue culture media containing FBS and antibiotics prior to DNA extraction.  
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 2.5.3.6 Extraction of genomic DNA 
Genomic DNA was extracted using a commercial extraction kit according 
to the manufacturer’s instructions (Qiagen). Briefly, cell suspensions were 
centrifuged at 1,200RPM for eight minutes using a Centurion Scientific C2000 
bench top centrifuge (Core Life Sciences) and cell pellets were suspended in 
PBS containing proteinase K and lysis buffer. Cells were incubated at 56°C for 
15 minutes, followed by ethanol precipitation and DNA purification by wash 
buffers specific to the Qiagen QIAamp DNA Mini Kit (Cat no. 51306). DNA was 
eluted in 20µl elution buffer and stored at -20°C for long-term storage.  
2.5.4 S. pombe techniques 
2.5.4.1 Growth of S. pombe  
All cultures were incubated at 30°C. All glassware and reagents were 
sterilised by autoclaving before use.  
2.5.4.2 Preparation of YEA and YEL  
YEA and YEL were prepared as outlined in section 2.2.4.2 and 
autoclaved on a liquid cycle. YEA was cooled to an appropriate temperature 
and subsequently poured into sterile petri dishes (25ml per dish) and allowed to 
solidify. Plates were stored at room temperature until use.  
2.5.4.3 Starter cultures 
For each culture, 10mls of YEL was added to sterile glass flasks. Using a 
sterile loop, a single colony was transferred from growing plates to the glass 
flask. Cultures were incubated at 30°C on an orbital shaker for up to 24 hours at 
200RPM. The following six strains of S. pombe were cultured: rad16WT, 
rad16Pro361Ser, rad16Arg399Gln, rad16Arg548Thr, rad16Ser585X and rad16Glu844Gly.   
2.5.4.4 Long-term storage of S. pombe  
Cultures were prepared for long-term storage by mixing 600ul of glycerol 
with 400ul of overnight culture in YEL and freezing to -80°C. Cultures were 
restored by thawing on ice, vortexing and streaking onto YEA plates, prior to 
incubation at 30°C for 3-5 days.  
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2.5.4.5 Oxaliplatin treatment 
Overnight cultures (1 x 107 cells in YEL) were incubated with 1mM 
oxaliplatin (R&D Systems) for 18 hours at 30°C. Following incubation, cells 
were centrifuged at 2000RPM for 3 minutes and the supernatant containing 
oxaliplatin was removed. The cell pellet was re-suspended in YEL in 
preparation for immunofluorescence.  
2.5.4.6 Immunofluorescence  
 Cultured cells were fixed in 3.7% formaldehyde and 0.25% 
glutaraldehyde for 1 hour at 30°C on an orbital shaker at 200RPM, followed by 
centrifuging at 2000RPM for 3 minutes to remove YEL containing fixative. Cell 
wall digestion was achieved by incubation with 0.1mg/ml zymolyase suspended 
in PEM at 37°C for 90 minutes. The cell membrane was permeabilised with 4% 
Triton X-100 for two minutes at room temperature, followed by blocking with 
PEMBALG for 1 hour at room temperature, with multiple washes in PEM 
between each step. Cells were incubated with primary antibody overnight and 
with secondary antibody for 1 hour, both at room temperature, with three wash 
steps in PEM in between. Cells were washed in PEM, incubated with DAPI 
nuclear stain (0.2µg/ml) for 5 minutes at room temperature, prior to cytospinning 
onto sterile glass microscope slides at 1,000 RPM for 4 minutes at medium 
acceleration. Cells were mounted with Mowiol-488 containing DABCO for 
antifade.  
2.5.5 Quantification of nucleic acids  
 To measure DNA concentration, a UV spectrophotometer was used at 
wavelengths of 260nm and 280nm. An absorbance ratio of 1.8 at these 
wavelengths indicated high purity in a given sample.  
 2.5.6 Variant prediction using whole exome resequencing data 
Using the GATK UnifedGenotyper tool, single nucleotide polymorphisms 
(SNPs) and insertions/deletions (indels) were called. Addition of rsIDs to called 
variants was performed using dbSNP v.132. Variant quality score recalibration 
was performed according to GATK guidelines; SNPs and indels were firstly 
separated since variant quality recalibration only applied to SNPs. Training sites 
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from HapMap release 3.3 (http://hapmap.ncbi.nlm.nih.gov) and Illumina’s 
Omni2.5M SNP microarray were used to recalibrate scores, to ascertain 
whether called variants were genuine or artefacts. 
Annotation of variants was applied using the SnpEff program and its 
database GRCh37.64. Annotations were assigned to variants called by the 
pipeline using GATK’s VariantAnnotator, producing files for each exome 
containing recalibrated quality scores. 
2.5.7 Primer design 
All primers were designed either using Primer3, version 0.4.0 
(http://frodo.wi.mit.edu/primer3/), or alternatively using a Perl script produced by 
Marc Naven (Naven, 2015; Chapter 2). Where possible, primers were designed 
to be 18-25 nucleotides in length, with annealing temperatures within 2°C of 
their partners, and demonstrated low predicted dimerisation and secondary 
structure formation. The locus specificity of all primers was checked using the 
Primer-Blast software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  
2.5.8 PCR 
Unless otherwise mentioned, standard PCR reaction mixtures comprised 
of 10pmols forward and reverse primer, 0.2mM dNTPs, GeneAmp 10x buffer 
(added to a final concentration of 10mM Tris-HCl, 50mM KCl, 1.5mM MgCl2, 
0.01% (w/v) gelatine, pH 8.3), 1U AmpliTaq Gold DNA polymerase, 5% DMSO 
and 40ng of DNA (final volume of 25µl). Cycling conditions involved an initial 
denaturisation step of 95°C for 2 minutes, followed by 35 cycles of 95°C for 30 
seconds, annealing temperature of between 50-60°C for 30 seconds and an 
elongation step of 72°C for 30 seconds. A final elongation step of 72°C for 10 
minutes followed these cycles.  
2.5.9 Agarose gel electrophoresis 
Agarose gels were formed using 1.5g agarose dissolved in 100mls 1X 
TAE buffer (depending on fragment sizes that required separation). Conical 
flasks were heated to melt the agarose, cooled slightly and 0.05µg/ml of either 
ethidium bromide or GelRed stain was added. This was poured into a gel tank 
between dams and allowed to cool. Once set, the gel was submerged in 1x TAE 
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buffer in an AB0708 100V gel tank. 8µl of PCR product was added to 2µl of 
loading dye (15% w/v ficol, 10mM Tris pH 8, 1mM EDTA and 0.2% orange G), 
mixed thoroughly and the entire volume was loaded onto the gel. Gels were run 
at 100V for 30-40 minutes with a 100bp or 1kb DNA ladder to visualise fragment 
separation. After separation, UV visualisation was carried out and photographed 
on the BioRad XR system. As a safety precaution, ethidium bromide destaining 
bags were added to running buffer for at least 24 hours prior to disposal to 
remove the dye. Where GelRed was used this practice was not necessary.  
2.5.10 ExoSap PCR purification 
ExoSap degrades excess primers, ssDNA and phosphate groups. Exo is 
a 3’-5’ exonuclease that degrades single stranded oligonucleotides from 
solutions that contain a double stranded product. SAP is an alkaline 
phosphatase responsible for removal of 5’-phosphates from the PCR product. 
1µl (3.2pmol) of ExoSap was added directly to the PCR product after 
electrophoresis and the samples were incubated at 37°C for 60 minutes, 
followed by an enzyme denaturising step of 80°C for 15 minutes.  
2.5.11 Sanger sequencing 
The BigDye Terminator version 3.1 Cycle Sequencing kit was used to 
sequence the ExoSap treated PCR products. The reaction mixture used was 
based on the manufacturer’s instructions; 5µl purified PCR product was added 
to 0.2% BigDye version 3.1, 10pmol desired primer (forward or reverse) and 1x 
BigDye sequencing buffer, all of which was made up to 10µl with dH2O.  
Cycling conditions involved 25 cycles of 96°C for 10 seconds, 50°C for 5 
seconds and 60°C for 3 minutes and 30 seconds. The products of the BigDye 
termination sequencing reactions were cleaned of excess unincorporated 
nucleotides and dyes by the isopropanol method, as outlined below. 
2.5.12 Isopropanol clean up method 
For isopropanol clean up, 40µl of 75% isopropanol was added to the 10µl 
BigDye reaction mixture and incubated for 30 minutes at room temperature. 
Samples were centrifuged at 4000RPM for 45 minutes to pellet the DNA, and 
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then inverted onto absorbent paper to remove the isopropanol supernatant. 
Samples were then centrifuged inverted for 500RPM for 30 seconds and air 
dried in the dark for 10 minutes to allow evaporation of remaining liquid. The 
DNA pellet was resuspended in 10µl of HiDi formamide, prior to Sanger 
sequencing.  
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Chapter 3 – Investigating viability of wild type and variant ERCC4 cell 
lines after DNA damage 
3.1 Introduction 
Mutations in XP genes have been associated with decreased survival in 
model organisms and clinical samples, resulting from defective DNA repair in 
numerous pathways, primarily NER and DSB repair. Studies looking at overall 
survival have been carried out in clinical trial patients undergoing chemotherapy 
(Grothey et al. 2004; Grothey et al. 2005; Andre et al. 2009), whilst in vitro 
models have primarily looked at biallelic cell lines carrying XP variants. A 
summary of studies investigating survival using in vitro and in vivo NER-
deficient models is shown in Table 3.1. We hoped to further this work by 
examining the in vitro consequences of potentially functional heterozygous 
variants in ERCC4.  
Platinum drugs including oxaliplatin have been shown to bind irreversibly 
to plasma proteins, in particular serum albumin (Graham et al. 2000; Yue et al. 
2009), and as a result cells were treated with oxaliplatin in serum-free (SF) 
media throughout optimisation stages to prevent this drug-serum interaction. 
Additionally, UV irradiation can be absorbed by serum molecules, which could 
prevent damage from occurring (Polet and Steinhardt, 1968). Therefore, cell 
lines were treated with UV in SF media to prevent absorption of UV light and 
potential interference with the viability phenotype.  
Trypan blue is an effective exclusion dye used for viability measurement 
based on its ability to enter non-viable cells that have lost membrane integrity 
(Krause et al. 1984). This assay is also advantageous because it does not 
require expensive, specialist equipment for viability measurement.  
We hypothesised that functional variants in ERCC4 may contribute to 
reduced repair capacity, which may directly correlate with reduced viability. 
Here we aimed to elucidate the functional consequences of variants in ERCC4 
on viability after DNA damage by oxaliplatin and UV light.  
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Gene 
(Protein) 
Model organism Effect seen References 
ERCC1 
(ERCC1) 
Human colorectal 
cancer cell lines wild 
type and KRAS-mutant 
(biallelic) 
Significantly higher sensitivity to 
oxaliplatin in KRAS-mutant cell 
lines, silencing of ERCC1 
significantly reduced survival 
following oxaliplatin, irrespective 
of KRAS status 
Orlandi et 
al. 2015 
ERCC2 
(XPD) 
Human lymphoblastoid 
cell lines with 
transfected constructs to 
induce heterozygous 
and homozygous 
ERCC2-deficient 
phenotypes 
Reduction in survival following UV 
treatment in heterozygous cell 
lines; significantly reduced 
survival with homozygous 
variants (2.5-fold increase in 
sensitivity to UV) 
Seker et al. 
2001 
ERCC3 
(XPB) 
Human heterozygous 
fibroblast cell lines 
Significantly reduced survival in 
XPB-deficient cell lines compared 
with wild type and cell lines 
isolated from patients with TTD 
Weeda et 
al. 1997 
ERCC4 
(XPF) 
Biallelic fibroblast cell 
lines isolated from 
patients with Fanconi 
anaemia (FA) 
Reduced survival in mutant-
ERCC4 patients after treatment 
with UV-C and mitomycin C 
(MMC), compared with wild type 
cells; Suggests a multifunctional 
role of XPF 
Bogliolo et 
al. 2013 
ERCC5 
(XPG) 
Fibroblasts isolated from 
XPG-deficient patients 
(one homozygous and 
two compound 
heterozygous cell lines) 
Significantly reduced survival 
after UV-C irradiation in XPG-
deficient fibroblasts compared 
with wild type cells; effect seen at 
varying UV doses (5-30J) 
Schafer et 
al. 2013 
XPA 
(XPA) 
Human heterozygous 
XPA-mutant fibroblast 
cell lines, which were 
transfected with 
constructs to induce a 
homozygous phenotype 
Increased sensitivity to UV 
treatment in mutant XPA cell lines 
compared with wild type 
Wu et al. 
2006 
XPC 
(XPC) 
HeLa cells with silenced 
XPC (using constructs to 
induce a homozygous 
phenotype) 
Reduced survival following UV 
treatment in XPC-silenced cells; 
Reduced cell division rate 
following UV treatment, 
suggesting that XPC is essential 
for survival and also regulates cell 
division following DNA damage 
Renaud et 
al. 2011 
 
Table 3.1 Summary of survival studies after treatment with DNA damaging 
agents in NER-deficient model organisms.  
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3.2 Materials and Methods 
 3.2.1 Cell line selection and genotyping 
Four hundred and eighty human EBV-transformed lymphoblastoid cell 
lines from healthy Caucasian blood donors were genotyped for Pro379Ser, 
Arg576Thr and Glu875Gly in ERCC4 using KBioscience® KASPar genotyping. 
From this analysis, twelve cell lines were selected for functional analysis; three 
wild type cell lines and three cell lines for Pro379Ser, Arg576Thr and Glu875Gly 
(all found in a heterozygous state). Cell lines were purchased from ECACC 
(Public Health England).  
3.2.2 Oxaliplatin treatment 
During optimisation, wild type cells were treated with oxaliplatin in SF 
media as an adherent monolayer on poly-L-lysine coated dishes and in their 
natural suspension state. A range of suspension media (serum-free [SF], 1% 
serum and phosphate buffered saline [PBS]) and doses (125-600µM) in SF 
media were tested over 48 hours in wild type cells and cells carrying 
Pro379Ser, followed by smaller dose ranges (100-200µM) and blind treatment 
of the selected dose (125µM) in SF media over 48 hours. A schematic of the 
stages of optimisation is given in Figure 3.1. 
Optimised conditions were as follows: cells were centrifuged at 1,200 
RPM for five minutes before removal of supernatant and re-suspension in SF 
media. Cells were incubated in SF media for 1 hour before treatment with 
oxaliplatin (125µm) by adding the drug directly to the cell suspension. The drug 
was incubated with cells for the duration of the experiment.  
 3.2.3 UV irradiation 
During optimisation, wild type cells were irradiated with a lower dose (20-
60J) and high dose (60-100J) UV-C over 3 and 48 hours. Wild type cells were 
suspended in SF media and PBS prior to UV (20-60J) treatment and viability 
was measured over 48 hours.  
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Viability Assay 
Oxaliplatin treatment UV-C irradiation 
Tested oxaliplatin (125µM) dose under 
different serum starving conditions to 
ensure loss of viability is due to drug 
treatment (Figure 3.2).  
Tested a range of oxaliplatin doses (125-
600µM) in SF media over 72 hours (Figure 
3.3a). Tested drug treatment in cells in 
suspension and as an adherent 
monolayer on a poly-L-lysine matrix (data 
not shown).  
Wild type cells treated with smaller dose 
range (100-200µM) over 48 hours, 
followed by blind treatment of selected 
dose (125µM) over 48 hours (Figure 3.3b 
and c). 
All control cell lines treated with UV 
(40J) in either PBS or SF media, to 
ensure that viability was not affected 
by the suspension medium used 
during UV treatment (Figure 3.5c and 
d). 
Wild type cells treated with UV dose 
range (20-60J) over 3 hours and 48 
hours (Figure 3.5a and b) 
Figure 3.1 Schematic diagram of optimisation of oxaliplatin and UV viability 
assays. Wild type cells were treated with oxaliplatin in suspension and as an 
adherent monolayer on a poly-L-lysine surface. Different serum starving conditions 
and a range of doses (125-600µM) were tested, which led to a narrower dose range 
(100-200µM) being tested over 48 hours. A final dose of 125µM was selected on the 
basis of these experiments and published data, which was tested blindly across all 
wild type cell lines to confirm adequate loss of viability over 48 hours at this dose.  
Wild type cells were treated with UV (20-60J) using a germicidal lamp and viability 
was measured over 3 hours and 48 hours. UV irradiation in phosphate buffered 
saline (PBS) and serum-free (SF) media were tested to rule out the possibility of UV-
C radiation being absorbed by other molecules including water molecules in the 
suspension medium. 
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Optimised conditions were as follows: cells were suspended in SF media 
as outlined in 3.2.2 and irradiated with UV (40J) using a germicidal lamp. After 
UV treatment, cells were resuspended in normal media containing foetal bovine 
serum (FBS) and antibiotics.  
 3.2.4 Viability measurement  
Percentage viability was measured by trypan blue exclusion as outlined 
in section 2.5.3.3 at 0, 4, 24 and 48 hours after treatment. Each experiment was 
carried out four times under identical conditions, and percentage viability for 
each cell line at each time point was averaged. Initial percentage viability across 
all cell lines varied considerably (61.5-90.9%; data not shown), so viability 
values were normalised to produce a starting viability of 100%, prior to 
averaging. Average percentage viability (n=4) for all ERCC4 variants was 
plotted against time (hr) with standard error bars. 
 3.2.5 Statistical analysis 
Statistical analysis was performed in SPSS v.20.0 using a two-way 
analysis of variance (ANOVA), using mutation status (wild type, Pro379Ser, 
Arg576Thr and Glu875Gly) and treatment (no treatment, oxaliplatin and UV 
treatment) as independent variables. Percentage viability at each time point was 
used as the dependent variable. Percentage viability values were averaged for 
cell lines carrying the same ERCC4 variant undergoing the same treatment and 
an ANOVA was performed to allow comparison of percentage viability between 
cell groups. We were unable to apply statistics to the viability at zero hours due 
to no standard deviations (counted as 100% starting viability). Statistics were 
applied to the viability values measured at 2, 4, 24 and 48 hours across all cell 
groups for each treatment type. 
3.3 Results  
 3.3.1 Genotyping of human cell lines for variants in NER genes 
 Of the 480 lymphoblastoid cell lines that were genotyped, nine (1.88%) 
carried Pro379Ser, four (0.83%) carried Arg576Thr and seventeen (3.54%) 
carried Glu875Gly. We selected three of each of these cell lines together with 
three wild type cell lines for subsequent analyses. 
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3.3.2 Optimisation of oxaliplatin treatment  
A summary of optimisation experiments is shown in Figure 3.1. Wild type 
cells were treated with oxaliplatin (125µM) over 4 hours in SF media and 
viability was measured every 30 minutes, which demonstrated no noticeable 
difference between treated and untreated cells (data not shown). 
The cell lines in question exist naturally in suspension. We tested the 
effect of treating cells as an adherent monolayer using poly-L-lysine as an 
adhesion matrix. Wild type cells were treated with oxaliplatin (125µM) in SF 
media over 4 hours and removed either by mechanical scraping or using trypsin 
at hourly intervals and viability was measured. This revealed a lower initial 
viability after trypsin treatment or scraping compared with initial viability when 
cells are treated in suspension (approximately 45-65% compared with 85% 
when treated in suspension; data not shown). This indicated that these cell lines 
are healthier when treated in their natural suspension state. 
We tested different serum conditions with oxaliplatin treatment (125µM) 
over 48 hours, by comparing 1% serum and serum-free media with 1-hour and 
overnight starvation in wild type cells and cells carrying Pro379Ser (Figure 3.2). 
Viability measurements over 48 hours revealed that neither duration of serum 
starving nor the presence of 1% serum in the tissue culture media had any 
detrimental effect on the viability of cells.  
Wild type cell lines were treated with range of concentrations (0, 125, 
250, 375, 500 and 600µM) over 48 hours, showing considerable reduction in 
viability in treated cells across all doses tested at 24, 48 and 72 hours (Figure 
3.3a). As a result, the concentration range was reduced (100, 125, 150, 175 
and 200µM) and tested over 48 hours in wild type cells, revealing similar 
viabilities at each concentration (Figure 3.3b). A final concentration of 125µM 
was used to treat control cells blindly, which effectively demonstrated a marked 
reduction in viability between treated and untreated cells at 24 and 48 hours 
(Figure 3.3c).  
3.3.3 Effect of oxaliplatin on viability of variant cell lines 
We observed very little reduction in viability over 48 hours across all cell 
lines without drug treatment (approx. 10% reduction; Figure 3.4). Oxaliplatin
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(A)          (B) 
           
(C)         (D) 
        
Figure 3.2 Effects of serum starvation on oxaliplatin treatment in wild type cells and cells carrying Pro379Ser. Wild type cells and cells 
carrying Pro379Ser were treated with oxaliplatin (125µM) over 48 hours under different serum starving conditions. Plots show cells treated in (A) 1% 
serum with 1 hour starvation prior to drug treatment, (B) serum-free media with 1 hour starvation, (C) 1% serum with overnight starvation and (D) 
serum-free media with overnight starvation. Different serum starving conditions had very little effect on viability in either wild type or variant cells 
during optimisation.
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  (B) 
  
  (C) 
               
 
Figure 3.3 Optimisation of oxaliplatin dose in wild type cell lines. (A) Cells from 
wild type cell line 1 were suspended in SF media containing a range of oxaliplatin 
doses (125-600uM) and viability was measured at 0, 24, 48 and 72 hours. (B) From 
this data, the dose range was narrowed down to 100-200µM, which was tested in wild 
type cells suspended in SF media over 48 hours. Oxaliplatin remained in the media for 
the duration of the experiment. (C) All wild type cell lines were suspended in SF media 
and treated with oxaliplatin (125uM). Viability was measured at 0, 30 and 48 hours. 
Drug treatment over 48 hours resulted in a noticeable reduction in viability in drug 
treated cells compared with untreated cells. NT = No treatment.  
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treated cell lines demonstrated a reduction in viability at 24 and 48 hours 
compared with untreated cell lines, with very little variation between wild type 
and variant cell lines at these time points (Figure 3.4). This was true for all 
ERCC4 variants in question.  
Comparison of each cell group based on ERCC4 mutation with and 
without oxaliplatin treatment by ANOVA revealed no statistically significant 
association between mutation status and treatment type after 24 and 48 hours 
(P = 0.941 and 0.975, respectively). Similarly no significant difference between 
different cell groups was identified at 24 and 48 hours (P= 0.149 and 0.108, 
respectively). A significant difference between treatment types was identified, as 
would be expected when comparing untreated and DNA damaged cell lines 
(P=0.000 at 24 and 48 hours; Table 3.2). 
3.3.4 Optimisation of UV treatment  
Wild type cells were treated with UV-C (20–60J) irradiation in SF media 
over 3 hours (Figure 3.5a) and over 48 hours (Figure 3.5b), demonstrating very 
little cell death after 3 hours and a marked reduction in viability at 24 and 48 
hours. This was repeated in the other two wild type cell lines, with similar results 
(data not shown). Wild type cells were treated with a higher UV dose range (60–
100J) in SF media over 3 hours and 48 hours, which showed similar results to 
the lower dose range (data not shown). We tested UV (20–60J) treatment in 
different suspension media in all wild type cell lines over 48 hours, to compare 
viability after DNA damage in SF media and in PBS (Figure 3.5 c and d). This 
showed a reduction in viability in UV irradiated cells at 24 and 48 hours 
compared to untreated cells, with very little difference in viability between cells 
treated in either suspension medium.  
3.3.5 Effect of UV on viability of variant cell lines  
We observed consistently high viability over 48 hours across cell lines 
without UV treatment (Figure 3.6). Percentage viability in UV treated cell lines 
reduced considerably 24 hours after irradiation and remained very similar 
across all cell lines at all time points, irrespective of ERCC4 variant (Figure 3.6).  
Comparison of percentage viability values between cell groups by 
ANOVA identified no significant association between mutation status and  
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Figure 3.4 Effect of oxaliplatin treatment on viability in wild type and variant cell 
lines. Wild type cell lines and cell lines carrying ERCC4 (A) Pro379Ser, (B) Arg576Thr 
and (C) Glu875Gly with and without oxaliplatin (125µM) treatment over 48 hours in SF 
media with standard error bars. Each plot represents four biological repeats of the 
same experiment performed on separate days using identical conditions. V = variant 
cell line; C = wild type cell line; 1-3 = three cell lines carrying the same ERCC4 variant. 
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A. 
 24hr 48hr 
Mutation Treatment Mean SD Mean SD 
Wild Type NT 94.4417 5.08946 89.3667 7.15139 
OXA 65.8833 14.94839 39.3333 9.33004 
Pro379Ser NT 95.2250 12.74164 95.9500 10.09874 
OXA 65.3750 11.02519 44.4250 14.25821 
Arg576Thr NT 100.8167 5.96731 94.9583 8.10067 
OXA 71.6000 10.28264 43.7500 11.53095 
Glu875Gly NT 96.6667 7.31478 91.6000 7.66420 
OXA 64.4750 13.45140 38.9500 8.74326 
 
B. 
 24hr 48hr 
Mutation 0.149 0.108 
Treatment 0.000 0.000 
Mutation*Treatment 0.941 0.975 
 
Table 3.2 Statistical analyses of cell groups after oxaliplatin treatment. 
Percentage viability values for cell lines carrying the same ERCC4 variant with and 
without oxaliplatin (125µM) treatment were averaged and compared using a two-way 
ANOVA. A) Mean and standard deviation values for each cell group without treatment 
and following oxaliplatin (OXA) treatment after 24 and 48 hours are shown. B) P values 
obtained by ANOVA are given for percentage viability values after 24 and 48 hours for 
the variables mutation, treatment and the association between mutation and treatment 
(mutation*treatment). Highlighted values were statistically significant (P<0.05). NT = no 
treatment; SD = Standard deviation. 
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treatment type at either 24 or 48 hours (P = 0.930 and 0.088, respectively; 
Table 3.3). A significant difference between cell groups undergoing different 
treatment was identified (P = 0.000 at 24 and 48 hours) was identified, as would 
be expected. However, a significant difference between percentage viability 
after 48 hours, but not 24 hours, based on cell group was identified (P = 0.004 
at 48 hours; P = 0.100 at 24 hours). Further investigation using a post hoc 
Tukey test identified a significant difference in viability between wild type cells 
and cells carrying Pro379Ser (P = 0.047), and between cells carrying 
Pro379Ser and Glu875Gly (P = 0.002; Table 3.3).  
3.4 Discussion 
 3.4.1 Selection of cell lines for functional analysis  
It is likely that each of the cell lines analysed carried other coding region 
variants in ERCC4, ERCC1 or other NER-related pathway genes. A search of 
dbSNP on 3rd August 2015, revealed two rare (MAF <1%) and sixteen common 
(MAF >1%) nonsynonymous variants in ERCC4, one rare (MAF<1%) and four 
common (MAF >1%) nonsynonymous variants in ERCC1, and, seven rare 
(MAF <1%) and six common (MAF >1%) nonsynonymous variants in other core 
NER-related pathway genes (ERCC2; ERCC3; ERCC5; RPA; TFIIH; XPA). It 
would therefore be impossible to account for all of these genetic variations and 
to find cell lines that were wild type at all of these mutant loci. Therefore, we 
selected three cell lines with each mutation of interest in an attempt to allow for 
possible differences in their genetic backgrounds. The fact that almost all of the 
individual mutant cell lines showed similar effects in the data presented in this 
chapter (and elsewhere in this thesis) suggests that other un-assayed variants 
did not affect the results or their reproducibility. 
3.4.2 Optimisation of assay 
We tested different serum conditions comparing 1% serum and SF 
media with 1 hour and overnight starvation prior to drug treatment, to ensure 
that loss of viability was a consequence of drug treatment, and not due to 
removal of serum. It was necessary to remove serum prior to oxaliplatin 
treatment due to the serum-drug interaction that can occur and prevent damage  
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(A) (B) 
                
(C)     (D) 
                    
 
Figure 3.5 Optimisation of UV dose and suspension medium. Wild type cell lines were treated with UV (20-60J), followed by re-suspension of 
cells for 48 hours in different suspension media. Cells were irradiated with UV (20-60J) using a UV-C germicidal lamp in SF media, prior to re-
suspension in normal media for (A) 3 hours and (B) 48 hours. All wild type cell lines were suspended in (C) SF media or (D) PBS prior to UV (40J) 
using a UV-C germicidal lamp. Cells were incubated for 48 hours and viability was measured at 0, 4, 24 and 48 hours. The suspension medium made 
very little difference to the viability of cells at each time point, regardless of whether cells were UV treated or untreated. A reduction in viability was 
only noticeable when cells were incubated for more than 4 hours. NT = No treatment. 
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Figure 3.6 Effect of UV irradiation on viability in wild type and variant cell lines. 
Wild type cell lines and cell lines carrying a (A) Pro379Ser, (B) Arg576Thr and (C) 
Glu875Gly variant with and without UV-C (40J) irradiation over 48 hours in SF media 
with standard error bars. Each plot represents four biological repeats of the same 
experiment performed on separate days using identical conditions. V = variant cell line; 
C = wild type cell line; 1-3 = three cell lines carrying the same ERCC4 variant.  
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A.  
 24hr 48hr 
Mutation Treatment Mean SD Mean SD 
Wild Type NT 94.4417 5.08946 89.3667 7.15139 
UV 69.6500 9.01115 47.0083 9.61225 
Pro379Ser NT 95.2250 12.74164 95.9500 10.09874 
UV 72.3500 8.30723 54.6167 9.60339 
Arg576Thr NT 100.8167 5.96731 94.9583 8.10067 
UV 75.7167 6.48352 44.1667 10.90607 
Glu875Gly NT 96.6667 7.31478 91.6000 7.66420 
UV 70.3833 13.26272 39.1750 10.51347 
B. 
 24hr 48hr 
Mutation 0.100 0.004 
Treatment 0.000 0.000 
Mutation*Treatment 0.930 0.088 
C. 
Mutation P value (48hr) 
 
Wild Type 
Pro379Ser 0.047 
Arg576Thr 0.956 
Glu875Gly 0.725 
 
Pro379Ser 
Wild Type 0.047 
Arg576Thr 0.151 
Glu875Gly 0.002 
 
Arg576Thr 
Wild Type 0.956 
Pro379Ser 0.151 
Glu875Gly 0.409 
 
Glu875Gly 
Wild Type 0.725 
Pro379Ser 0.002 
Arg576Thr 0.409 
Table 3.3 Statistical analyses of cell groups after UV irradiation. Percentage 
viability values for cell lines carrying the same ERCC4 variant with and without UV 
(40J) treatment were averaged and compared using a two-way ANOVA. A) Mean and 
standard deviation values for each cell group without treatment and following UV 
treatment after 24 and 48 hours are shown. B) P values obtained by ANOVA are given 
for percentage viability values after 24 and 48 hours for the variables mutation, 
treatment and the association between mutation and treatment (mutation*treatment). 
Highlighted values were statistically significant (P<0.05). C) A post hoc Tukey test was 
performed to identify which groups significantly differed from one another after 48 
hours, with significant p values (<0.05) highlighted. NT = no treatment; SD = Standard 
deviation. 
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from taking place (Yue et al. 2009). However, we were unsure whether 
complete serum removal would create an unfavourable environment for cell 
growth and replication. Overnight starvation was intended to induce cell cycle 
arrest, although this results in changes in gene expression (Collier et al. 2006), 
and we were unsure of the effects this could have on viability after damage. It 
was also unknown whether this overnight starvation, followed by drug treatment 
for 48 hours in the absence of serum, would be either too detrimental to cells to 
promote proliferation, or prevent cell cycle arrest from occurring entirely. There 
is evidence to suggest that mitochondrial electron transport chain activity, but 
not ATP synthesis, is required to drive certain cell types through apoptosis (Jia 
et al. 1997), although it is unclear whether this mitochondrial activity can take 
place in non-dividing cells. However, the consistently high viability in untreated 
cells and similar patterns of cell death after drug treatment, irrespective of 
serum conditions, suggested that loss of viability was directly due to oxaliplatin 
treatment. 
A range of oxaliplatin doses were tested to ensure that loss of viability in 
treated cells was apparent enough to distinguish between untreated cell lines. 
The larger dose range showed similar cell death across all doses, with viability 
that was substantially lower than in untreated cells. The dose range was 
narrowed down, followed by eventual selection of 125µM as the dose for 
oxaliplatin treatment. During other studies, researchers have previously used 
similar doses of oxaliplatin for treatment of colorectal cancer cell lines for 
assessment of ERCC1 expression (Orlandi et al. 2015) and to induce cell cycle 
arrest and apoptosis (Flis et al. 2009).  
For UV treatment, we tested a range of UV doses to select a dose that 
allowed for a distinct reduction in viability compared to untreated cell lines. A 
number of protocols recommended UV treatment in PBS (Bruins et al. 2004; 
Stiff et al. 2006). We therefore compared UV treatment in PBS and SF media, 
to rule out the possibility of UV absorption by other molecules in tissue culture 
media, in the same way that UV light can be absorbed by serum and water 
molecules (Polet and Steinhardt, 1968). We observed comparable cell death in 
cells after UV treatment in PBS and SF media, confirming that our protocol for 
UV irradiation was appropriate for this viability assay.  
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3.4.3 Effect of ERCC4 variants on viability after DNA damage 
Comparison of percentage viability in wild type cell lines after both 
oxaliplatin and UV treatment was very similar, suggesting there was little 
variation between individual wild type cell lines. As a result, the decision was 
made to analyse the percentage viability values for cell lines carrying the same 
ERCC4 variant collectively. For the purpose of this thesis, cell lines carrying the 
same variant will be referred to as ‘cell groups’.  
 Percentage viability of wild type and variant cell groups showed very little 
apparent difference in cell death after oxaliplatin treatment, regardless of 
ERCC4 variant. UV treatment in wild type and variant cell groups showed very 
similar results. Statistical comparison of percentage viability for each cell group 
following oxaliplatin treatment revealed no significant differences. However, 
comparison of percentage viability values by ANOVA in cell groups following UV 
treatment identified statistical differences between wild type cell lines and cell 
lines carrying Pro379Ser, and between cells carrying Pro379Ser and 
Glu875Gly. It is possible that this could have been an artefact of statistical 
analysis, due to analysis of percentage viability data from multiple biological 
repeat experiments. 
Despite the statistically significant difference identified between three cell 
groups following UV treatment only, the average percentage viability values 
between cell groups following oxaliplatin and UV treatment remained small. This 
suggested that the variants did not appear to affect XPF function severely 
enough to impact upon viability. This could be due to the heterozygous nature 
of the cell lines, meaning that there may not be enough mutated protein present 
in variant cell lines to impair DNA repair efficiently enough, in order to see a 
difference in viability following DNA damage.   
Previous work in our lab has shown a statistically significant decrease in 
viability (<20% compared with 100% in rad16WT cells) after oxaliplatin treatment 
in the fission yeast Schizosaccharomyces pombe (S. pombe) carrying a novel 
stop gain in the S. pombe homolog of ERCC4, rad16. All strains carrying 
nonsynonymous rad16 variants, including the S. pombe homologs of 
Pro379Ser, Arg576Thr and Glu875Gly, displayed <60% viability after oxaliplatin 
treatment. Percentage viability in all strains after UV treatment showed a very 
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similar trend (West, 2013, Chapter 7). This clear pattern of reduced viability 
after UV and oxaliplatin treatment in S. pombe strains suggested that a haploid 
model for functional analysis of viability might be more ideal. It is possible that 
the variant cell lines are haploinsufficient due to the presence of one wild type 
allele, and that consequently the ERCC4 variants affect function in a subtle 
way. One indication to support this hypothesis is the fact that their predicted 
effect on function using Align-GVGD was only statistically significant once all 
three variants were combined for statistical analysis (Table 1.11).  
Lymphoblastoid cell lines were selected as a model for functional 
analyses on the basis that they were commercially available, relatively 
inexpensive and the reagents and consumables required for culturing and 
maintenance of these cell lines were widely available at a reasonable cost. 
Additionally they proliferate rapidly, with doubling times of 3-4 days, allowing 
growth of large enough cell numbers to perform standard cell-based assays 
such as immunofluorescence and ELISA. A particular advantage was the 
presence of their genotyping data, which facilitated selection of cells based on 
their ERCC4 mutation status. A potential mechanism by which oxaliplatin is 
thought to exert its cytotoxic effects is via platinum accumulation in dorsal root 
ganglia (DRG) of treated individuals, which has been demonstrated in mice 
following cisplatin and oxaliplatin treatment (Dzagnidze et al. 2007; Ta et al. 
2006). Therefore, with regard to investigation of PNAO in vitro, despite their 
numerous advantages, lymphoblastoid cells may not be the most ideal model 
organism due to their high replication rates, which are not representative of fully 
differentiated neuronal cells with low replication potential. Additionally, we 
ideally hoped to assess the functional effects of ERCC4 variants in human cell 
lines; we were unable to find commercially available human neuronal cell lines 
for in vitro culture. Even if this was a possibility, there were additional concerns 
that the use of differentiated neuronal cell lines as a model organism would not 
reflect the properties of rapidly dividing cells in the body, including cells of the 
bone marrow, gastrointestinal tract and hair follicles, which are typically targeted 
by chemotherapeutic drugs. Therefore, this may not have yielded results that 
were representative of the effects of oxaliplatin-mediated toxicity in patients.  
Viral transformation of primary cell lines involves mutation or deletion of 
the cell’s genetic material as a consequence of integration of the viral genome 
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into the host cell. Typically this adversely impacts the cell’s replicative cycle, 
resulting in stimulation of continuous proliferation and/or inhibition of apoptosis 
(Klein and Ernberg, 2007). Although these properties are useful for culturing cell 
lines in vitro, this suggests that virally transformed cell lines are not ideal for 
assessing the functional effects of genetic variants on survival, as the 
transformed cells are likely to demonstrate reduced apoptosis, therefore 
resulting in biased results. Similarly, it is possible that transformed cell lines 
may have a selective advantage with regard to proliferation following DNA 
damage compared with primary cell lines. This enhanced proliferative potential 
could result in apparently larger cell numbers during DNA repair, therefore 
skewing the amount of DNA damage that is quantified by standard assays, than 
would be seen using primary cell lines.  
EBV transformation of primary resting B cells results in several genetic 
changes within cells; firstly the viral Wp promoter is activated and several 
protein-coding genes, including Epstein-Barr nuclear antigen-2 and –leader 
protein (EBNA-2 and –LP) and latent BamHI-H right reading frame-1 (BHRF1) 
are expressed. These proteins are critical for cellular transformation. This 
results in activation of a second promoter Cp, followed by subsequent 
expression of all six Epstein-Barr nuclear antigens (EBNA; EBNA1, 2, 3A, 3B, 
3C and LP) and three latent membrane proteins LMP1, 2A and 2B (Tierney et 
al. 2015). The coordinated expression of these proteins in newly infected B cells 
triggers cell growth, resulting in B cell transformation. In particular the LMP 
proteins are known to modulate signalling pathways within cells undergoing 
transformation; LMP1 confers a survival advantage in EBV-infected B cells via 
LMP1-induced disruption of p53-mediated apoptosis and upregulation of the 
anti-apoptotic protein Bcl-2 (Henderson et al. 1991). LMP2A inhibits the 
activation of EBV replication via cell-surface-mediated signal transduction, 
which contributes to the latent phase of EBV infection of B cells (Miller et al. 
1994). This series of latent gene expression events is known as Latency III and 
results in the establishment of lymphoblastoid cell lines with infinite growth 
potential (Tierney et al. 2000). Therefore, it is possible that the effects of EBV 
transformation on our ERCC4 variant cell lines have resulted in enhanced 
proliferation, which could have increased the percentage viability at each time 
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point, therefore resulting in unreliable viability measurements throughout the 
assay.  
 The viability assays were repeated four times for each variant and 
treatment type, with very similar results acquired each time, suggesting that the 
assay was very consistent. However, it is possible that the trypan blue exclusion 
method of quantifying viability may not be the most sensitive or reliable method. 
Trypan blue exclusion can only detect cells that are no longer viable due to 
influx of the stain into cells via their damaged membranes. However, this offers 
no information on whether the cells are apoptotic due to DNA damage or 
whether they have undergone necrosis or autophagy, since multiple cell death 
pathways may be in progress simultaneously (Lenardo et al. 2009). Therefore, it 
is possible that a more sensitive method of viability measurement may be 
required to elucidate any true differences in viability between wild type and 
variant cell lines.  
3.4.4 Alternative assays for viability studies 
Alternative assays may be useful for viability studies in mammalian cell 
lines; one potential alternative is the enzyme-linked immunosorbent assay 
(ELISA) for detection of caspases, a group of cysteine-proteases that hydrolyse 
target sequences and become activated during apoptosis (Chen and Wang, 
2002). This assay allows absolute quantitation of fluorescent substrates that 
indicate caspase activation, which can be quantified by changes in optical 
density (Lenardo et al. 2009). This is considered a relatively specific assay, 
since caspase activation is considered a hallmark of apoptosis, and is not 
thought to stimulate necrosis (Elmore, 2007).  
Similar to caspase ELISA, a lactate dehydrogenase (LDH)-cytotoxicity 
assay can be used to quantify LDH, a soluble cytosolic enzyme that leaks from 
cells upon death due to increased cell membrane permeability. The assay is 
also quantified by changes in optical density similar to ELISA, which quantifies 
amounts of LDH relative to the negative and positive controls. For this reason, it 
is considered less sensitive than ELISA, which can quantify absolute 
concentrations of proteins, but more sensitive than trypan blue exclusion. 
However, LDH-cytotoxicity assays lack specificity, since LDH is released from 
cells upon death by necrosis as well as apoptosis (Lenardo et al. 2009). 
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Flow cytometric methods for viability measurement require exclusion of 
non-viable cells by propidium iodide (PI) staining, which detects loss of 
membrane integrity in the same way as trypan blue. PI stain penetrates non-
viable cells and causes a strong emission at 620nm, which can be detected in 
the FL-3 channel, allowing quantitation of survival (Lenardo et al. 2009). This is 
a rapid and more sensitive method of cell viability detection than trypan blue 
exclusion, although it requires expensive, specialist equipment. Additionally its 
specificity for apoptotic cells is low, since PI stain will penetrate cells with semi-
permeable membranes resulting from other cell death pathways (Ross et al. 
1989). 
A major limitation of viability measurement by trypan blue exclusion is its 
inability to distinguish cells that have lost their membrane integrity due to 
induction of cell death pathways other than apoptosis. A slightly more 
sophisticated method is the standard comet assay, which is typically used for 
measurement of DNA strand breaks by gel electrophoresis of single cells 
embedded in agarose on microscope slides (Fairbairn et al. 1995). It is a rapid, 
relatively inexpensive assay that provides greater sensitivity than that 
associated with more standard forms of gel electrophoresis for DNA separation 
(in the region of 109 Da compared with kDa respectively) (Collins et al. 1997; 
Collins, 2004). However, one limitation experienced previously was a tendency 
towards false positive results, owing to the standard assay’s inability to 
discriminate between apoptotic and necrotic cells (Collins et al. 1997). More 
recently, a modified version of the comet assay was developed that can 
distinguish viable, apoptotic and necrotic single cells. This modified assay 
incorporates simultaneous staining with ethidium-homodimer exclusion dye, 
calcein-blue-AM and Annexin-V, for assessment of membrane integrity, cellular 
esterase activity and translocation of phosphadidyl-serine respectively, to 
quantify cell numbers at different stages of cell death. This appeared to resolve 
the issue of false positive results seen previously with the standard comet assay 
(Morley et al. 2006).  
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Chapter Four – Localisation of ERCC1-XPF in wild type and variant ERCC4 
cell lines after DNA damage 
 
4.1 Introduction 
Several studies in mammalian cell lines have suggested that ERCC1 and 
XPF are unstable in the absence of their protein partner. Research by Yagi et 
al. (1997) using fibroblasts isolated from XP-F patients revealed low levels of 
ERCC1 and the ERCC1-XPF complex overall. In addition, the same has been 
identified for XPF, identifying low XPF levels in the absence of ERCC1 (Gaillard 
and Wood, 2001). Other research has shown that ERCC1 and XPF mutant cell 
extracts do not complement one another when mixed together in vitro, 
suggesting that unstable unconjugated proteins most likely mis-fold and 
become marked for degradation (Biggerstaff et al. 1993; Van Vuuren et al. 
1993). For our assay, each protein was probed for using separate antibodies 
and any ERCC1 or XPF detected by immunofluorescence was therefore 
assumed to be conjugated protein as part of the ERCC1-XPF repair complex.  
Ahmad et al. (2010) previously showed mislocalisation of both ERCC1 
and XPF to the cytoplasm in XPF mutant cell lines, including cells carrying 
Pro379Ser, without treatment. This was in comparison to exclusively nuclear 
ERCC1 and XPF localisation in wild type fibroblast cells. We hoped to further 
this work by investigating the effect of DNA damage on localisation of the repair 
complex in human Epstein Barr virus (EBV)-transformed lymphoblastoid cell 
lines and various strains of S. pombe. Human EBV-transformed lymphoblastoid 
cells are spherical and consist of a large, dense nucleus (approx. 90% of cell 
volume) and a narrow cytoplasm. Typically these cells range from 10-30m in 
diameter (Thompson et al. 1984; Ryan et al. 2006). In contrast, S. pombe cells 
are cylindrical in shape due to growth by extension of cell ends, with a small 
spherical nucleus at the centre of each cell and a large cytoplasm. Typically 
cells range in length from 4-10m; cell division usually occurs once cells reach 
approx. 9.5m (Mitchison and Nurse, 1985). 
Here, we sought to identify the functional consequences of three ERCC4 
variants on cellular localisation of ERCC1-XPF and Rad16 before and after 
damage with oxaliplatin treatment by indirect immunofluorescence. 
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Optimisation of 
Immunofluorescence Assay 
NO TREATMENT OXALIPLATIN (125µM) 
TREATMENT 
Tested fluorescence analysis in 
maximum projection files vs. 
section-by-section files (Figures 
4.2 & 4.3) 
Tested wild type cell lines 
stained with primary 
antibody only and secondary 
antibody only to test for 
genuine fluorescence (Figure 
4.4) 
Stained all cell lines under 
same serum conditions using 
optimised antibody 
conditions (Figures 4.5 – 4.8) 
Tested different serum starvation 
times prior to oxaliplatin treatment. 
Tested serum starving conditions in 
the presence and absence of 
oxaliplatin (data not shown) 
Tested different antibody 
concentrations with oxaliplatin 
treatment (data not shown) 
Tested wild type cell lines with 
oxaliplatin treatment stained with 
primary antibody only and secondary 
antibody only (Figure 4.10) 
Stained all cell lines after 
oxaliplatin treatment under 
optimised conditions (Figure 4.11) 
 
Figure 4.1 Schematic diagram of optimisation of immunofluorescence assay 
in human cell lines with and without oxaliplatin treatment. Wild type cells were 
imaged as a combination of maximum projection and section-by-section files, and 
fluorescence was quantified to identify the best approach. Different serum starving 
times were tested and cells were stained with and without oxaliplatin to rule out the 
drug as an inhibitor of fluorescent activity. Wild type cells were stained with primary 
antibody only and secondary antibody only as a negative control. This identified 
optimum antibody conditions for immunofluorescence of all cell lines without and 
with oxaliplatin treatment.  
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4.2 Materials and Methods 
 4.2.1 Immunofluorescence of cell lines without treatment 
 A schematic diagram summarising the stages of optimisation is shown in 
Figure 4.1. During optimisation, wild type cells were adhered to microscope 
slides using various adhesion matrices and by cytospinning, prior to staining. 
Wild type cells were imaged as maximum projection (MP) and section-by-
section files and total fluorescence quantified for each file type were compared. 
Different concentrations of permeabilising agent and antibodies were tested. 
Wild type cells were stained with primary antibodies only and secondary 
antibodies only as negative controls.  
Optimised conditions are described in section 2.5.3.3; antibody species 
and concentrations are shown in Table 4.1a. Cell lines were imaged using a 
Leica SP5 confocal laser scanning microscope using optimised imaging 
parameters (Table 4.1b).  
 4.2.2 Immunofluorescence of cell lines with oxaliplatin treatment 
 During optimisation, wild type cells were treated with and without 
oxaliplatin in normal and serum-free (SF) media over 16 hours. Higher 
concentrations of secondary antibodies were tested and both primary and 
secondary antibodies for XPF detection were replaced. Negative control wild 
type cells were stained with primary antibodies and secondary antibodies only 
after oxaliplatin treatment.  
 Optimised conditions were as follows: cells were suspended in SF media 
and treated with oxaliplatin (125µM) for 1 hour without prior serum starvation. 
Cells were resuspended in normal media containing FBS and antibiotics for two 
hours, prior to cytospinning, fixation, permeabilising and blocking as outlined in 
section 2.5.3.3. Cells were incubated with antibodies and DAPI nuclear stain in 
the same way as untreated cells, with the exception of different antibodies for 
XPF detection after oxaliplatin treatment (antibody names and concentrations 
are shown in Table 4.1a). Cells were mounted and imaged as in section 4.2.1 
(imaging parameters in Table 4.1b).   
 4.2.3 Quantifying localisation in cell lines 
Cellular fluorescence was quantified using LAS-AF Lite software by 
manually encircling the nucleus (region of interest 1; ROI1) and entire cell  
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A. 
Antibody Primary/ 
Secondary 
Species Concentration Dilution Staining 
conditions 
ERCC1 Primary Rabbit 
polyclonal 
4µg/mL 
 
1:50 Overnight at 
4°C 
Diluted in 1% 
BSA in PBS 
 
Alexa 488 Secondary Goat anti-
rabbit IgG 
10µg/mL 
 
1:200 1 hour at RT 
Diluted in 1% 
BSA in PBS 
 
XPF 
(3F2/3) 
XPF  
(M-16)* 
 
Primary  Mouse 
monoclonal 
Goat 
polyclonal 
11µg/mL 
 
11µg/ml 
1:100 
 
1:100 
Overnight at 
4°C 
Diluted in 1% 
BSA in PBS 
Alexa 546 
 
Alexa 
546* 
 
Secondary Goat anti-
mouse IgG 
Donkey anti-
goat IgG 
1µg/mL 
 
10µ/ml 
1:2000 
 
1:200 
1 hour at RT 
Diluted in 1% 
BSA in PBS 
 
B. 
Fluorescent 
stain 
DAPI ERCC1 - Alexa 488 XPF - Alexa 546 
Laser 405 Diode Argon HeNe 543 
Overall laser 
power 
30% 30% 30% 
Individual laser 
powers 
10% 
30%* 
 
20% 90% 
Format 512x512 512x512 512x512 
Speed 8000 Hz 8000 Hz 8000 Hz 
Zoom factor 1.7 1.7 1.7 
Image size 144.72 x 144.72µm 144.72 x 144.72µm 144.72 x 144.72µm 
Pixel size 283.22 x 283.22 x 
42.00nm 
283.22 x 283.22 x 
42.00nm 
283.22 x 283.22 x 
42.00nm 
Section thickness 0.772µm 0.772µm 0.772µm 
Line/Frame 
average 
4/4 4/4 4/4 
Rotation 0.00 0.00 0.00 
Voltage of 
channel 
570 530 780 
Section thickness 
of Z-stacks 
0.49µm 0.49µm 0.49µm 
Table 4.1 Summary of antibody concentrations and imaging parameters for 
immunofluorescence using human cell lines. A) Summary of staining conditions 
after optimisation of the immunofluorescence assay showing conditions with* and 
without oxaliplatin (125µM) treatment. B) Summary of imaging parameters used to 
image cells on the Leica SP5 confocal microscope using the 63x oil objective, showing 
conditions with* and without oxaliplatin (125µM) treatment.  
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Intensity 
Number of pixels Fluorescent count 
ROI1 ROI2 ROI1   ROI2 
0 a1 a2 a1 x 0 a2 x 0 
1 b1 b2 b1 x 1 b2 x 1 
2 c1 c2 c1 x 2 c2 x 2 
     
     
253 x1 x2 x1 x 253 x2 x 253 
254 y1 y2 y1 x 254 y2 x 254 
255 z1 z2 z1 x 255 z2 x 255 
TOTAL FLUORESCENT COUNT Sum of ROI1 
values 
Sum of ROI2 
values 
 
Table 4.2 Schematic of template table for calculation of total fluorescent count. 
Fluorescent counts and total fluorescent count of ERCC1 and XPF in each cell during 
fluorescence quantification were calculated using this table. Imaging files were 
acquired in an 8-bit format with a maximum of 256 different intensities (minimum 
intensity of 0; maximum intensity of 255). The following equations were used: 
Fluorescent Count = Pixel Number x Pixel Intensity 
Total fluorescent count (F) = Sum of all Fluorescent counts  
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perimeter (ROI2). For each pixel intensity ranging from 0 to 255, fluorescent 
counts were calculated for ROI1 and ROI2 independently as outlined in Table 
4.2. During optimisation, imaging of the same wild type cells was performed as 
MP and as section-by-section files, where MP files were an overlay of all 
individual sections throughout the depth of the cell (Figure 4.2). This involved 
manually encircling all ROI1 and ROI2 regions of cells for every individual 
section in a section-by-section file, compared with only one manual encircling 
per MP file. For section-by-section files, the total fluorescent counts of each 
section were added together.  
 Optimised conditions involved imaging all cell lines as MP files, which 
required only a single fluorescence calculation per cell. Total fluorescent count 
was calculated for ROI1 and ROI2 as the sum of every fluorescent count across 
all intensities (0-255). Total fluorescent count in ROI1 and ROI2 for both 
ERCC1 and XPF was calculated for 50 and 20 cells per cell line for untreated 
and oxaliplatin treated cells respectively. These values were converted to 
percentage localisation values for nuclear and cytoplasmic ERCC1 and XPF, 
before averaging.  
 Relative-fold increase (RFI) of nuclear ERCC1 and XPF localisation was 
calculated by the following equation: 
RFI =  % localisation after oxaliplatin treatment 
% localisation without treatment 
 
RFI values were calculated in 20 cells per cell line for both ERCC1 and XPF 
localisation, before averaging.  
 4.2.4 Statistical analysis 
Statistical analysis was performed in SPSS v.20.0 using a two-way 
ANOVA, with mutation status (wild type, Pro379Ser, Arg576Thr and Glu875Gly) 
and treatment (no treatment and oxaliplatin treatment) as independent 
variables. Percentage localisation of ERCC1 and XPF was used as the 
dependent variable. Percentage localisation values for ERCC1 and XPF for 
each cell line with and without oxaliplatin treatment were averaged and the 
mean values for cell lines carrying the same ERCC4 variant were compared by 
ANOVA. This allowed comparison of localisation for cell groups. Statistical 
comparison of RFI values for nuclear ERCC1 and XPF following oxaliplatin  
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(A) 
 
 
Figure 4.2 Schematic of Z-stack imaging carried out by confocal laser scanning 
microscope. Cells were imaged in 0.5µm sections throughout the depth of the cell (as 
shown in A) and merged to form an overlaid image of all sections, called a maximum 
projection image. Maximum projection files were acquired using (B) the 405nm laser for 
DAPI nuclear staining, (C) phase contrast to show entire cell outline, (D) the 488nm 
laser for Alexa 488 staining to detect ERCC1 and (E) the 543nm laser for Alexa 546 
staining to detect XPF. The regions of interest (ROI) 1 and 2 represent the nucleus and 
perimeter of the cell respectively.  
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treatment for each cell group was performed using a one-way ANOVA, using 
the mean RFI values for each cell line carrying the same ERCC4 variant. Where 
a statistically significant interaction was identified, a Tukey post-test was 
performed to identify statistical significance between specific cell groups.  
4.2.5 Construction of S. pombe strains carrying rad16 variants 
All S. pombe strains were constructed using site directed mutagenesis to 
induce specific mutations in rad16 into each strain. Firstly, a rad16 deletion 
base strain was constructed and transformed into a wild type strain of S. pombe 
to produce a knockout strain. This included incorporation of lox sites to allow 
future homologous incorporation of nonsynonymous rad16 variants by colony 
PCR and cloning. The deletion base strain was distinguished from wild type 
cells via enrichment of UV sensitivity. The truncating Ser585X variant and 
remaining nonsynonymous variants were then incorporated by transfection of 
vectors. All vectors used for cloning contained an N-terminal (5’) His tag to allow 
probing via immunofluorescence. All rad16 variants are listed with their 
respective human homologs in Table 4.3. All strains were constructed and 
kindly donated by Dr Oliver Fleck (Bangor University). Full details of the S. 
pombe strain construction process can be found in Dr Hannah West’s PhD 
thesis (West, 2013, Chapter 6).  
4.2.6 Immunofluorescence of S. pombe without treatment 
During optimisation, wild type and variant S. pombe cells were treated 
with different concentrations of zymolyase (0.1-1mg/ml) to achieve cell wall 
digestion, and were permeabilised using varying concentrations of Triton X-100 
(2-5%). Different concentrations of primary His tag antibody (5-30µg/ml) were 
also tested to achieve optimum staining conditions.  
Optimised conditions are outlined in section 2.5.4.6; antibody species 
and concentrations are shown in Table 4.4a. Cell lines were imaged using a 
Leica SP5 confocal laser scanning microscope using optimised imaging 
parameters (Table 4.4b).  
4.2.7 Immunofluorescence of S. pombe with oxaliplatin treatment  
During optimisation, different concentrations of primary His tag antibody 
(5-30µg/ml) and secondary Alexa 488 antibody (2-20µg/ml) were tested. During  
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Strain name Rad16 variant Human homolog    
(ERCC4 variant) 
rad16WT Wild type Wild type 
rad16Pro361Ser Pro361Ser Pro379Ser 
rad16Arg399Gln Arg399Gln Arg415Gln 
rad16Arg548Thr Arg548Thr Arg576Thr 
rad16Ser585X Ser585X Ser613X 
rad16Glu844Gly Glu844Gly Glu875Gly 
 
Table 4.3 Summary of S. pombe strains with their rad16 variants and respective 
human homologs.
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A. 
Antibody Primary/ 
Secondary 
Species Concentration Dilution Staining 
conditions 
His tag Primary Rabbit 
polyclonal 
10µg/mL 
 
1:100 Overnight at 
RT 
Diluted in 
PEMBALG 
buffer 
 
Alexa 488 Secondary Goat anti-
rabbit IgG 
5µg/mL 
 
1:100 4 hours at RT 
Diluted in 
PEMBALG 
buffer 
 
      
 
B. 
Fluorescent 
stain 
DAPI Rad16 - Alexa 488 
Laser 405 Diode Argon 
Overall laser 
power 
30% 30% 
Individual laser 
powers 
10% 
30%* 
 
20% 
Format 512x512 512x512 
Speed 8000 Hz 8000 Hz 
Zoom factor 3.0 3.0 
Image size 82.01 x 82.01µm 82.01 x 82.01µm 
Pixel size 160.49 x 160.49 x 
49.4nm 
160.49 x 160.49 x 
49.4nm 
Section thickness 0.772µm 0.772µm 
Line/Frame 
average 
4/4 4/4 
Rotation 0.00 0.00 
Voltage of 
channel 
611.0; 660.0* 800.0; 1100.0* 
Section thickness 
of Z-stacks 
0.49µm 0.49µm 
 
Table 4.4 Summary of antibody concentrations and imaging parameters for 
immunofluorescence using S. pombe strains. A) Summary of staining conditions 
after optimisation of the immunofluorescence assay showing conditions with* and 
without oxaliplatin (1mM) treatment. B) Summary of imaging parameters used to image 
cells on the Leica SP5 confocal microscope using the 63x oil objective, showing 
conditions with* and without oxaliplatin (1mM) treatment.  
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confocal imaging, a higher voltage was tested to achieve higher intensity 
images whilst maintaining low background fluorescence.  
Optimised conditions were as follows: cells were treated with oxaliplatin 
(1mM) for 18 hours in YEL as outlined in section 2.5.4.5. Fixation, cell wall 
digestion, membrane permeabilisation and blocking were carried out as 
described in section 2.5.4.6. Cells were incubated with antibodies and DAPI 
nuclear stain in the same way as untreated cells, and mounted and imaged as 
in 4.2.5 (imaging parameters in Table 4.4b). 
4.2.8 Quantifying localisation of rad16 in S. pombe 
Nuclear and cytoplasmic rad16 was quantified using the same method as 
that used for ERCC1/XPF localisation in cell lines (section 4.2.3), using 20 cells 
per S. pombe strain. RFI values were calculated as outlined in section 4.2.3.  
4.2.9 Statistical analysis of rad16 localisation 
Statistical analysis of percentage localisation values was performed in 
SPSS v20.0 using a two-way ANOVA, with mutation status (rad16WT, 
rad16Pro361Ser, rad16Arg399Gln, rad16Arg548Thr, rad16Ser585X and rad16Glu844Gly) and 
treatment type (no treatment and oxaliplatin treatment) as independent 
variables. Percentage nuclear localisation of rad16 was used as the dependent 
variable. Percentage localisation values (n=20) per strain with and without 
treatment were given as input for comparison of each strain by ANOVA; 
however, despite this, individual localisation values for the same S. pombe 
strain cannot be considered as different experiments since all localisation 
values were acquired during the same experiment. RFI values (n=20) per strain 
were given as input for a one-way ANOVA to compare RFI between variant 
strains; similarly these values were acquired during the same experiment and 
therefore cannot be considered as different experiments. Where a statistically 
significant interaction was identified, a Tukey post-test was performed to identify 
statistical significance between specific cell groups.  
4.3 Results  
 4.3.1 Percentage localisation of ERCC1 and XPF without treatment 
During optimisation, wild type cells were seeded onto coverslips coated 
with poly-L-lysine, fibronectin and laminin prior to fixation, permeabilisation and 
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(C) 
 
Figure 4.3 Comparison of total fluorescence in cells quantified as maximum projection vs. section-by-section files. 
Immunofluorescent staining of wild type cells were imaged as a maximum projection file (A) and as a Z stack comprised of 0.5µm sections 
(B). Fluorescent counts in DAPI, ERCC1 and XPF channels were quantified as maximum projection and section-by-section (S-by-S) files 
for comparison and are plotted in (C). Total fluorescence of twenty cells stained and imaged during the same experiment was quantified.    
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Figure 4.4 Negative controls in wild type cell lines without treatment. Wild type cells (no starvation) without drug treatment stained with (A) DAPI 
nuclear stain with anti-ERCC1 and anti-XPF IgGs with corresponding Alexa 488 and Alexa 546 IgGs, (B) DAPI nuclear stain with anti-ERCC1 and 
anti-XPF primary IgGs only and (C) DAPI nuclear stain with Alexa 488 and Alexa 564 secondary IgGs only. Intensity peaks (right) indicate intensity of 
ERCC1 (above) and XPF (below) staining respectively and nuclear/cytoplasmic fluorescent count (N/C F) is shown on the far right. Fluorescent 
counts are the average of fifty cells per cell line (150 cells per cell group) stained and imaged as part of the same biological repeat experiment.  
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Figure 4.5 Immunofluorescence of wild type cell lines without treatment. Wild type cell lines for ERCC4 without drug treatment stained with 
DAPI nuclear stain, anti-ERCC1 IgG with corresponding Alexa 488 IgG and anti-XPF IgG with corresponding Alexa 546 IgG, showing (A) wild type 1, 
(B) wild type 2 and (C) wild type 3 cell lines (HRC Collection). Intensity peaks (right) indicate intensity of ERCC1 (above) and XPF (below) staining 
respectively and nuclear/cytoplasmic fluorescent count (N/C F) is shown on the far right. Fluorescent counts are the average of fifty cells per cell line 
(150 cells per cell group) stained and imaged as part of the same biological repeat experiment.
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blocking. Microscopic examination between wash steps revealed that our cell 
lines did not successfully adhere to coverslips (data not shown).  
Cells were cytospun onto glass slides and fixed, permeabilised and 
blocked according to 4.2.1. Different concentrations of Triton-X100 for 
permeabilisation were tested (data not shown). Cells were imaged as MP files 
and as 0.5µm section-by-section files (Figure 4.3a and b). Nuclear and 
cytoplasmic fluorescent counts in DAPI, ERCC1 and XPF channels were 
compared for MP and section-by-section files, which indicated higher 
fluorescence values for MP files. Although fluorescent counts for MP and 
individual section files differed considerably, there was an overall trend showing 
that fluorescence counted across individual sections amounted to approximately 
half of the total fluorescence in MP files of the same region and antibody (Figure 
4.3c).  
 Wild type cells were stained with primary and secondary antibodies for 
ERCC1 and XPF, and with primary and secondary antibodies only as negative 
controls (Figure 4.4). This identified negligible levels of fluorescence in primary 
only and secondary only stained cells.   
Wild type cell lines fully stained with primary and secondary antibodies 
without treatment are shown in Figure 4.5. Quantification of MP fluorescence in 
wild type cell lines without treatment showed reasonable variation in average 
nuclear and cytoplasmic ERCC1 and XPF percentage localisation (Figure 4.6). 
This apparent variation between individual wild type cell lines meant that it was 
important to consider percentage localisation of cell lines carrying the same 
ERCC4 variant collectively. Cell lines carrying Pro379Ser, Arg576Thr and 
Glu875 fully stained with primary and secondary antibodies without treatment 
are shown in Figures 4.7, 4.8 and 4.9 respectively. Average percentage 
localisation of nuclear ERCC1 in cell lines carrying Pro379Ser and Arg576Thr 
showed a trend towards the lower end of the wild type localisation range, with 
Arg576Thr showing the greatest localisation to the cytoplasm, whereas cell 
lines carrying Glu875Gly localised towards the upper end of the wild type range 
(Figure 4.6a). Average localisation of nuclear XPF in all cell lines showed a very 
similar pattern, with slightly lower percentage values (Figure 4.6b). 
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(A) 
 
(B) 
 
Figure 4.6 Percentage localisation of nuclear ERCC1 and XPF without treatment. 
Average percentage localisation of nuclear (A) ERCC1 and (B) XPF across all cell lines 
without treatment (n=50), with standard error bars. Horizontal lines indicate the 
maximum (green) and minimum (red) percentage localisation in wild type cell lines. 
Nuclear percentage localisation values for each cell line are indicated in blue on each 
plot. Percentage localisation values are the average of fifty cells per cell line stained 
and imaged as part of the same biological repeat experiment.  
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Figure 4.7 Immunofluorescence of cell lines carrying Pro379Ser without treatment. Cell lines carrying Pro379Ser without drug treatment stained 
with DAPI nuclear stain, anti-ERCC1 IgG with corresponding Alexa 488 IgG and anti-XPF IgG with corresponding Alexa 546 IgG, showing (A) 
Pro379Ser 1, (B) Pro379Ser 2 and (C) Pro379Ser 3 cell lines (HRC Collection). Intensity peaks (right) indicate intensity of ERCC1 (above) and XPF 
(below) staining respectively and nuclear/cytoplasmic fluorescent count (N/C F) is shown on the far right. Fluorescent counts are the average of fifty 
cells per cell line (150 cells per cell group) stained and imaged as part of the same biological repeat experiment. 
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Figure 4.8 Immunofluorescence of cell lines carrying Arg576Thr without treatment. Cell lines carrying Arg576Thr without drug treatment stained 
with DAPI nuclear stain, anti-ERCC1 IgG with corresponding Alexa 488 IgG and anti-XPF IgG with corresponding Alexa 546 IgG, showing (A) 
Arg576Thr 1, (B) Arg576Thr 2 and (C) Arg576Thr 3 cell lines (HRC Collection). Intensity peaks (right) indicate intensity of ERCC1 (above) and XPF 
(below) staining respectively and nuclear/cytoplasmic fluorescent count (N/C F) is shown on the far right. Fluorescent counts are the average of fifty 
cells per cell line (150 cells per cell group) stained and imaged as part of the same biological repeat experiment. 
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Figure 4.9 Immunofluorescence of cell lines carrying Glu875Gly without treatment. Cell lines carrying Glu875Gly without drug treatment stained 
with DAPI nuclear stain, anti-ERCC1 IgG with corresponding Alexa 488 IgG and anti-XPF IgG with corresponding Alexa 546 IgG, showing (A) 
Glu875Gly 1, (B) Glu875Gly 2 and (C) Glu875Gly 3 cell lines (HRC Collection). Intensity peaks (right) indicate intensity of ERCC1 (above) and XPF 
(below) staining respectively and nuclear/cytoplasmic fluorescent count (N/C F) is shown on the far right. Fluorescent counts are the average of fifty 
cells per cell line (150 cells per cell group) stained and imaged as part of the same biological repeat experiment.
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Comparison of nuclear ERCC1 and XPF localisation between cell groups 
was performed using a two-way ANOVA; therefore the results of statistical 
analysis are outlined in section 4.3.2.  
4.3.2 Percentage localisation of ERCC1 and XPF with oxaliplatin 
treatment  
During optimisation, we tested the effect of serum starving duration (0-16 
hrs) prior to oxaliplatin treatment on staining intensity in wild type cell lines. 
Fluorescent count was significantly higher in the presence of serum. Removal of 
serum resulted in a reduction in fluorescent count of approximately 80%, with 
similar low levels of fluorescence regardless of duration of serum starvation 
(data not shown). 
All wild type cell lines were subjected to different serum starving 
conditions with and without oxaliplatin (125µM) treatment. Cells treated with 
oxaliplatin in normal tissue culture media showed high fluorescent counts. 
Removal of serum resulted in reduced fluorescence levels, irrespective of 
whether oxaliplatin was added or not (data not shown).  
Different concentrations of secondary antibodies were tested, which 
resulted in brighter and specific staining for ERCC1 only (data not shown). 
Primary and secondary antibodies for XPF detection were substituted, resulting 
in brighter and specific XPF staining (data not shown). Staining with primary 
and secondary antibodies only as a negative control produced negligible 
fluorescent counts in comparison with fully stained cells (Figure 4.10).  
Wild type and variant cell lines fully stained with primary and secondary 
antibodies after oxaliplatin treatment are shown in Figure 4.11. Nuclear and 
cytoplasmic percentage localisation of ERCC1 and XPF in individual wild type 
cell lines after oxaliplatin treatment showed considerable variation 
(approximately 10% and 9% range respectively) (Figure 4.12). 
Average nuclear ERCC1 in cell lines carrying Pro379Ser and Arg576Thr 
localised towards the lower end of the wild type localisation range, whereas cell 
lines carrying Glu875Gly localised towards the upper end of the wild type range 
(Figure 4.12a), with marked variation between localisation in cell lines carrying 
the same variant. Average localisation of nuclear XPF showed a very similar 
pattern in all cell lines (Figure 4.12b).  
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Figure 4.10 Negative controls in wild type cell lines with oxaliplatin treatment. Wild type cells starved for 1 hour in SF media followed by 
oxaliplatin (125µM) treatment for 1 hour. Cells were incubated for 2 hours after drug treatment and stained with (A) DAPI nuclear stain with anti-
ERCC1 and anti-XPF IgGs with corresponding Alexa 488 and Alexa 546 IgGs, (B) DAPI nuclear stain with anti-ERCC1 and anti-XPF primary IgGs 
only and (C) DAPI nuclear stain with Alexa 488 and Alexa 564 secondary IgGs only. Intensity peaks (right) indicate intensity of ERCC1 (above) and 
XPF (below) staining respectively and nuclear/cytoplasmic fluorescent count (N/C F) is shown on the far right. Fluorescent counts are the average of 
twenty cells per cell line (sixty cells per cell group) stained and imaged as part of the same biological repeat experiment. 
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Figure 4.11 Immunofluorescence of all cell lines with oxaliplatin treatment. Cell lines treated with oxaliplatin (125µM) for 1 hour in SF media, 
followed by 2 hour incubation and staining with DAPI nuclear stain and anti-ERCC1 and anti-XPF IgGs with corresponding Alexa 488 and Alexa 546 
IgGs, showing (A) wild type cells and cells carrying (B) Pro379Ser, (C) Arg576Thr and (D) Glu875Gly. Intensity peaks (right) indicate intensity of 
ERCC1 (above) and XPF (below) staining respectively and nuclear/cytoplasmic fluorescent count (N/C F) is shown on the far right. Fluorescent 
counts are the average of twenty cells per cell line (sixty cells per cell group) stained and imaged as part of the same biological repeat experiment.
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 (A) 
 
(B) 
 
 
Figure 4.12 Percentage localisation of nuclear ERCC1 and XPF with oxaliplatin 
treatment. Average percentage localisation of nuclear (A) ERCC1 and (B) XPF across 
all cell lines with oxaliplatin (125µM; 1 hour) treatment (n=20), with standard error bars. 
Horizontal lines indicate the maximum (green) and minimum (red) percentage 
localisation in wild type cell lines. Nuclear percentage localisation values for each cell 
line are indicated in blue on each plot. Percentage localisation values are the average 
of twenty cells per cell line stained and imaged as part of the same biological repeat 
experiment.  
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Statistical analysis of nuclear ERCC1 and XPF localisation was 
performed using a two-way ANOVA, comparing mean localisation values for 
each cell line carrying the same ERCC4 variant. Comparison of localisation per 
cell group in this way revealed no statistically significant interaction between the 
effects of mutation and treatment on the percentage localisation of ERCC1 and 
XPF (P = 0.147 and P = 0.569, respectively; Table 4.5b). However, there was a 
statistically significant difference between cell groups with regard to mutation for 
ERCC1 localisation (P = 0.004) and with regard to mutation and treatment type 
for XPF localisation (P = 0.017 and P = 0.009, respectively; Table 4.5b).  
A Tukey post-test was performed to identify which cell groups differed 
from one another with statistical significance with regard to percentage 
localisation. This revealed statistically significant differences in localisation of 
ERCC1 and XPF between Pro379Ser and Glu875Gly cell groups (P = 0.033 
and P = 0.021, respectively), and between Arg576Thr and Glu875Gly cell 
groups (P = 0.003 and P = 0.031, respectively; Table 4.5c). All other 
associations showed no statistical significance, which was consistent with the 
relatively small percentage localisation differences across all cell lines (Figure 
4.12). 
4.3.3 Relative-fold increase of ERCC1-XPF after damage  
The RFI of nuclear ERCC1 and XPF localisation after oxaliplatin damage 
was calculated for all cell lines. In wild type cell lines, we observed influx of 
ERCC1 and XPF in two and three wild type cell lines respectively. Cell lines 
carrying Pro379Ser and Glu875Gly showed similar recruitment levels of both 
ERCC1 and XPF as wild type cell lines, whereas cell lines carrying Arg576Thr 
demonstrated greater recruitment overall than wild type cell lines. Recruitment 
profiles for each cell line for both ERCC1 and XPF were very similar (Figure 
4.13).  
Statistical analysis of nuclear RFI for ERCC1 and XPF was performed 
using a one-way ANOVA, comparing mean RFI values for each cell line 
carrying the same ERCC4 variant. Comparison of RFI per cell group in this way  
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A.  
 ERCC1 XPF 
Mutation Treatment Mean SD Mean SD 
Wild Type NT 60.02667 6.272522 50.95000 2.311623 
OXA 59.66667 5.398614 55.80333 4.978045 
Pro379Ser NT 55.84667 1.807881 49.28667 1.408699 
OXA 55.98000 1.736462 51.71000 4.813772 
Arg576Thr NT 45.90667 10.637111 46.21333 8.198112 
OXA 57.88333 4.742756 55.78333 3.541050 
Glu875Gly NT 66.78333 5.287025 56.69000 3.596679 
OXA 64.66333 2.230254 61.23333 3.047004 
B. 
 ERCC1 XPF 
Mutation 0.004 0.017 
Treatment 0.301 0.009 
Mutation*Treatment 0.147 0.569 
C. 
Mutation P value (ERCC1) P value (XPF) 
 
Wild Type 
Pro379Ser 0.615 0.680 
Arg576Thr 0.099 0.790 
Glu875Gly 0.289 0.171 
 
Pro379Ser 
Wild Type 0.615 0.680 
Arg576Thr 0.599 0.997 
Glu875Gly 0.033 0.021 
 
Arg576Thr 
Wild Type 0.099 0.790 
Pro379Ser 0.599 0.997 
Glu875Gly 0.003 0.031 
 
Glu875Gly 
Wild Type 0.289 0.171 
Pro379Ser 0.033 0.021 
Arg576Thr 0.003 0.031 
 
Table 4.5 Statistical analysis of percentage localisation values of nuclear ERCC1 
and XPF in cell groups with and without treatment. Percentage localisation values 
for ERCC1 and XPF per cell line were averaged and mean localisation values were 
compared for cell lines carrying the same ERCC4 variant using a two-way ANOVA. (A) 
Mean localisation values and their standard deviations (SD) are given for each cell 
group. (B) P values are given for mutation, treatment type and the combination of both 
variables (mutation*treatment) for ERCC1 and XPF between different cell groups. (C) 
Results of the Tukey post test comparing mean localisation of ERCC1 and XPF across 
cell groups are listed with P values. Statistically significant values (<0.05) are 
highlighted. NT = no treatment; OXA = oxaliplatin (125µM; 1 hour) treatment.  
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(A) 
 
(B) 
 
 
Figure 4.13 Relative-fold increase of nuclear ERCC1 and XPF after oxaliplatin 
treatment. Average relative fold increase of (A) ERCC1 and (B) XPF localisation to the 
nucleus after DNA damage by oxaliplatin (n=20), with standard error bars. A relative 
fold increase of 1.0 indicates no recruitment (shown in red). RFI values are shown in 
blue on each plot. A RFI value greater than 1 indicates recruitment into the nucleus, 
whereas a value less than 1 indicates recruitment from the nucleus into the cytoplasm 
upon DNA damage. RFI values were calculated using percentage localisation values 
from twenty cells without treatment and twenty cells following oxaliplatin treatment per 
cell line, taken from two separate biological experiments.  
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revealed a statistically significant difference in RFI between cell groups for 
ERCC1 only (P = 0.031; Table 4.6b). A Tukey post-test was performed to 
identify which cell groups differed from one another with statistical significance. 
This revealed statistically significant differences in RFI of ERCC1 between 
Arg576Thr and Glu875Gly cell groups (P = 0.047). No RFI values for XPF were 
statistically significant (Table 4.6c).  
4.3.4 Percentage localisation of rad16 without treatment 
 During optimisation, cells from the wild type and rad16Pro361Ser strains 
were treated with varying concentrations of zymolyase to catalyse cell wall 
degradation. We observed the greatest degree of cell wall destruction at the 
lowest concentration tested (0.1mg/ml) when incubated for up to 90 minutes. 
We tested different concentrations of Triton X-100 for cell membrane 
permeabilisation, which revealed optimum antibody penetration into cells when 
using a Triton X-100 concentration of 4% in combination with 0.1mg/ml 
zymolyase (data not shown). Different primary His tag antibody concentrations 
(5-30µg/ml) were also tested to identify the maximum concentration that could 
be used whilst maintaining low background noise (data not shown). 
 The wild type and rad16Pro361Ser strains were stained with primary and 
secondary antibodies for the His tag conjugated to rad16, and with primary and 
secondary antibody only as negative controls (Figure 4.14). This revealed 
negligible fluorescence levels in primary only and secondary only stained cells.  
 Wild type and variant strains fully stained with primary and secondary 
antibodies without treatment are shown in Figure 4.15. Average percentage 
localisation of rad16 in wild type and variant strains without treatment was very 
similar (Figure 4.16a). Comparison of nuclear rad16 localisation between S. 
pombe strains was performed using a two-way ANOVA; therefore the results of 
statistical analysis are outlined in section 4.3.5. 
4.3.5 Percentage localisation of rad16 with oxaliplatin treatment 
 During optimisation, S. pombe strains were prepared for oxaliplatin 
treatment and subsequent immunofluorescence using identical conditions for 
fixation, cell wall digestion, permeabilisation and blocking as those used in 
strains without treatment. Different primary His tag antibody and secondary 
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 A.  
Mutation ERCC1 XPF 
Mean SD Mean SD 
Wild Type 
1.00587 0.094101 1.10154 0.056347 
Pro379Ser 
0.99103 0.063116 1.07762 0.035810 
Arg576Thr 
1.34284 0.224836 1.27033 0.180077 
Glu875Gly 
0.98066 0.105328 1.09437 0.122005 
B. 
 P value (ERCC1) P value (XPF) 
Mutation (Between cell 
groups) 
0.031 0.211 
C. 
Mutation P value (ERCC1) P value (XPF) 
 
Wild Type 
Pro379Ser 0.999 0.994 
Arg576Thr 0.064 0.333 
Glu875Gly 0.996 1.000 
 
Pro379Ser 
Wild Type 0.999 0.994 
Arg576Thr 0.053 0.240 
Glu875Gly 1.000 0.998 
 
Arg576Thr 
Wild Type 0.064 0.333 
Pro379Ser 0.053 0.240 
Glu875Gly 0.047 0.302 
 
Glu875Gly 
Wild Type 0.996 1.000 
Pro379Ser 1.000 0.998 
Arg576Thr 0.047 0.302 
 
Table 4.6 Statistical analysis of relative-fold increase values of nuclear ERCC1 
and XPF after oxaliplatin treatment of cell groups. RFI values for ERCC1 and XPF 
per cell line were averaged and mean localisation values were compared for cell lines 
carrying the same ERCC4 variant using a one-way ANOVA. (A) Mean RFI values and 
their standard deviations (SD) are given for each cell group. (B) P values are given for 
comparison of RFI between different mutation groups for ERCC1 and XPF. (C) Results 
of the Tukey post-test comparing mean RFI of ERCC1 and XPF across cell groups are 
listed with P values. Statistically significant values (<0.05) are highlighted.  
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Figure 4.14 Negative controls in cells from the S. pombe wild type strain without treatment. Wild type S. pombe cells stained with (A) DAPI 
nuclear stain with primary anti-His tag IgG with corresponding secondary Alexa 488 IgG, (B) DAPI nuclear stain with anti-His tag IgG only, and (C) 
DAPI nuclear stain with Alexa 488 IgG only. Intensity peaks (right) indicate intensity of His tag staining and nuclear/cytoplasmic fluorescent count 
(N/C F) is shown on the far right. Fluorescent counts are the average of twenty cells per strain stained and imaged as part of the same biological 
repeat experiment.
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Figure 4.15 Immunofluorescence of wild type and variant S. pombe strains 
without treatment. Wild type and variant rad16 strains without drug treatment stained 
with DAPI nuclear stain, anti-His tag IgG and corresponding Alexa 488 IgG, showing 
(A) wild type, (B) rad16Pro361Ser, (C) rad16Arg399Gln, (D) rad16Arg548Thr, (E) rad16Ser585X and 
(F) rad16Glu844Gly. Intensity peaks (right) indicate intensity of His tag staining and 
nuclear/cytoplasmic fluorescent count (N/C F) is shown on the far right. Fluorescent 
counts are the average of twenty cells per strain stained and imaged as part of the 
same biological repeat experiment. 
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 (A) 
 
(B) 
 
Figure 4.16 Percentage localisation of nuclear rad16 with and without oxaliplatin 
treatment. Average percentage localisation of nuclear rad16 across all S. pombe 
strains (A) without treatment and (B) with oxaliplatin (1mM; 1 hour) treatment (n=20), 
with standard error bars. Horizontal red lines indicate the average percentage 
localisation of rad16 in the wild type strain. Percentage localisation values for each 
strain are indicated in blue on each plot. Percentage localisation values are the 
average of twenty cells per strain stained and imaged as part of the same biological 
repeat experiment.  
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Alexa 488 antibody concentrations were tested, resulting in optimum staining 
conditions when the maximum concentrations were used (data not shown). 
Additionally, during confocal imaging, higher voltages were tested for imaging 
strains treated with oxaliplatin compared to those without treatment. This 
revealed that strains treated with oxaliplatin and stained immunofluorescently 
could be imaged at higher voltages whilst maintaining low background noise.   
 Wild type and rad16Pro361Ser strains were stained with primary and 
secondary antibodies for the His tag conjugated to rad16, and with primary and 
secondary antibody only as negative controls, which revealed negligible 
fluorescence levels in primary only and secondary only stained cells (data not 
shown).  
Wild type and variant strains fully stained with primary and secondary 
antibodies after oxaliplatin treatment are shown in Figure 4.17. Similar to 
untreated strains, average percentage localisation of nuclear rad16 in wild type 
and variant strains was very similar (approximately 2% range; Figure 4.16b).  
  Statistical analysis of nuclear rad16 localisation was performed using a 
two-way ANOVA, comparing all percentage localisation values (n=20) for each 
S. pombe strain. Since these values were acquired during the same 
experiment, these cannot be considered different experiments. Comparison of 
localisation per strain in this way revealed a statistically significant interaction 
between the effects of mutation and treatment on the percentage localisation of 
rad16 (P = 0.029; Table 4.7b). However, there was no statistically significant 
difference between variant strains with regard to mutation or treatment only for 
rad16 localisation (P = 0.242 and P = 0.670, respectively; Table 4.7b). A Tukey 
post-test confirmed that there were no statistically significant differences 
between variant strains with regard to rad16 localisation (Table 4.7c). This was 
consistent with the small range of percentage localisation between all strains 
(range of approximately 2%; Figure 4.16b).  
4.3.6 Relative-fold increase of rad16 after damage  
 The RFI of nuclear rad16 localisation after DNA damage by oxaliplatin 
was calculated for all S. pombe strains. In wild type cells, we observed marginal 
recruitment into the nucleus upon DNA damage, whilst the rad16Ser585X strain 
displayed no recruitment. All remaining strains showed virtually no recruitment 
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Figure 4.17 Immunofluorescence of wild type and variant S. pombe strains with 
oxaliplatin treatment. Wild type and variant rad16 strains with oxaliplatin (1mM) drug 
treatment stained with DAPI nuclear stain, anti-His tag IgG and corresponding Alexa 
488 IgG, showing (A) wild type, (B) rad16Pro361Ser, (C) rad16Arg399Gln, (D) rad16Arg548Thr, 
(E) rad16Ser585X and (F) rad16Glu844Gly. Intensity peaks (right) indicate intensity of His tag 
staining and nuclear/cytoplasmic fluorescent count (N/C F) is shown on the far right. 
Fluorescent counts are the average of twenty cells per strain stained and imaged as 
part of the same biological repeat experiment. 
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A.  
 Rad16 
Mutation Treatment Mean SD 
 
Rad16WT 
NT 
49.40259 1.899078 
OXA 
51.29602 2.883166 
 
Rad16Pro361Ser 
NT 
50.27336 1.989772 
OXA 
49.38623 3.069647 
 
Rad16Arg399Gln 
NT 
49.73494 2.834460 
OXA 
49.12789 3.716874 
 
Rad16Arg548Thr 
NT 
49.30107 1.768717 
OXA 
49.99595 3.255106 
 
Rad16Ser585X 
NT 
50.69731 2.219011 
OXA 
50.61944 2.344482 
 
Rad16Glu844Gly 
NT 
51.30586 2.122648 
OXA 
49.42664 2.401261 
 
B. 
 Rad16 
Mutation 0.242 
Treatment 0.670 
Mutation*Treatment 0.029 
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C. 
Mutation P value (Rad16) 
 
 
Rad16WT 
Rad16Pro361Ser 0.948 
Rad16Arg399Gln 0.616 
Rad16Arg548Thr 0.836 
Rad16Ser585X 0.995 
Rad16Glu844Gly 1.000 
 
 
Rad16Pro361Ser 
Rad16WT 0.948 
Rad16Arg399Gln 0.984 
Rad16Arg548Thr 1.000 
Rad16Ser585X 0.714 
Rad16Glu844Gly 0.941 
 
 
Rad16Arg399Gln 
Rad16WT 0.616 
Rad16Pro361Ser 0.984 
Rad16Arg548Thr 0.999 
Rad16Ser585X 0.289 
Rad16Glu844Gly 0.597 
 
 
Rad16Arg548Thr 
Rad16WT 0.836 
Rad16Pro361Ser 1.000 
Rad16Arg399Gln 0.999 
Rad16Ser585X 0.512 
Rad16Glu844Gly 0.821 
 
 
Rad16Ser585X 
Rad16WT 0.995 
Rad16Pro361Ser 0.714 
Rad16Arg399Gln 0.289 
Rad16Arg548Thr 0.512 
Rad16Glu844Gly 0.996 
 
 
Rad16Glu844Gly 
Rad16WT 1.000 
Rad16Pro361Ser 0.941 
Rad16Arg399Gln 0.597 
Rad16Arg548Thr 0.821 
Rad16Ser585X 0.996 
 
Table 4.7 Statistical analysis of percentage localisation values of nuclear rad16 
in S. pombe strains with and without treatment. Percentage localisation values for 
rad16 per S. pombe strain (n=20) were compared using a two-way ANOVA. All twenty 
localisation values per strain were acquired using the same slides that were 
immunofluorescently stained at the same time, therefore these values cannot be 
considered as separate experiments. (A) Mean localisation values and their standard 
deviations (SD) are given for strain. (B) P values are given for mutation, treatment type 
and the combination of both variables (mutation*treatment) for rad16 between different 
S. pombe strains. (C) Results of the Tukey post-test comparing mean localisation of 
rad16 across between strains are listed with P values. Statistically significant values 
(<0.05) are highlighted. NT = no treatment; OXA = oxaliplatin (125µM; 1 hour) 
treatment.  
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in comparison with wild type cells (Figure 4.18).  
Statistical analysis of nuclear RFI for rad16 was performed using a one-
way ANOVA, comparing all RFI values (n=20) for each S. pombe strain. Since 
these values were acquired during the same experiment, these cannot be 
considered different experiments. Comparison of RFI per strain in this way 
revealed a statistically significant difference in RFI between strains for rad16 
RFI (P = 0.024; Table 4.8b). A Tukey post-test was performed to identify which 
cell groups differed from one another with statistical significance. This revealed 
statistically significant differences in RFI of rad16 between wild type and 
Glu844Gly strains only (P = 0.014; Table 4.8c).  
4.4 Discussion 
4.4.1 Optimisation of immunofluorescence assay in cell lines 
Staining for both ERCC1 and XPF was pan-cellular throughout the vast majority 
of cells seen in all cell lines. It was not possible to ascertain by eye whether 
fluorescence was primarily nuclear or cytoplasmic in nature; therefore the 
method used to quantify fluorescence was important to optimise correctly. 
Comparison of the same wild type cells imaged as MP and section-by-section 
files revealed large discrepancies in total fluorescent count, despite an overall 
trend in a similar direction for each stain. This is potentially due to the 
incorporation of numerous 0.5µm sections without any fluorescence at the top 
and bottom of the cell, which could skew the overall fluorescent count towards 
the lower range when using the section-by-section approach. Additionally, this 
approach required manual encircling of ROI1 and ROI2 areas for every section 
throughout the Z-stack, resulting in a much larger degree of human error than is 
involved for MP files. This large degree of human error, coupled with the fact 
that MP files showed a much higher degree of fluorescence, made data 
acquisition by MP files the preferable imaging method.  
Wild type cells stained with primary antibody and secondary antibody 
only were used as negative controls to ensure fluorescence was specific. It was 
evident from the low background fluorescence that immunofluorescence was 
detected only within the cells. Negative control samples were quantified, 
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Figure 4.18 Relative fold increase of nuclear rad16 after oxaliplatin treatment. 
Average relative fold increase of rad16 localisation to the nucleus after DNA damage 
by oxaliplatin (n=20), with standard error bars. A relative fold increase of 1.0 indicates 
no recruitment (shown in red). A RFI value greater than 1 indicates recruitment into the 
nucleus, whereas a value less than 1 indicates recruitment from the nucleus into the 
cytoplasm upon DNA damage. RFI values for each strain are indicated in blue above 
each column on the graph. RFI values were calculated using percentage localisation 
values from twenty cells without treatment and twenty cells following oxaliplatin 
treatment per strain, taken from two separate biological experiments.  
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A.  
Mutation Rad16 
Mean SD 
Rad16WT 
1.03894 0.056186 
Rad16Pro361Ser 
0.98311 0.061508 
Rad16Arg399Gln 
0.99143 0.099953 
Rad16Arg548Thr 
1.01529 0.073366 
Rad16Ser585X 
0.99987 0.056152 
Rad16Glu844Gly 
0.96502 0.063826 
 
 
 
B. 
 P value (Rad16) 
Mutation (Between cell 
groups) 
0.024 
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C. 
Mutation P value (Rad16) 
 
 
Rad16WT 
Rad16Pro361Ser 0.128 
Rad16Arg399Gln 0.274 
Rad16Arg548Thr 0.894 
Rad16Ser585X 0.495 
Rad16Glu844Gly 0.014 
 
 
Rad16Pro361Ser 
Rad16WT 0.128 
Rad16Arg399Gln 0.999 
Rad16Arg548Thr 0.696 
Rad16Ser585X 0.974 
Rad16Glu844Gly 0.964 
 
 
Rad16Arg399Gln 
Rad16WT 0.274 
Rad16Pro361Ser 0.999 
Rad16Arg548Thr 0.890 
Rad16Ser585X 0.999 
Rad16Glu844Gly 0.841 
 
 
Rad16Arg548Thr 
Rad16WT 0.894 
Rad16Pro361Ser 0.696 
Rad16Arg399Gln 0.890 
Rad16Ser585X 0.982 
Rad16Glu844Gly 0.217 
 
 
Rad16Ser585X 
Rad16WT 0.495 
Rad16Pro361Ser 0.974 
Rad16Arg399Gln 0.999 
Rad16Arg548Thr 0.982 
Rad16Glu844Gly 0.619 
 
 
Rad16Glu844Gly 
Rad16WT 0.014 
Rad16Pro361Ser 0.964 
Rad16Arg399Gln 0.841 
Rad16Arg548Thr 0.217 
Rad16Ser585X 0.619 
 
Table 4.8 Statistical analysis of relative-fold increase values of nuclear rad16 
after oxaliplatin treatment of S. pombe strains. RFI values for rad16 per S. pombe 
strain (n=20) were compared using a one-way ANOVA. All twenty RFI values per strain 
were acquired using the same slides that were immunofluorescently stained at the 
same time, therefore these values cannot be considered as separate experiments. (A) 
Mean RFI values and their standard deviations (SD) are given for each cell group. (B) 
P values are given for comparison of RFI between different mutation groups for rad16. 
(C) Results of the Tukey post-test comparing mean RFI of rad16 between strains are 
listed with P values. Statistically significant values (<0.05) are highlighted. 
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demonstrating negligible fluorescence in the absence of either primary or 
secondary antibody. All negative controls showed slightly higher background 
fluorescence in the XPF (red) channel than the ERCC1 (green) channel, most 
likely resulting from autofluorescence of cellular structures in the red spectrum. 
Several cellular flavins have been associated with autofluorescence in the red 
spectrum (approx. 500-700nm), including flavin adenine dinucleotide (FAD), a 
redox cofactor naturally present in all cells, which has been shown to auto-
fluoresce in the region of 500-600nm (Sivabalan et al. 2010). 
  Prior to oxaliplatin treatment, serum was removed from tissue culture 
media to prevent the drug from binding to serum molecules (Yue et al. 2009), 
which could potentially prevent DNA damage from occurring. Interestingly, 
removal of serum resulted in significantly reduced fluorescence, regardless of 
duration of serum starving. We hypothesised that this could be due to (1) a 
reduction in protein turnover rate, (2) autofluorescence caused by serum when 
present or (3) protein-protein interactions resulting from starving that could 
mask one or both antibody epitopes. We observed reduction of fluorescence 
immediately after removal of serum, suggesting that a reduction in protein 
turnover rate is unlikely. Similarly, we would expect medium-high background 
fluorescence if serum presence produced autofluorescence, which was not 
apparent in cell lines stained in normal media without treatment. Therefore, the 
most likely assumption is that starving alters the epitope structure in some way, 
although there is currently nothing in the literature to support this hypothesis.  
In order to ensure that this reduction in fluorescence was due to removal 
of serum and not a consequence of oxaliplatin treatment, wild type cells were 
stained after removal of serum in the presence and absence of oxaliplatin, 
which confirmed that oxaliplatin treatment had no effect on fluorescence 
reduction.  
The reduction of fluorescence after serum removal proved problematic 
for localisation detection. Higher concentrations of secondary antibody were 
tested and staining with primary antibody only and secondary antibody only 
revealed specific staining for ERCC1 detection. Specific staining for XPF 
detection was achieved by substitution of antibodies. These changes in serum 
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and antibody conditions mean that it was necessary to repeat the negative 
controls after oxaliplatin treatment, which again confirmed that fluorescence 
was specific. 
4.4.2 Percentage localisation of ERCC1 and XPF  
Percentage localisation of ERCC1 and XPF for each cell line was very 
similar, both before and after oxaliplatin treatment, suggesting that our 
immunofluorescence assay was consistent and was probing for conjugated 
repair protein. This also indicated that the method used to quantify fluorescence 
was consistent across all cell lines, even where different antibodies were used 
for XPF detection after oxaliplatin treatment.  
There was considerable variation in percentage localisation of ERCC1 
and XPF between individual wild type cell lines, both before and after oxaliplatin 
treatment. This could be the result of the subtle nature of the ERCC4 variants, 
or due to the presence of additional polymorphisms in other NER genes in 
these cell lines. We genotyped all cell lines for common polymorphisms in 
ERCC1 and ERCC4 (section 3.3.1); however, it is possible that there were 
polymorphisms present in other NER-related genes that we were not aware of, 
which could have additional functional effects on localisation in wild type cell 
lines. Alternatively, this may be the result of an assay limitation in either the 
detection of ERCC1 and XPF, or the method used for quantification of 
fluorescence.  
The percentage localisation differences between cell groups for ERCC1 
and XPF were relatively small. All cell lines carrying Arg576Thr showed reduced 
nuclear localisation of ERCC1 and XPF without treatment, compared with wild 
type cell lines. In contrast, cell lines carrying Glu875Gly showed markedly 
increased nuclear localisation of ERCC1 and XPF without treatment compared 
with wild type cell lines.  
Despite the variation in percentage localisation of ERCC1 and XPF 
between individual wild type cell lines, we decided to analyse the percentage 
viability values for cell lines carrying the same ERCC4 variant collectively to 
allow comparison of localisation between cell groups. The percentage 
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localisation values obtained per cell line were acquired using the same 
microscope slides that were immunofluorescently stained during the same 
experiment; therefore these localisation values cannot be considered 
independent experiments. As a result, localisation values acquired for each cell 
line were averaged, and the mean values for cell lines carrying the same 
ERCC4 variant were analysed by ANOVA.  
The differences in percentage localisation between wild type and variant 
cell lines were relatively small, before and after treatment. The differences in 
localisation were not large enough to suggest that our ERCC4 variants affect 
localisation, either before or after damage. Statistical analysis of ERCC1 and 
XPF localisation between cell groups identified statistically significant 
differences in localisation between Pro379Ser and Glu875Gly cell groups, and 
between Arg576Thr and Glu875Gly cell groups only. All other cell groups 
showed no statistical significance during comparison by ANOVA, which was 
consistent with the relatively small percentage localisation differences between 
wild type and variant cell groups. Therefore, the results do not appear to 
represent a functional difference in the localisation of the repair complex.  
 Recruitment of ERCC1 and XPF into the nucleus after oxaliplatin 
damage, indicated by the RFI value, was similar across all cell lines for both 
ERCC1 and XPF. Following damage by oxaliplatin, we observed ERCC1 
recruitment into the nucleus in nine of twelve cell lines and XPF recruitment in 
eleven cell lines. This indicated that our recruitment assay was consistent, 
including where substitution of antibodies was necessary for XPF detection. 
Statistical analysis of RFI values by ANOVA revealed a statistically significant 
difference between Arg576Thr and Glu875Gly cell groups for ERCC1 
recruitment only, despite very small differences in percentage localisation 
before and after oxaliplatin treatment. However, all other cell groups showed no 
statistical significance with regard to RFI, suggesting that our results do not 
represent a functional difference in recruitment of the repair complex in the 
presence of ERCC4 variants.  
 One variant in particular (Arg576Thr) showed the highest degree of 
recruitment into the nucleus after damage across all cell lines carrying this 
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variant, with a markedly higher recruitment in one cell line in particular 
(Arg576Thr 2). Additionally, cell lines carrying Arg576Thr showed the highest 
degree of mislocalisation to the cytoplasm without treatment, followed by the 
highest degree of nuclear recruitment after oxaliplatin treatment. Despite this, 
comparison of the Arg576Thr cell group with all other cell groups identified 
statistical significance with the Glu875Gly group only.  
Mislocalisation of ERCC1 and XPF to the cytoplasm has been shown 
previously in monoallelic XPF mutant cell lines by immunofluorescence, 
including cells carrying Pro379Ser, without treatment. Similar to our data, these 
XPF mutant cell lines also showed pancellular XPF localisation with some cells 
demonstrating exclusively cytoplasmic localisation, which was consistent with 
ERCC1 staining (Ahmad et al. 2010). Our variant cell lines were 
haploinsufficient due to the presence of only one variant allele, and therefore 
consistently demonstrated pancellular localisation of ERCC1 and XPF with and 
without treatment.  
 Despite the consistency with regard to percentage localisation values 
acquired using this assay, there is a lack of similarity in the staining patterns 
between ERCC1 and XPF, which is demonstrated in Figures 4.2 and 4.3. 
During optimisation, the specificity of the primary antibodies was not validated; 
therefore, although we have confirmed that the secondary antibodies bind 
correctly to the primary antibodies, it is possible that the primary antibodies are 
not specific enough to detect only ERCC1 and XPF, respectively. This could 
result in observation and quantification of additional proteins, which could 
potentially produce unreliable percentage localisation values. The specificity of 
the primary antibodies could have been confirmed by transfection of bacterial 
plasmids containing the protein of interest and a fluorescent tag, which could be 
immunofluorescently stained and viewed by confocal microscopy. A specific 
antibody would co-localise with the fluorescent construct containing the protein 
of interest. An alternative positive control assay for specificity would involve 
transfection of cells with small interfering RNA (siRNA) to knock down the 
expression of ERCC1 and XPF, resulting in reduced or negligible fluorescence 
following immunofluorescent staining, depending on the degree of transfection 
that is achieved.   
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 4.4.3 Optimisation of immunofluorescence assay in S. pombe  
During optimisation, we tested different conditions for zymolyase 
treatment and cell membrane permeabilisation, as these are the two most 
critical factors of the protocol to enable antibody molecules to diffuse into the 
cell’s interior. Once this was successfully optimised, different primary antibody 
concentrations were tested to maximise the fluorescent signal.   
We stained both wild type and rad16Pro361Ser strains without treatment as 
negative controls to account for the different cell wall thicknesses exhibited by 
different strains of S. pombe (Osumi et al. 1998; Calonge et al. 2000). This 
could adversely affect the amount of antibody that is able to penetrate the cell 
membrane; by testing optimised conditions in multiple strains we ensured that 
the staining conditions would be applicable to all strains of interest.  
  Similar to the fluorescence pattern seen in human cell lines, rad16 
fluorescence was pancellular across all S. pombe strains. As a result, we 
decided to image the S. pombe strains as MP files using similar parameters to 
those used for imaging cell lines, although a higher zoom factor was necessary 
to account for the smaller size of cells (10m compared with 30m in human 
lymphoblastoid cells; Mitchison and Nurse, 1985). This avoided the need for 
repeating the optimisation process for the confocal microscope.  
4.4.4 Percentage localisation of rad16 
Percentage localisation of rad16 was very similar across wild type and 
variant strains of S. pombe, with and without oxaliplatin treatment. The 
percentage localisation range was approximately 2%, compared with >10% in 
human cell lines for localisation of ERCC1 and XPF. Statistical analysis of 
percentage localisation of rad16 between strains was performed by ANOVA, 
using all localisation values per strain (n=20) as input. Despite this, all values 
acquired for each strain cannot be considered independent experiments, since 
all values were acquired using the same microscope slides that were 
immunofluorescently stained and imaged during the same experiment. 
Statistical analysis of rad16 localisation between strains produced no 
statistically significant findings, which was consistent with the small differences 
in percentage localisation. This suggested that our assay was unable to detect 
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differences in rad16 localisation between wild type and variant S. pombe 
strains. 
Following oxaliplatin treatment, the wild type strain demonstrated very 
little recruitment of rad16 into the nucleus to facilitate DNA repair as we would 
expect. We also observed no recruitment of rad16 in the rad16Ser585X strain; 
since this strain carried the novel stop gain truncating variant present in Patient 
8, we would have expected this strain to show considerably higher recruitment 
than wild type and remaining variant cells. However, this strain demonstrated no 
recruitment, whilst all other variant strains demonstrated very little recruitment. 
This suggested that we cannot conclude that there was any trend in rad16 
recruitment after damage by oxaliplatin.  
 Statistical analysis of RFI following DNA damage by ANOVA showed a 
significant difference in recruitment patterns between the wild type and 
rad16Glu844Gly variant strain, whereas comparison of RFI between all remaining 
strains demonstrated no statistical significance. Statistical analysis of RFI 
between strains was performed by ANOVA, using all RFI values per strain 
(n=20) as input. Therefore, this statistically significant difference was most likely 
the result of comparison of large cell numbers per strain. All RFI values per 
strain were acquired using the same microscope slides that were 
immunofluorescently stained and imaged during the same experiment, therefore 
they cannot be considered independent experiments. 
Since S. pombe is a haploid model organism, there is no issue with 
haploinsufficiency, unlike in the variant cell lines. Therefore we hoped that, by 
probing for the His tag conjugated to rad16 before and after damage, we would 
observe a more distinct difference in the localisation and recruitment of the 
repair protein than that seen in the heterozygous mammalian cell lines. 
Unfortunately, this was not the case. It is possible that there was a limitation 
within the assay. The low background noise seen during imaging of S. pombe 
suggested that the antibody was specific. However, it is possible that the 
antibody was not sensitive enough to detect the levels of His tag present, or 
alternatively the protocol may have required further optimisation to increase cell 
wall degradation or cell membrane permeabilisation. If either of these steps 
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were not entirely successful, the antibody’s ability to reach its target antigen 
could have been compromised, resulting in a reduction in fluorescent count. 
Alternatively, there may have been other novel repair pathways involved; it has 
been reported that S. pombe have an additional repair pathway to remove UV-
induced lesions, the UV-damaged DNA endonuclease (UVDE)-dependent 
excision repair (UVER) pathway (Yasuhira and Yasui, 2000). Therefore it is 
possible that S. pombe could harbour other novel DNA repair pathways that 
could be repairing damage before rad16 localisation becomes necessary to 
carry out repair via the typical NER pathway.  
4.4.5 Alternative assays for localisation studies 
Alternative assays may be useful for protein localisation studies; these 
include co-immunoprecipitation (co-IP) and western blotting (WB), both of which 
involve cell lysis followed by probing for proteins using antibodies. For these 
assays, cells are lysed into nuclear and cytoplasmic fractions and protein 
localisation is identified by development of bands in a dark room using a 
chemiluminescent substrate. These can be viewed subjectively or quantified by 
densitometry (Bronstein et al. 1992).  
During WB, cells are lysed into cellular fractions and polypeptides are 
separated by electrophoresis in polyacrylamide gels. Proteins are isolated from 
electrophoretic gels and blotted directly onto membranes, typically by electro-
blotting which has a high degree of speed and efficiency (Kurien and Scofield, 
2006). This potentially increases accuracy of protein yield, prior to probing with 
antibodies, which may be advantageous when compared with 
immunofluorescence, which requires optimisation of several steps for effective 
antigen detection. If any one of the fixation, permeabilisation and blocking steps 
are not efficient enough, antigen detection is compromised (Mosedale et al. 
1996).  
However, similar to immunofluorescence, the specificity and sensitivity of 
these assays is largely dependent on the antibodies used. For this reason, the 
quantitation of protein localisation by WB is limited to the activity of the 
antibody, meaning that co-IP and WB are most likely alternative assays with 
equally limited sensitivity and specificity (Chang and Lovett, 2011). 
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Chapter Five – Rate of repair in wild type and variant ERCC4 cell lines 
after DNA damage 
5.1 Introduction  
Mutations in XP genes have been linked to defects in numerous repair 
pathways, including NER, DSB repair and ICL repair by homologous 
recombination (HR). DNA repair studies in a variety of model organisms 
carrying mutations in XP genes are outlined in Table 5.1.  
 A study designed to assess XPF function in vivo using homozygous 
XPF-deficient mice and a separate group of homozygous ERCC1-deficient mice 
revealed severe postnatal growth defects followed by premature death at three 
weeks of age. Embryonic fibroblasts isolated from these mice were 
hypersensitive to UV irradiation and mitomycin C treatment, indicative of an 
NER defect (Tian et al. 2004). Other studies using fibroblasts from homozygous 
ERCC4- and ERCC1-deficient mice have demonstrated a role for the ERCC1-
XPF complex in processing ICL-induced DSBs in preparation for repair by HR. 
This was indicated by chromatid fusions and inhibition of downstream DSB 
repair in mutant cell lines after mitomycin C treatment. Identical effects were 
shown in ERCC1- and ERCC4-deficient mice, consistent with the functional link 
between ERCC1 and XPF (Niedernhofer et al. 2004). This was supported by 
further work by Zhang et al. (2007) using a combination of heterozygous human 
lymphoid cell lines and homozygous mouse fibroblast cells, who reported that 
ERCC1-XPF acts in conjunction with the mismatch repair protein MSH2 to 
uncouple the ICL lesion prior to HR. This suggested a more specific role for 
ERCC1-XPF in HR, in addition to recruitment to the DSB site.  
The majority of repair studies investigating ERCC1 and XPF were carried 
out using biallelic mutant models. We hoped to further previous work by 
investigating the rate of repair after damage in cell lines carrying heterozygous 
variants in ERCC4, which may affect function of the ERCC1-XPF complex 
responsible for 5’ incision during NER.  
Propidium iodide (PI) is a fluorescent dye that permeates the damaged 
cell membranes of non-viable cells, making it ideal for exclusion of non-viable  
149 
 
Gene 
(Protein) 
Model organism Effect seen References 
XPA (XPA) Human XPA-deficient 
(heterozygous) 
lymphoblast and 
fibroblast cell lines  
Reduced affinity between XPA and 
ERCC1, required for correct 
positioning of ERCC1-XPF during 
NER, leading to defective NER 
Li et al. 1995 
XPA/ERCC2 
(XPA/XPD) 
Mice carrying double 
homozygous 
mutations in XPA and 
ERCC2 
Accelerated ageing phenotype 
when XPA and ERCC2 mutations 
were combined  
De Boer et 
al. 2002 
XPE (DDB2) Heterozygous XPE 
human 
lymphoblastoid and 
fibroblast cell lines 
No degradation of p48, suggesting 
a functional connection between 
UV-damaged DNA binding protein 
complex (UV-DDB binding) and 
proteasomal degradation of p48 in 
early NER, which is impaired with 
XPE mutation 
Rapic-Otrin 
et al. 2002 
ERCC4 and 
ERCC1  
(XPF and 
ERCC1) 
ERCC4- and ERCC1-
deficient mice 
(homozygous mutant) 
Severe postnatal growth defect 
resulting in death after 3 weeks; 
embryonic fibroblasts showed 
hypersensitivity to UV and 
mitomycin C; effects seen in mice 
deficient for ERCC1 and ERCC4 
independently  
Tian et al. 
2004 
ERCC4 and 
ERCC1 
(XPF and 
ERCC1) 
Homozygous ERCC4 
and ERCC1 
embryonic stem cell 
fibroblasts isolated 
from mice  
Mitomycin C treatment caused 
chromatid fusions and inhibition of 
downstream DSB repair, 
highlighting a role in DSB repair.  
Niedernhofer 
et al. 2004 
ERCC4 and 
ERCC1 
(XPF and 
ERCC1) 
Mutant heterozygous 
ERCC4 and ERCC1 
human lymphoid cell 
lines, homozygous 
ERCC4- and ERCC1- 
deficient mouse 
fibroblasts  
Cell lines were deficient in ICL-
induced HR, suggesting that 
ERCC1-XPF has a role more 
specific to HR of ICL-induced 
DSBs, rather than being recruited to 
the site of DSBs only. 
Zhang et al. 
2007 
TTD-A 
(Smallest 
subunit of 
TFIIH) 
Homozygous 
fibroblasts isolated 
from human patients 
with photosensitive 
TTD-A 
Severely delayed repair of UV 
damage in TTD-A mutant cells 
compared with wild type cells, 
which could explain relatively mild 
photosensitivity suffered by patients 
with TTD-A. 
Theil et al. 
2011 
ERCC2 
(XPD) 
Fibroblasts from a 
patient with TTD 
caused by 
homozygous XPD 
mutations 
Deficient in repair of both CPDs and 
(6-4)PPs after UV irradiation, 
suggesting that cancer-free 
phenotype in TTD may be linked to 
a transcription defect. 
Nishiwaki et 
al. 2004; 
Berneburg et 
al. 2000 
ERCC2  
 (XPD) 
Baculovirus 
expression system 
transfected with 
heterozygous ERCC2 
variants 
Normal DNA repair and 
transcription, suggesting that single 
polymorphisms in ERCC2 may be 
benign; numerous polymorphisms 
required for cancer-prone 
phenotype in XP. 
Laine et al. 
2007 
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Gene 
(Protein) 
Model organism Effect seen References 
ERCC2   
(XPD) 
DNA isolated from 
female Caucasian 
participants 
(heterozygous and 
homozygous variants 
identified at codons 
312 and 751) 
Homozygous ERCC2 mutations at 
the Lys/Lys codon 751 locus 
associated with significantly 
reduced repair of X-ray-induced 
DNA damage  
Lunn et al. 
2000 
ERCC8 
(CSA) 
DNA isolated from 
dermal fibroblasts of 
a patient with CSA 
(homozygous or 
dominant 
heterozygous for 
ERCC8 variant) 
Impaired removal of UV-induced 
lesions by TC-NER, without 
affecting the protein’s role in 
oxidative damage response. Variant 
could be homozygous or dominant 
heterozygous for mutation (paternal 
DNA not available for sequencing).  
Nardo et al. 
2009 
ERCC8/ 
ERCC6 
(CSA/CSB) 
Human wild type, 
CSA, CSB and XPA 
fibroblast cell lines 
(heterozygous) 
Reduced transcription (indicated by 
reduced RNA synthesis) after UV 
damage in CS cell extracts 
correlated with a marked reduction 
in RNA polymerase II (RNAPII); 
suggesting that repression of 
transcription initiation is partially 
responsible for inhibition of 
transcription after damage in CS 
patients.  
Rockx et al. 
2000 
ERCC8/ 
ERCC6 
(CSA/CSB) 
ERCC6- and ERCC8-
deficient embryonic 
fibroblasts and stem 
cells isolated from 
mice (homozygous 
mutant) 
Distinct differences between CSA 
and CSB in terms of sensitivity to 
oxidative damage by gamma ray 
treatment, despite similar clinical 
manifestations of CSA and CSB 
patients; this suggests a role of 
CSB in repair of oxidative DNA 
damage. 
De Waard et 
al. 2004 
ERCC5 
(XPG) 
Fibroblasts from non-
sun exposed skin 
isolated from siblings 
with XP (homozygous 
variants in ERCC5)  
Corrected repair of oxidative stress 
but not UV damage; this suggests 
that the XP phenotype in these 
patients is the result of novel 
ERCC5 mutations and their inability 
to repair UV damage. 
Soltys et al. 
2013 
 
Table 5.1 Summary of DNA repair studies in model organisms carrying mutations 
in NER genes.  
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cells during FACS (Banerjee et al. 2014). There are a number of examples in 
the literature where removal of non-viable cells in vitro has been used to 
improve experimental conditions. Rogers et al. (2010) showed that bacterial 
DNA-based techniques are unable to differentiate between viable, non-viable 
bacteria and extracellular DNA, resulting in false positive results and an inability 
to predict therapy response in cystic fibrosis patients, requiring removal of non-
viable DNA prior to analysis. Additionally, Gregory et al (2009) demonstrated 
that removal of non-viable cells greatly improves antibody production in vitro. 
UV light produces intrastrand crosslinks of two adjacent pyrimidines, 
resulting in cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts [(6-
4)PPs] (Dreze et al. 2014). (6-4)PPs are highly distorting lesions that can be 
rapidly repaired by TC- NER, whereas CPDs are able to form base pairs with 
the opposite DNA strand, resulting in slower repair by global genome (GG)-NER 
(Hyka-Nouspikel et al. 2012). Several studies have shown that the ratio of 
overall formation of CPDs to (6-4)PPs by UV-C light is 3:1 (Mitchell, 1988), 
making CPDs the preferable lesion to probe for to investigate repair rates.  
Here, we sought to identify the functional consequences of ERCC4 
variants on repair capacity after DNA damage by enzyme-linked 
immunosorbent assay (ELISA). We administered cell lines with UV-C irradiation 
and oxaliplatin to examine the repair rate of lesions in wild type and variant cell 
lines.  
5.2 Materials and Methods 
 5.2.1 UV irradiation 
During optimisation, wild type cells were seeded onto poly-L-lysine 
coated dishes and UV (20J) treated in SF media, prior to ELISA using a 
commercial kit to detect CPD formation within cells. Wild type cells and cells 
carrying Pro379Ser were irradiated in suspension with different UV doses (20-
400J) over 48 hours under different serum starving conditions. UV irradiation 
was carried out with cells suspended in SF media and PBS, and cells were UV 
treated using a germicidal lamp and a crosslinker for comparison. 
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Optimised conditions were as follows: cells were centrifuged at 1,200 
RPM for five minutes to produce a cell pellet. The supernatant was removed 
and cells were suspended in SF media. Cells were irradiated with UV-C (70J) in 
large single well dishes using a UV crosslinker, followed by immediate re-
suspension in normal tissue culture media containing FBS and antibiotics. 
Aliquots of cell suspension were removed at 0, 4, 24 and 48 hours after UV 
treatment. 
 5.2.2 Oxaliplatin treatment 
During optimisation, wild type cells were treated with different 
concentrations (1.25-10µg/ml) of primary cisplatin modified-DNA antibody and 
for different incubation times (1-3 hours), prior to DNA extraction and assay by 
ELISA.  
Optimised conditions were as follows: cells were suspended in SF media 
by centrifugation as outlined in 5.2.1, followed by immediate addition of 
oxaliplatin (125µM) to tissue culture media for 1 hour at 37°C. After treatment, 
cells were re-suspended in normal media containing FBS and antibiotics and 
aliquots of cell suspension were removed at 0, 4, 24 and 48 hours. 
 5.2.3 FACS  
Aliquots of cell suspension were sorted by FACS as described in section 
2.5.3.4. Only viable cells were retrieved in normal tissue culture media 
containing FBS and antibiotics (purity > 98%) prior to DNA extraction.  
 5.2.4 DNA extraction  
Genomic DNA was extracted from viable cell suspensions using a 
commercial extraction kit according to the manufacturer’s instructions (Qiagen; 
Section 2.5.3.5). DNA was eluted in 20µl elution buffer and stored at -20°C for 
long-term storage.  
 5.2.5 ELISA for CPD detection 
 DNA samples were probed for CPDs using a commercial ELISA kit 
according to the manufacturer’s instructions (Cell BioLabs). Briefly, DNA 
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samples and a DNA standard conjugated to a known amount of CPDs were 
converted to single stranded (ss) DNA by incubation at 96°C for ten minutes 
followed by rapid chilling on ice for ten minutes. DNA was diluted to 200ng/ml in 
cold PBS and incubated overnight at 4°C prior to ELISA.  
 Wells were washed twice with cold PBS, followed by hour-long 
incubations at room temperature with assay diluent, primary CPD antibody, 
blocking reagent and secondary horseradish peroxidase (HRP)-conjugated 
antibody, with wash steps between each incubation. Substrate solution was 
added to each well and incubated for 20 minutes at room temperature, before 
addition of stop solution to terminate the enzyme reaction. Absorbance was 
read at 450nm using a plate reader, with a reference range of 620nm. 
DNA samples from treated and untreated cell lines were assayed for 
CPDs by ELISA and CPD formation was plotted against time. Duplicate DNA 
samples from wild type and variant cell lines with and without UV treatment 
were assayed on separate ELISA plates and CPD levels were averaged. This 
initial data was then validated by repeating UV treatments across all cell lines 
and again assaying duplicate DNA samples on separate plates.  
 5.2.6 ELISA for oxaliplatin adduct detection  
 DNA samples were probed for oxaliplatin adducts using the same 
commercial ELISA kit in 5.2.5, with substituted primary and secondary antibody. 
Antibodies used were a rat cisplatin modified-DNA primary antibody and goat 
anti-rat HRP-conjugated secondary antibody (both purchased from Abcam). 
Absorbance was read in the same way as in 5.2.5.  
There is no commercially available antibody for detection of oxaliplatin-
DNA adducts or a cisplatin-DNA standard to allow quantification of lesions by 
ELISA. As a result, oxaliplatin lesions were quantified as arbitrary units (AU) 
based on the absorbance reading of each sample. The cisplatin-modified DNA 
primary antibody was selected because it probes for the same epitope as that 
produced by oxaliplatin adduct formation. 
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 5.2.7 Statistical analysis 
Statistical analysis was performed in SPSS v.20.0 using a two-way 
ANOVA, with mutation status (wild type, Pro379Ser, Arg576Thr and Glu875Gly) 
and treatment (no treatment and UV treatment) as the independent variables. 
The dependent variable was CPD formation (ng/ml) as a measure of DNA 
damage. CPD formations for all cell lines carrying the same ERCC4 variant 
were averaged to allow comparison of CPD formation with and without UV 
treatment for individual cell groups. Individual ANOVAs were run on CPD 
formations acquired at 24 and 48 hours. The duplicate values for cell groups 
acquired during the initial test experiment were analysed independently of 
duplicate values acquired during validation. Only CPD values from samples run 
on the same ELISA plate were compared with one another, which meant that 
one set of wild type samples were analysed with Pro379Ser and Arg576Thr 
samples, and another set of wild type samples were analysed with Glu875Gly 
samples. Oxaliplatin treated samples showed no difference in the primary 
results, therefore no statistics were applied to this data set. 
5.3 Results 
5.3.1 Optimisation of UV assay 
A summary of the optimisation stages is shown in Figure 5.1. Wild type 
cells were seeded onto tissue culture dishes coated with poly-L-lysine, 
fibronectin and laminin and allowed to form a monolayer overnight, prior to UV 
(20J) treatment in SF media. Cells were probed for CPD formation over 24 
hours using a cellular ELISA kit (Cell BioLabs), which resulted in low CPD 
formation. Microscopic examination of the dishes indicated that the vast majority 
of cells were washed off during the wash steps of the protocol, irrespective of 
adhesion matrix used (data not shown). 
 We therefore extracted DNA from cells for analysis. Wild type cells and 
cells carrying Pro379Ser were irradiated with UV (20J) using a germicidal lamp 
in SF media after overnight starvation. DNA was extracted at 0, 4 and 24 hours 
from UV treated and untreated cell lines and assayed for CPD formation using 
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Figure 5.1 Schematic diagram of optimisation of both UV and oxaliplatin ELISAs. A cellular ELISA kit for CPD detection was tested in cells seeded 
onto tissue culture plates, which showed cells being removed from plates during wash steps. A non-cellular ELISA kit was therefore used, requiring DNA 
extraction prior to ELISA. Initial experiments using this kit showed that the ELISA could differentiate between untreated and UV irradiated samples, but no 
repair was seen. We incorporated fluorescence activated cell sorting (FACS) to remove non-viable cells prior to DNA extraction, which revealed repair after 
UV treatment. However other technical challenges arose, resulting in substitution of the original germicidal lamp for a UV cross-linker to allow a single UV 
dose per experiment, which allowed collection of experimental data. The non-cellular ELISA kit was modified for oxaliplatin adduct detection by substituting 
primary and secondary antibodies. Various concentrations of primary antibody and duration of oxaliplatin treatment (1-3hr) were tested, resulting in optimum 
conditions for the oxaliplatin adduct ELISA. 
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Figure 5.2 Initial testing of UV treated and untreated DNA samples in the 
commercial ELISA kit. Wild type and cell lines carrying Pro379Ser were incubated in 
SF media overnight prior to UV irradiation (20J). DNA was extracted at 0, 4 and 24hrs 
post-treatment and assayed for CPDs using a commercial ELISA kit. CPD formation 
(ng/ml) was plotted against time (hr). The data shown in A) and B) were acquired in 
separate experiments under identical conditions, highlighting a discrepancy in the 
amount of damage cells receive when using the UV-C germicidal lamp (maximum CPD 
formation of approximately 130 and 440ng/ml in A) and B) respectively). This data 
indicated that the ELISA kit can differentiate between UV irradiated and untreated DNA 
samples, but further improvements were needed to address the inconsistencies in CPD 
formation and lack of repair. 
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the non-cellular CPD ELISA kit. Separate experiments under identical 
conditions revealed that the non-cellular ELISA kit was capable of differentiating 
between untreated and treated cells (Figure 5.2), although no repair was seen. 
Additionally, there were discrepancies in the maximum CPD formation seen 
under identical experiments, suggesting a potential problem with reproducibility 
of UV irradiation when using the germicidal lamp (Figure 5.2). We tested higher 
UV doses (100-500J) in SF media without prior starvation in wild type cell lines 
and carried out DNA extraction at 0, 0.5, 4, 24 and 48 hours. Cells used for 
DNA extraction at 0 hours were placed on ice immediately after UV irradiation, 
in an attempt to slow the damage process. This had no effect on reducing the 
initial CPD formation seen at 0 hours with UV treatment, and again no repair 
was seen (data not shown).  
Wild type cell lines and cells carrying Pro379Ser were irradiated with 
high dose UV (100-400J) in SF media with and without fluorescence activated 
cell sorting (FACS) to remove non-viable cells prior to DNA extraction and 
ELISA. We observed no apparent repair over 24 hours without FACS. However, 
once FACS was incorporated, repair was seen between 4 and 48 hours after 
UV treatment (Figure 5.3). However, when conditions were tested in remaining 
cell lines, results were still inconsistent (data not shown).  
In an attempt to reduce these inconsistencies, we (i) modified the DNA 
extraction protocol to prevent carry-over of wash buffers into eluted DNA, (ii) 
analysed the accuracy of DNA extractions and (iii) tested the effect of SF media 
and PBS on CPD formation after UV treatment. These modifications still 
produced inconsistent results, despite revealing that the DNA concentrations by 
nanodrop were accurate. During FACS we observed a higher viability of cells 
treated in SF media compared with PBS, which made the FACS process 
quicker and the DNA yield higher. Following FACS and dilution of DNA prior to 
ELISA, we observed comparable CPD formation in UV irradiated samples, 
irrespective of suspension medium used (data not shown).  
We considered whether the method of UV irradiation could be the reason 
why no consistent repair had been demonstrated, even after removal of non-
viable cells by FACS. When using a germicidal UV-lamp for UV irradiation, 
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Figure 5.3 Incorporation of FACS to remove non-viable cells before DNA extraction. Wild type cells and cells carrying Pro379Ser were treated 
with high dose UV in SF media and incubated for 24 and 48 hours. DNA was extracted at the time points shown A) without FACS and B) after FACS 
prior to ELISA (sample purity 98-99% at time of sorting). In both experiments the kit was able to differentiate between treated and untreated samples. 
However, repair between 4 and 48 hours was only seen after removal of non-viable cells by FACS prior to DNA extraction. During FACS, cells are 
analysed by forward scatter according to area and height (FSC-A and FSC-H, respectively) and side scatter (SSC-A) and gated to allow passage of 
only viable cells through the sorting apparatus, as shown in (C). The number of events and percentage of parent and total populations at each gating 
stage (P1-3) are shown in (D). P1 = cells selected based on morphology (FSC-A/FSC-H versus SSC-A); P2 = single unstained cells; P3 = negative 
(viable) cells. 
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Figure 5.4 Substitution of a UV-C germicidal lamp for a UV-crosslinker to produce more consistent results. Wild type cells and cells carrying 
Pro379Ser were treated with (A) UV (40J) using the UV-C germicidal lamp and (B) UV (70J) using a UV-crosslinker in SF media. The substitution of 
the UV-crosslinker enabled a switch to large tissue culture dishes, allowing for one uniform UV treatment of the entire cell suspension. At each time 
point, cells were sorted by FACS and DNA was extracted using the modified method, prior to assay for CPDs by ELISA. Individual UV treatments per 
time point using the germicidal lamp produced inconsistent results (A), suggesting that a uniform UV treatment using the UV-crosslinker followed by 
removal of aliquots at each time point might be a better approach. This modification to the method produced more consistent results (B). 
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there was a maximum area (a circle of approx. 100mm diameter) that can be 
irradiated to ensure uniform treatment of all cells within the suspension. This 
required a separate tissue culture dish per time point and several different UV 
treatments per experiment. Alternatively, a UV crosslinker had a much larger 
area for uniform UV irradiation (approx. 200 x 300mm). We compared UV (40J) 
treatment using a germicidal lamp with UV (70J) treatment using a UV 
crosslinker in wild type cells and cells carrying Pro379Ser. Cells irradiated with 
the germicidal lamp showed inconsistent results (Figure 5.4a). UV treatment 
using a crosslinker in a single dish followed by removal of aliquots at each time 
point produced more consistent results, demonstrating repair in all wild type cell 
lines between 4 and 48 hours after treatment, with delayed repair in all cell lines 
carrying Pro379Ser (Figure 5.4b). 
5.3.2 Effect of UV light on repair in variant cell lines 
Wild type and ERCC4 variant cell lines were irradiated with UV (70J) light 
in SF media and CPD formation was measured by ELISA over 48 hours. All cell 
lines without UV treatment showed negligible CPD formation (<1ng/ml) at all 
time points.  
Wild type cell lines with UV treatment achieved CPD levels of 
approximately 210-260ng/ml at 0 and 4 hours, followed by noticeable repair 
between 4 and 48 hours, reaching comparable levels with untreated samples 
after 48 hours, with minimal variation between individual wild type cell lines. Cell 
lines carrying Pro379Ser with UV treatment achieved similar CPD levels to wild 
type cell lines at 0 and 4 hours, but failed to repair lesions after 48 hours in two 
cell lines (Pro379Ser 1 and 2) and demonstrated delayed repair in one cell line 
(Pro379Ser 3) during the test experiment (Figure 5.5a). The Pro379Ser 3 cell 
line began repair after 24 hours, indicated by CPD levels of 257ng/ml and 
121ng/ml at 24 and 48 hours respectively. Validation of this data showed very 
similar results, with the exception of a lack of repair after 48 hours in the 
Pro379Ser 3 cell line (Figure 5.5b).  
Cell lines carrying Arg576Thr treated with UV similarly showed relatively 
stable levels of CPDs between 0 and 24 hours before commencement of repair, 
indicated by CPD formation ranges of approximately 259-260ng/ml and 104- 
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Figure 5.5 Effect of UV treatment on repair in cell lines carrying Pro379Ser. 
Average CPD formation (ng/ml) in wild type cells and cells carrying Pro379Ser in 
ERCC4 with and without UV-C (70J) irradiation, showing the initial (A) and validation 
(B) experiment. CPD concentrations for each experiment are plotted as an average of 
two duplicate samples from the same experiment run on separate ELISA plates, which 
are plotted against time with standard error bars. The test and validation experiments 
were biological repeats of the same experiment performed on separate days under 
identical conditions.  
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Figure 5.6 Effect of UV treatment on repair in cell lines carrying Arg576Thr. CPD 
formation (ng/ml) in wild type cells and cells carrying Arg576Thr in ERCC4 with and 
without UV-C (70J) irradiation, showing the initial (A) and validation (B) experiment. 
CPD concentrations for each experiment are plotted as an average of two duplicate 
samples from the same experiment run on separate ELISA plates, which are plotted 
against time with standard error bars. The test and validation experiments were 
biological repeats of the same experiment performed on separate days under identical 
conditions.  
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113ng/ml at 24 and 48 hours respectively (Figure 5.6a). Validation of this data 
showed similar results (Figure 5.6b).  
Cell lines carrying Glu875Gly treated with UV showed a very similar 
repair trend to cells carrying Arg576Thr, with high levels of CPDs between 0 
and 24 hours and repair between 24 and 48 hours, indicated by CPD level 
ranges of 209-276ng/ml and 90-141ng/ml at 24 and 48 hours respectively 
(Figure 5.7a). Validation of this data showed similar results (Figure 5.7b).  
Statistical analysis of CPD formation in cell groups was performed by 
two-way ANOVA, as separate analyses for the initial test experiment and the 
validation experiment. Comparison of each cell group based on association 
between ERCC4 mutation and treatment type during the initial test experiment 
revealed a statistically significant association at both 24 and 48 hours (P = 
0.000; Table 5.2). Further investigation using a post hoc Tukey test identified a 
statistically significant difference in CPD formation between wild type cells and 
all ERCC4 variant cell groups (P = 0.000) at 24 hours. Additionally, after 48 
hours, statistical significance was identified between Pro379Ser and Arg576Thr 
cell groups (P = 0.000), and between Pro379Ser and Glu875Gly cell groups 
undergoing UV treatment (P = 0.001; Table 3.2). Statistical analysis of CPD 
formations acquired during validation showed very similar results, with 
additional statistically significant differences between Pro379Ser and Arg576Thr 
cell groups (P = 0.000), and between Pro379Ser and Glu875Gly cell groups (P 
= 0.000) after 24 hours (Table 3.3).   
5.3.3 Optimisation of oxaliplatin assay  
Wild type cells were treated with oxaliplatin (125µM) for 1 hour in SF 
media, followed by incubation in normal media for up to 48 hours. At 2 and 4 
hours after treatment, cells were sorted by FACS and DNA was extracted, 
followed by ELISA using substituted antibodies. This revealed low adduct 
formation in untreated cells and a peak in adduct formation after 2 hours in 
treated cells, indicating potential for the antibodies used to assay for oxaliplatin 
adducts (data not shown).  
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Figure 5.7 Effect of UV treatment on repair in cell lines carrying Glu875Gly. CPD 
formation (ng/ml) in wild type cells and cells carrying Glu875Gly in ERCC4 with and 
without UV-C (70J) irradiation, showing the initial (A) and validation (B) experiment. 
CPD concentrations for each experiment are plotted as an average of two duplicate 
samples from the same experiment run on separate ELISA plates, which are plotted 
against time with standard error bars. The test and validation experiments were 
biological repeats of the same experiment performed on separate days under identical 
conditions. 
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A. 
 24hr 48hr 
Mutation Treatment Mean SD Mean SD 
Wild Type NT 0.0000 0.00000 1.8117 2.18417 
UV 137.7533 12.19263 24.1100 18.38379 
Pro379Ser NT 0.2267 0.23577 0.5550 0.64246 
UV 261.8800 7.46706 218.9933 76.70514 
Arg576Thr NT 1.0567 0.46620 0.0000 0.00000 
UV 259.7817 7.65487 108.9217 6.76938 
Glu875Gly NT 0.0183 0.03251 0.0100 0.01673 
UV 249.3883 32.44602 119.3883 26.15201 
B. 
 24hr 48hr 
Mutation 0.000 0.000 
Treatment 0.000 0.000 
Mutation*Treatment 0.000 0.000 
C. 
Mutation P value (24hr) P value (48hr) 
 
Wild Type 
Pro379Ser 0.000 0.000 
Arg576Thr 0.000 0.007 
Glu875Gly 0.000 0.002 
 
Pro379Ser 
Wild Type 0.000 0.000 
Arg576Thr 0.999 0.000 
Glu875Gly 0.623 0.001 
 
Arg576Thr 
Wild Type 0.000 0.007 
Pro379Ser 0.999 0.000 
Glu875Gly 0.697 0.972 
 
Glu875Gly 
Wild Type 0.000 0.002 
Pro379Ser 0.623 0.001 
Arg576Thr 0.697 0.972 
Table 5.2 Statistical analysis of cell groups during initial test experiment 
following UV treatment. CPD formations for cell lines carrying the same ERCC4 
variant with and without UV (70J) treatment were averaged and compared using a two-
way ANOVA. (A) Mean and standard deviations for each cell group before and after UV 
treatment at 24 and 48 hours are shown. (B) P values obtained by ANOVA are given 
for CPD formation after 24 and 48 hours for the variables mutation, treatment and the 
association between mutation and treatment (mutation*treatment). Highlighted values 
were statistically significant (P<0.05). A post hoc Tukey test was performed to identify 
which groups significantly differed from one another at 24 and 48 hours, with significant 
p values (<0.05) highlighted. NT = no treatment; SD = Standard deviation. 
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A. 
 24hr 48hr 
Mutation Treatment Mean SD Mean SD 
Wild Type NT 0.2183 0.26716 0.3767 0.19075 
UV 88.2583 1.68842 5.1950 .93104 
Pro379Ser NT 0.0233 0.05715 0.1933 0.13895 
UV 199.4450 11.88586 173.6117 16.97074 
Arg576Thr NT 0.2517 0.29963 0.2533 0.34180 
UV 161.9433 13.86127 83.0417 5.65300 
Glu875Gly NT 0.1067 0.13779 0.0617 0.08256 
UV 157.0833 8.59053 74.6017 9.81068 
B. 
 24hr 48hr 
Mutation 0.000 0.000 
Treatment 0.000 0.000 
Mutation*Treatment 0.000 0.000 
C. 
Mutation P value (24hr) P value (48hr) 
 
Wild Type 
Pro379Ser 0.000 0.000 
Arg576Thr 0.000 0.000 
Glu875Gly 0.000 0.000 
 
Pro379Ser 
Wild Type 0.000 0.000 
Arg576Thr 0.000 0.000 
Glu875Gly 0.000 0.000 
 
Arg576Thr 
Wild Type 0.000 0.000 
Pro379Ser 0.000 0.000 
Glu875Gly 0.827 0.468 
 
Glu875Gly 
Wild Type 0.000 0.000 
Pro379Ser 0.000 0.000 
Arg576Thr 0.827 0.468 
Table 5.3 Statistical analysis of cell groups during the validation experiment 
following UV treatment. CPD formations for cell lines carrying the same ERCC4 
variant with and without UV (70J) treatment were averaged and compared using a two-
way ANOVA. (A) Mean and standard deviations for each cell group before and after UV 
treatment at 24 and 48 hours are shown. (B) P values obtained by ANOVA are given 
for CPD formation after 24 and 48 hours for the variables mutation, treatment and the 
association between mutation and treatment (mutation*treatment). Highlighted values 
were statistically significant (P<0.05). A post hoc Tukey test was performed to identify 
which groups significantly differed from one another at 24 and 48 hours, with significant 
p values (<0.05) highlighted. NT = no treatment; SD = Standard deviation. 
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We tested longer drug incubation times and compared viability of cells during 
FACS. Wild type cells were treated with oxaliplatin (125µM) for 2 and 3 hours, 
followed by incubation in normal media for up to 48 hours. Removal of aliquots 
for FACS and DNA extraction followed by ELISA revealed a peak in oxaliplatin 
adduct formation at 4 hours, followed by repair between 4 and 48 hours in 
treated cells (data not shown). Additionally, during FACS we observed a higher 
viability in cells treated for 2 hours, resulting in a more rapid FACS process and 
a higher yield of DNA for ELISA.  
5.3.4 Effect of oxaliplatin on repair in variant cell lines  
 Wild type and ERCC4 variant cell lines were treated with oxaliplatin 
(125µM) for 2 hours, followed by incubation for 48 hours. DNA samples 
extracted from untreated and treated cell lines were assayed for oxaliplatin 
adducts by ELISA and adduct levels were plotted against time (Figure 5.8). We 
observed low adduct levels in all cell lines without treatment (<0.1 AU). 
Oxaliplatin treated cell lines demonstrated a peak in adduct formation at either 0 
or 4 hours, followed by repair between 4 and 48 hours, with no noticeable 
difference in repair rate between wild type and variant cell lines. At 48 hours, all 
cell lines displayed oxaliplatin adduct levels comparable with untreated cell 
lines, regardless of ERCC4 status. For all three variants in question, between 4 
and 48 hours, variant cell lines consistently showed similar repair rates to wild 
type cell lines. 
5.4 Discussion 
5.4.1 Optimisation of ELISA  
Previous experiments outlined in chapter 4 have shown that our cell lines 
do not adhere successfully to adhesion matrices, since they naturally exist in 
suspension. Initial experiments using a cellular ELISA kit showed that cells were 
removed from the surface of poly-L-lysine coated wells during wash steps, 
confirming that a cellular ELISA kit was not appropriate for this assay.  
A substitution of a non-cellular ELISA kit to detect CPD formation 
required extraction of genomic DNA prior to assay. Initial testing of the non-  
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Figure 5.8 DNA repair in ERCC4 variant and wild type cell lines, with and without 
oxaliplatin treatment. Oxaliplatin adduct formation (AU) in wild type and cells carrying 
(A) Pro379Ser, (B) Arg576Thr and (C) Glu875Gly with and without oxaliplatin (OXA; 
125µM). Adduct formation was measured as optical density. Optical density values for 
each experiment are plotted as an average of two duplicate samples from the same 
experiment run on separate ELISA plates, which are plotted against time with standard 
error bars.
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cellular ELISA kit with DNA samples from untreated and UV treated cell lines 
showed high CPD formations in UV treated cell lines compared with low levels 
in untreated cell lines. This suggested that extracted genomic DNA adhered 
correctly to the wells, therefore resolving the previous issue seen with cell 
removal using the cellular ELISA kit.  
DNA extracted from UV treated cell lines initially appeared to show no 
repair over 24 hours. We incorporated FACS to remove non-viable cells prior to 
DNA extraction, which led to apparent repair between 4 and 48 hours after UV 
treatment. This suggested that the presence of DNA from non-viable cells 
masked repair previously. Despite this modification to the protocol, when these 
conditions were tested in remaining cell lines, inconsistent results were still 
seen. We previously noticed a potential discrepancy in CPD formation after UV 
irradiation by germicidal lamp, despite treating cell lines with the same dose at 
the same intensity. We therefore tested UV treatment in wild type cell lines 
using a UV crosslinker, which allowed for one single UV treatment of the entire 
cell suspension, followed by removal of aliquots at each time point for FACS 
and DNA extraction. This amendment led to more consistent results, most likely 
as a result of more consistent UV irradiation. UV treatment using the germicidal 
lamp required different dishes per time point, resulting in numerous UV 
treatments per cell line per experiment, therefore increasing the potential for 
inconsistent UV doses to reach cells. This made UV irradiation by UV 
crosslinker the preferable irradiation method.    
The non-cellular ELISA kit for CPD detection was modified to probe for 
oxaliplatin-DNA adducts by substituting cisplatin-modified DNA primary antibody 
and an appropriate species specific HRP-conjugated secondary antibody, while 
using all other reagents according to the manufacturer’s protocol. We tested 2 
hour and 3 hour incubation times with oxaliplatin, prior to FACS, DNA extraction 
and ELISA, which demonstrated a peak in damage at 4 hours followed by repair 
between 4 and 48 hours. This was irrespective of treatment time; however, the 
shorter treatment time resulted in a higher viability of cells, meaning that sorting 
by FACS was more efficient and the overall DNA yield was higher. This was 
important because, more rapid FACS resulted in a shorter time between FACS 
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and DNA extraction, which reduced the opportunity for cell death and allowed 
for higher purity samples for analysis by ELISA.  
5.4.2 Repair of ERCC4 variant cell lines after UV treatment  
Untreated samples across all cell lines showed negligible CPD levels 
(<2ng/ml), which showed there were no problems with the specificity of the 
commercial ELISA kit for CPD detection, or its ability to differentiate between 
treated and untreated samples. This was true of both the commercial ELISA kit 
for CPD detection and the use of substituted antibodies to detect oxaliplatin 
adducts. 
UV treatment of wild type cell lines showed high CPD formation at 0 and 
4 hours, followed by marked repair between 4 and 48 hours. The high CPD 
levels seen at 0 hours suggests that damage occurs within the first 30 minutes 
after treatment, since this is the time that elapses between UV treatment and 
cell lysis during DNA extraction. Our data suggests that wild type cell lines 
undergo repair within the first 24 hours, as would be expected (Mailand et al. 
2000). Additionally, CPD levels at each time point were remarkably similar 
across all wild type cell lines, during both test and validation experiments.  
UV treatment of cell lines carrying Pro379Ser showed a distinct lack of 
repair in two cell lines and delayed repair after 24 hours in one cell line. Cell 
lines carrying Arg576Thr and Glu875Gly showed delayed repair that began 24 
hours after UV treatment, compared with repair after 4 hours in wild type cell 
lines. Validation of this data showed very similar results, with consistent CPD 
formations between cell lines carrying the same ERCC4 variant.  
Statistical analysis showed significant differences in CPD formation 
between wild type and all ERCC4 variant groups at 24 hours, followed by 
significant differences in CPD formation between the majority of cell groups at 
48 hours. Statistical comparison of the validation experiment yielded very 
similar results. The only exception was a lack of a significant difference between 
Arg576Thr and Glu875Gly cell groups following UV treatment. These data 
suggest that the presence of our ERCC4 variants adversely affected DNA 
repair.  
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Although the data suggests that the presence of an ERCC4 variant 
disrupts NER following damage by UV light, it is important to consider that the 
absolute concentrations of CPDs measured may have been confounded by 
proliferation of the cells between UV exposure and CPD measurement. The 
assay involved UV irradiation of cell lines followed by incubation in normal 
tissue culture media for up to 48 hours prior to CPD measurement. Since the 
assay used did not account for cell proliferation during this incubation time, it is 
possible that our measurements are lower than would have been measured in a 
population of cells that have not undergone proliferation.  
5.4.3 Repair of ERCC4 variant cell lines after oxaliplatin treatment 
 Oxaliplatin adduct formation in untreated cell lines was negligible, 
suggesting that the use of substituted primary and secondary antibodies in the 
commercial ELISA kit was specific for measurement of oxaliplatin-induced 
lesions. Wild type cell lines treated with oxaliplatin demonstrated a peak in 
oxaliplatin adducts at either 0 or 4 hours, followed by subsequent repair after 4 
hours, reaching lesion levels comparable with untreated samples after 48 hours. 
There appeared to be some degree of variation in peak damage levels and 
repair rates between wild type cell lines.  
Oxaliplatin treatment of cell lines carrying Pro379Ser, Arg576Thr and 
Glu875Gly showed repair rates that were similar to those of wild type cell lines, 
with no distinct differences in repair rate. These findings differed from the effect 
seen in variant cell lines after UV treatment, which could indicate that the 
variants in ERCC4 have little or no effect on the cell’s ability to perform NER 
after oxaliplatin treatment. This may suggest that other pathways are involved in 
repair of damage by drugs such as oxaliplatin, but not UV, which may be 
upregulated to compensate for reduced NER. 
Alternatively, the repair trend seen after oxaliplatin treatment could be 
due to an issue with the specificity of the antibody used, since the primary 
antibody has only been tested in cisplatin treated model organisms. We 
observed consistent repair across all cell lines after oxaliplatin treatment, which 
suggests that the repair phenotype is present. However, we cannot be certain 
that the similar repair pattern between wild type and variant cell lines is a 
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consequence of a reduction in the sensitivity of the antibody as a direct 
consequence of its non-specific nature, resulting in an inability to detect small 
differences in repair rates.  
The ELISA for detection of oxaliplatin adducts was performed in a similar 
way to the ELISA for CPD detection, such that the cells were treated with 
oxaliplatin and maintained in normal tissue culture media for up to 48 hours 
prior to ELISA. Therefore, it is similarly possible that the oxaliplatin adduct 
levels measured by ELISA were confounded by cell proliferation, therefore 
potentially resulting in lower or skewed optical density values for this assay.  
5.4.4 Alternative assays for investigation of repair rates  
Alternative assays may be useful for the investigation of repair after DNA 
damage. A potential alternative is the slot blot (SB) assay, a semi-quantitative 
assay in which a mixture containing biomolecules of interest is applied directly 
to a membrane, followed by detection by either nucleotide probes for northern 
and southern blotting, or by antibodies for western blotting (WB). The SB assay 
has been used previously to show a role of the 19S subunit of the proteasome 
in the regulation of NER (Gillette et al. 2001), in addition to the identification of 
two distinct mechanisms of the ubiquitin-proteasome pathway that control NER 
in Saccharomyces cerevisiae (Gillette et al. 2006). 
 The assay differs from traditional WB because samples are not 
separated by electrophoresis prior to assay, and there are no complex electro-
blotting procedures required, which offers the significant advantage of saving 
time (Kumar et al. 2014; Walsh et al. 1992). It is also more sensitive than ELISA 
in terms of detection, since lower nucleic acid content samples can be run 
successfully in a SB assay, compared with ELISA (allowing detection of 
picograms and nanograms, respectively). Additionally, there is potential for 
increased variability during the numerous wash steps during ELISA (Alamdari et 
al. 2005).  
However, unlike WB, the assay provides no information on the size of the 
target nucleic acid, and where more than one DNA lesion is present, the assay 
is unable to detect the proportions of each nucleic acid; therefore it can only 
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confirm the presence or absence of DNA lesion detected by the antibodies 
being used (Dalle-Donne et al. 2003). Although the immunoblots produced may 
be quantified by densitometry, this can only provide data on the relative 
abundance of different nucleic acids in the same mixture (Brown et al. 2004), 
whereas quantitative ELISA can provide an absolute concentration.  
Other DNA repair capacity assays have been designed, including a 
cellular phenotype comet assay for detection of NER, by probing for 
benzo(a)pyrene diolepoxide (BPDE)-DNA adducts. Measurement of inter- and 
intra-assay variation using this assay identified low variation in peripheral blood 
mononuclear cells (PBMCs), but noticeably higher variation in lymphoblastoid 
cells (Allione et al. 2013), suggesting that this assay was not a suitable 
alternative for our investigation. 
More recently, the SB and ELISA assays were combined for detection of 
carcinoembryonic antigen (CEA) in urine samples from patients with 
gastrointestinal (GI) cancers. The aim was to provide a more rapid, sensitive, 
specific and non-invasive immunodiagnostic test for GI malignancies, in an 
attempt to produce an assay more appropriate for mass screening, in 
comparison to more traditional assays that required expensive specialist 
equipment and longer time periods for incubation (El-Masry et al. 2006). 
 More recent advances in the DNA repair field have led to the 
combination of chromatin immunoprecipitation (ChIP) with either microarray or 
sequencing technology (ChIP-chip and ChIP-Seq, respectively), to allow high-
throughput analysis of repair events throughout the entire genome. These 
assays may be used to investigate epigenetic modifications and DNA-protein 
binding in cells, and can be applied to all DNA damage pathways as long as 
antibodies or tagged DNA damage recognition enzymes are available for 
immunoprecipitation of the respective lesions (Wu et al. 2006; Teng et al. 2010). 
 ChIP-chip technology involves crosslinking DNA and protein or lesion 
with formaldehyde in vivo, immunoprecipitation using antibodies raised against 
the protein or lesion of interest, followed by sonication of DNA bound to protein 
to produce small fragments (0.2-2kb in length). The DNA fragments and 
relevant controls are fluorescently labelled and applied to microscope slides for 
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microarray analysis, in which control DNA acts as a background control and 
comparison of this DNA with immunoprecipitated DNA ensures accurate 
profiling of the position of specific proteins within the genome (Wu et al. 2006). 
This technology is advantageous due to its high specificity for detection of 
genes directly bound by the protein of interest, unlike other classic expression 
arrays that cannot distinguish between genes that are directly regulated or 
modified indirectly. Additionally, its ‘reverse-genetic’ approach allows genome-
wide detection of specific proteins (Buck and Lieb, 2004).  
However, ChIP-chip technology is limited by the amount of starting 
material required for successful array hybridization, which varies considerably 
between applications; previous studies have reported that <10ng DNA is 
hybridised from >50µg sample DNA, requiring hundreds of individual ChIP DNA 
samples to acquire enough DNA for hybridization (Oberley et al. 2004; Orlando 
et al. 1997). The starting material may be amplified by PCR, although in many 
cases PCR bias occurs, particularly in mammalian models where large areas of 
nucleotide repeats can skew data. Additionally, since microarrays covering all 
human chromosomes are not commercially available, the assay is only 
applicable to certain organisms (Wu et al. 2006).    
 Where appropriate microarray technology has not been developed for 
the organism of interest, ChIP-Seq technology can be used; this involves DNA-
protein crosslinking and immunoprecipitation using an identical protocol to that 
of ChIP-chip, followed by direct NGS of small (~35bp) DNA fragments of 
interest (Park, 2009). As a result of rapid progress in NGS technology, ChIP-
Seq provides an alternative assay with higher resolution, reduced noise and 
fewer artefacts than ChIP-chip (Bentley, 2006; Shendure and Ji, 2008). 
Additionally there is markedly greater genome coverage associated with ChIP-
Seq, which is particularly useful for analysis of repetitive regions that are 
typically masked out on arrays (Park, 2009). Similar to ChIP-chip, ChIP-seq 
technology is highly specific for genes of interest, with approximately 80% of the 
human genome which can be readily aligned to the correct DNA fragment using 
30bp short reads (Rozowsky et al. 2009).  
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However, despite the numerous advantages of ChIP-Seq over ChIP-
chip, the major limitation is the cost and availability of the technology. Additional 
challenges include presence of sequencing errors, bias towards GC-rich 
content in fragment selection and loss of sensitivity and specificity in enriched 
regions, despite significant improvements in optimisation of the assay (Hillier et 
al. 2008; Quail et al. 2008). Technical issues surrounding loading samples can 
also contribute to low quality sequencing data (Park, 2009).  
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Chapter Six – Exome wide approach to identify genes that may cause 
PNAO  
6.1 Introduction  
Prior to the advent of genome-wide analyses, the traditional approach for 
pharmacogenomic analysis was the candidate gene approach, in which a group 
of related genes or a pathway that is relevant to a specific phenotype is 
selected based on literature searches. Otherwise known as a ‘prior hypothesis’ 
approach, this typically involves selection of a gene or pathway for further 
analysis (Hartford and Dolan, 2007). With regard to toxicities in the field of 
oncology, this approach has been useful in the study of genes involved in drug 
metabolism, transport and DNA repair, and has provided clinically relevant 
information that has aided treatment decisions for several drugs (Bosch et al. 
2006; Efferth and Volm, 2005). Well known examples of polymorphisms 
identified via a candidate gene approach include the effects of variants in the 
cytochrome P450 enzyme on side effects to tamoxifen and the effect of the 
UGT1A1*6 polymorphism on irinotecan-induced toxicity (discussed in section 
1.1.1.2). Genetic variants in another drug metabolising enzyme, thiopurine 
methyltransferase, encoded by the TPMT gene, have been associated with 
severe thiopurine-induced toxicity. The enzyme catalyses the S-methylation of 
the thiopurine class of drugs, which are used in the treatment of leukaemia. Up 
to 20 variant alleles in TPMT have been identified, of which three (TPMT*2, *3A 
and *3C) are defective alleles that result in poor enzymatic activity, leading to 
elevated levels of cytotoxic thiopurine nucleotides and severe haematological 
toxicity (Ma and Lu, 2011). 
The candidate gene approach is advantageous for several reasons; the 
techniques and genetic analyses used are well established and the costs 
incurred are reasonable. Additionally, this approach is considered useful for 
furthering our understanding of the functional implications of genetic variation 
within a gene or pathway, and provides a rationale for bringing this information 
into the clinic (Hartford and Dolan, 2007). However, several limitations exist, 
including the potential to overlook novel genes or pathways associated with 
disease or toxicity. Additionally, the simplicity of this approach means that the 
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influences of other genetic variants on cell behaviour are not considered 
(Schully et al. 2011).  
The candidate gene approach is most successful for detection of single 
genes carrying variants that disrupt a drug’s metabolism and are present in a 
reasonable proportion of the population (Hartford and Dolan, 2007). However, 
since chemotherapy-induced toxicity is most likely a multigenic trait (Moen et al. 
2012) and may be influenced by genes present in a smaller proportion of the 
population, a broader approach is typically required. In contrast, a whole-
genome or whole-exome approach may be used to consider a patient’s entire 
genome or exome and evaluate multiple genes to identify genetic variants that 
contribute to a phenotype without bias. Previously, most candidate-based 
studies have revealed genetic variants that influence drug pharmacokinetics, 
whilst GWAS and exome sequencing methods have offered the potential for 
identifying rare and novel variants that influence drug pharmacodynamics and 
gene-phenotype interactions (Low et al. 2014). For multigenic traits, subtle 
variants in numerous genes may contribute in a cumulative manner to produce 
a more severe phenotype than a dramatic change in a single gene. For 
example, Easton et al. (2007) used a GWAS to identify five novel susceptibility 
loci for breast cancer in four genes (FGFR2, TNRC9, MAP3K1 and LSP1) that 
had not previously been identified using candidate gene approaches, which 
contributed to overall risk in a cumulative manner. Additionally, a rare 
susceptibility locus on chromosome 8q24 for colorectal cancer was identified 
through GWAS, which similarly had not been identified using other approaches 
(Zanke et al. 2007). A rare variant at this susceptibility locus has since been 
associated with prostate cancer using a genome-wide sequencing approach 
(Gudmundsson et al. 2012). 
However, limitations of genome-wide technologies still exist, including 
primarily high rates of false-positive variant predictions, as well as a high 
chance of missing rare genetic variants that could be important. Additionally, 
GWAS is limited in terms of accessibility to validation cohorts, since large 
control populations are needed to validate rare variants (Moen et al. 2012). 
Additional limitations include the cost of genome-wide and exome-wide 
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technologies; therefore experiments must be well designed prior to committing 
to the use of expensive technologies (Low et al. 2014).  
Previous work by Dr Hannah West identified an association between 
variants in ERCC4 and an increased incidence of PNAO in patients with CRC 
via a candidate based approach (section 1.9.5). Here we sought to identify 
other genes that may cause peripheral neuropathy by identifying rare or novel 
truncating variants in patients with PNAO using an exome wide approach.   
6.2 Materials and Methods 
6.2.1 Selection of patients 
Patients were selected from 2,445 individuals with colorectal cancer 
undergoing therapy with 5-fluorouracil or capecitabine, oxaliplatin and, in a 
proportion of cases, cetuximab during the MRC COIN trial. A panel of patients 
(n=10) with severe PNAO (Grade ≥3) after oxaliplatin treatment were selected 
after review of their toxicity data (see section 1.9.2). An additional 45 patients 
were selected based on their clinical data, which indicated that they 
experienced a maximum of PNAO grade 0 or 1 throughout the duration of the 
trial. For the purpose of this chapter, we will refer to these no/low grade PNAO 
patients as controls. DNA from these patients was isolated for exome 
resequencing. 
6.2.2 Exome resequencing  
Exome resequencing, read alignment and variant calling of DNA from the 
ten patients with severe PNAO was performed by James Colley as outlined in 
section 1.9.2. Exome resequencing of 45 control exomes was performed 
independently by BGI (Hong Kong), using the Agilent SureSelectAll system for 
exome capture and sequencing at a depth of up to 50x coverage (section 
2.3.6). Library fragments of exomic DNA from the 45 control patients were 
randomly fragmented by Covaris and adapters were ligated to both ends of 
each fragment. The adapter-ligated fragments were purified using Agencourt 
AMPure SPRI breads, which allowed extraction of fragments of approximately 
250bp in size. Extracted DNA was amplified by ligation-mediated (LM) PCR, 
purified and hybridised to the SureSelect Biotinylated RNA Library for 
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enrichment. The magnitude of enrichment was assessed using the Agilent 2100 
Bioanalyzer, followed by high throughput sequencing using the Hiseq2000 
platform. Fastq files were processed by Illumina Basecalling software v1.7 and 
mapping of reads was carried out using SOAPaligner v2.21.  
6.2.3 Selection of variants of interest 
 The bioinformatic output from the pipeline was altered to include only 
variants present in the 10 exomes from patients with grade ≥3 PNAO and 
absent from 45 control exomes. The initial filtering strategy (Strategy 1) involved 
exclusion of all non-synonymous SNPs, leaving only likely truncating mutations 
(stop gains, frame shifts and splice donor and acceptor sites) present in the 
same gene in ≥2 patients with PNAO. Common variants (those with MAF >1%) 
were removed by searching for MAF data in dbSNP v.132 and 1000 Genomes 
database v.3 (released 23/11/2010). Intronic variants were excluded by 
searching for all alternatively spliced transcripts in Ensembl.  
6.2.4 Assessment of quality status of variants 
 Quality status of predicted variants was assessed during bioinformatic 
analysis. During Fastq file processing, variants were assigned a quality filter (P 
= high quality; VQSRT = medium quality; LQ = low quality), which combined the 
quality of the variant read during exome resequencing with the quality of 
alignment during bioinformatic analysis. Recalibration of quality scores was 
performed during bioinformatic analysis as described in section 2.5.6.  
6.2.5 Validation by PCR and Sanger sequencing  
 All predicted variants of interest were validated by Sanger sequencing 
using an independent PCR product. All primers for PCR were designed by Marc 
Naven using a custom bioinformatic pipeline incorporating information from 
Primer3 v4.0.0 (section 2.5.6). PCR of individual variants, verification by 
agarose gel electrophoresis, product purification, Sanger sequencing and clean 
up were carried out as outlined in sections 2.5.7 to 2.5.11. Sequences were 
analysed using Sequencher v5.3.  
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Approaches for 
filtering for variants of 
interest 
Description 
Strategy 1 ≥2 out of ten patients with PNAO carrying 
truncating variants in the same gene 
Strategy 2 1 patient with PNAO carrying a truncating variant 
Strategy 3 ≥2 patients with PNAO, both carrying one 
truncating and one nonsynonymous variant in the 
same gene 
Strategy 4 1 patient with PNAO carrying both one truncating 
and one nonsynonymous variant in the same gene 
Strategy 5 ≥2 patients with PNAO carrying either one 
truncating or one nonsynonymous variant in the 
same gene 
 
Table 6.1 Approaches used to filter the bioinformatic pipeline’s output of exome 
resequencing data, to identify variants that cause PNAO.  
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6.2.6 Identification of gene function  
 A literature review of one identified candidate gene was carried out using 
NCBI and other internet search engines, to identify any previously known 
association between the gene of interest and neuron function or peripheral 
neuropathy.  
6.2.7 Alternative strategies for identifying genes of interest 
 The bioinformatic pipeline’s output of exome resequencing data was 
filtered according to several different strategies; 1) ≥2 patients with PNAO 
carrying truncating variants in the same gene, 2) 1 patient with PNAO carrying a 
truncating variant, 3) ≥2 patients with PNAO both carrying one truncating and 
one nonsynonymous variant in the same gene, 4) 1 patient with PNAO carrying 
one truncating and one nonsynonymous variant in the same gene, and 5) ≥2 
patients with PNAO carrying either one truncating or one nonsynonymous 
variant in the same gene (Table 6.1).  
 6.2.8 Removal of indels containing homopolymers and STRs 
 The exome resequencing data acquired by each filtering strategy was 
reduced further by removing indels containing repetitive base sequences in their 
flanking regions. A bioinformatic pipeline was established to find flanking 
regions of 100bp upstream and downstream of each variant. This information 
was used to manually filter out truncating indels that contained homopolymer 
runs of ≥5 single bases or ≥4 double base pairs (e.g. runs of GTs) and ≥2 STRs 
of ≥3bp.  
 6.3 Results  
6.3.1 Selection criteria 1 
All stages of filtering for variants of interest using Strategy 1 are outlined 
in Figure 6.1. All variants that were called during exome resequencing in 10 
patients with severe PNAO and 45 control patients amounted to 643,354 
variants. The list was reduced by filtering for variants present in our ten patients 
with PNAO and absent from all control exomes (3,578 variants). We then 
selected only truncating mutations present in the same gene in ≥2 PNAO  
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Figure 6.1 Strategy 1 – Schematic diagram of stages involved in filtering variants. 
All variants called during exome resequencing of DNA from ten patients with severe 
PNAO and 45 control patients were filtered and validated by Sanger sequencing to 
identify a list of candidate genes that may cause PNAO.  
10 Grade ≥3 PNAO patients and 45 
Grade 0/1 control patients  
Filtered for variants present in 10 
Grade ≥3 PNAO patients and not 
present in 45 Grade 0/1 control 
patients 
Filtered for severe SNPs only (Stop 
gains, Splice site acceptors and 
donors, frameshifts)  
Filtered for variants found in the 
same gene in ≥2 Grade ≥3 PNAO 
patients  
Filtered out common variants 
and those present in retained 
introns  
VALIDATION BY SANGER 
SEQUENCING 
Variants present during 
validation (n=1) 
Variants absent during 
validation (n=51) 
Variants that failed 
sequencing (n=0) 
Filtered for quality status during 
bioinformatic analysis 
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Stage of filtering 
 
No. variants 
(genes) present 
No. of variant types 
Stop 
gains 
Indels 
Variants in 10 PNAO exomes 
and not in control exomes 
3,578 (2,997)  N/A N/A 
Truncating variants only 82 (23) 12 70 
Truncating variants in the same 
gene present in two or more 
PNAO patients 
74 (20) 12 62 
Removal of common (MAF>1%) 
variants  
64 (18) 10 54 
Removal of intronic variants 61 (17) 10 51 
Exclusion of low quality variants 52 (14) 2 50 
 
VALIDATION 
BY SANGER 
SEQUENCING 
Genuine 
variants 
1 (1)  0 1 
False positives 51 (14) 2 49 
Failed 
sequencing 
0 (0) 0 0 
Final list of variants 1 (1) 0 1 
 
Table 6.2 Strategy 1 – Total numbers of variants and genes present at each stage 
of filtering. Validation of the two predicted variants in PAPLN revealed that only one 
variant was genuine, and therefore this gene is relevant only to filtering Strategy 2.  
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patients, resulting in 74 variants in 20 genes (MACF1, OR2T35, FGFR3, 
FGFR4, SLC17A5, SMOC2, LRCC4, PRDM12, ANXA7, TAF1D, SPERT, 
TMCO3, PAPLN, ASGR2, GOSR1, STXBP2, KRI1, ANKLE1, ACSS2 and 
ZFP64). The numbers of variants (stop gains and indels) and genes at each 
stage of filtering are shown in Table 6.2.  
6.3.2 Selection of rare and novel protein-encoding variants 
Investigation of common variants (MAF >1%) resulted in exclusion of 
three variants present in ten patients: one novel deletion in SMOC2 (MAF 
14.4%), one novel stop gain in SPERT (MAF 7.4%) and one common insertion 
in STXBP2 (rs35042054; MAF 43.9%). This resulted in 64 variants in 18 genes. 
We then cross-referenced all predicted frame shift and splice site 
variants with their transcript IDs in Ensembl, which identified two novel 
frameshift variants located deep within the intron of ASGR2 (ATG→A deletion 
at position 7011116 in two patients; A→AC insertion at position 7011120 in one 
patient; Ensembl transcript ID ENST00000450034). Exclusion of these variants 
resulted in 61 variants in 17 genes.  
6.3.3 Exclusion of low quality variants  
We excluded all variants assigned a VQSRT or LQ quality score, which 
resulted in removal of nine variants in five genes (OR2T35, SLC17A5, 
PRDM12, ANXA7 and TAF1D). Other predicted variants in these genes showed 
good quality scores, and therefore this exclusion resulted in 52 variants in 14 
genes.  
6.3.4 Validation of variants by Sanger sequencing   
We validated one novel frameshift in the PAPLN gene in one patient with 
severe PNAO by Sanger sequencing. We failed to validate the second 
predicted variant in PAPLN, a rare splice acceptor site variant, and therefore 
PAPLN can only be considered as an output of filtering Strategy 2 (Figure 6.2).  
We failed to validate a total of fifty-one variants in fourteen genes (Table 
6.3), including the rare splice acceptor site variant in PAPLN, which amounted 
to a 98.1% rate of false-positive variant calls. Chromatograms for a selection of  
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(A)  PAPLN (Chromosome 14:73716735) – Control and Patient 7 
(Control) No deletion  
 
(Patient 7) CT→C deletion  
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(B)  PAPLN (Chromosome 14:73731293) – Control and Patient 6 
 
(Control) No deletion 
 
 
(Patient 6) No deletion 
 
 
Figure 6.2 Chromatograms showing (A) one genuine frameshift variant and (B) one false-positive splice accepter site variant in PAPLN in 2 
patients with grade ≥3 PNAO. The arrow indicates the variant allele in the control and PNAO exome.  
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Gene  
Variants not present upon 
validation  
(Wild type  variant allele) 
 
Zygosity 
 
Flanking region of variant (60bp up/downstream of variant) 
ACSS2 Splice donor site (AGT→A) 
(rs72449308) 
Het GATGCCGAGGACCCACTCTTCATCCTGTACACCAGTGGCTCCACAGGCAA
ACCCAAGGCAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT
GTGTATTATGTAGGGGTAAG 
ANKLE1 Splice acceptor site (GTGTT 
G) (rs10606406) 
 
Splice acceptor site (GTTG) 
(novel) 
 
Frame shift (GTGTGTTG) 
(novel) 
Hom 
 
Hom                                    
 
Het 
CATCTCTGGTTTCAGAAGGGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG
TGTGTGTGTGTGTTTGTGTGTGTGTGTGTGTGTGTAGGGAGCACCCAGGC
AGATCTCCCCCAGGCTGAGA 
TCTCTGGTTTCAGAAGGGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG
TGTGTGTGTGTTTGTGTGTGTGTGTGTGTGTGTAGGGAGCACCCAGGCAG
ATCTCCCCCAGGCTGAGAGA 
CCCATCTCTGGTTTCAGAAGGGGTGTGTGTGTGTGTGTGTGTGTGTGTGTG
TGTGTGTGTGTGTGTTTGTGTGTGTGTGTGTGTGTGTAGGGAGCACCCAG
GCAGATCTCCCCCAGGCTGA 
FGFR3 Frame shift (CGT→C) 
(rs34003391) 
Hom GAGACTCAGTGCAGATGGAGAGACAGCTACACAGAGCTTTGGTCTGTGTG
TGTGTGTGTGCGTGTGTGTGTGTGTGTGTGCACATCCGCGTGTGCCTGTG
TGCGTGCGCATCTTGCCTCCA 
FGFR4 Frame shift (C→CGTGT) 
(rs59390048) 
 
 
Het ATGTGGCACCAACAGCATGTGCCTTGTGTGTGTGTGTGTCCGTATGTGTGT
GTGTGTATGCGTGTGTGTGTGTGTGTGTGTCTTGGCCACTGTCGTGTGCAC
TAAATGCTGTGTGTGTGAC 
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Gene  
Variants not present upon 
validation  
(Wild type  variant allele) 
 
Zygosity 
 
Flanking region of variant (60bp up/downstream of variant) 
GOSR1 Frame shift (GGT) (novel) Het AGAGACATATTGCAGGTAATATATTGGGCTCGAGATGTTTTCATTATCACAG
GAGTTTGGGTTTTTTTTTTTTTAATCCCTGCATTGGATATGTGCACATATATT
TAAAAGGACAAAGAGA 
KRI1 Frame shift (GGC) 
(rs34864064) 
Hom GAGTCGCTGCTGCTGTCTCGGTCCCCGTAGCGATCCTTCACTGCGGGACA
CAGACGGGATGCCCCCCCCCAGGTCAGCCGGCGGGGCCACTCGACTCCC
CACTTCCCAACCGGCCGGCGCG 
LRCC4 Frame shift (T→TG) (novel) Het CAAAGGCCCCGCTAGGGATGACTGTCAGCCAGTTGTCGAACAGCTCCAGG
GTGTTGAGGCTGGCCAGGCCGTTGAAGGCCCCCACCTCAATCTGCCGGAT
GGAGTTCCTGCCCAACTGCAG 
MACF1 
 
Frame shift (A→AG) (novel) Het CAGAACATCGCAGGTGGTAGTATGATGATGTCAGAAAAGACCGATGAGGA
AGATAGTGGCAGGGAAATTTTTCTGTCATGCAGTCATCCATTAGAATTGCTT
GAAGAAGCTACCTTAAATG 
PRDM12 Splice donor site (GGT→G) 
(novel) 
Het ACAGGAGCAGAACCTGGAGGTGGTCCAGATCGGCACCAGCATCTTCTACA
AGGCCATTGAGGTGTGTGTGTGTGTGTGCACTGTTGTGTAGGGACCAGCC
GGTAAACCCGGCGGGGGGAGG 
STXBP2 Splice acceptor site 
(TATGTGTGTGC→T) 
(rs11278818) 
 
Het 
 
TATGTCTGCATGCATGTGATTGCATGTGTGCATGTGTATACGTGTGCATGT
GTCCATGTGTATGTGTGTGCATGTGTGTGCATGTGTGTGTGCATCTGTGTA
TGCATGTGTGTGCGTGTTT 
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Gene  
Variants not present upon 
validation  
(Wild type  variant allele) 
 
Zygosity 
 
Flanking region of variant (60bp up/downstream of variant) 
STXBP2 Frame shift (A→ATG) 
(rs112703251)  
 
Splice acceptor site (ATG→A) 
(novel) 
 
Frame shift 
(CATCTGTGTGTGTGT→C) 
(rs76937271) 
Het 
 
 
 
Het 
 
 
 
Het 
GCATGTGTGTATGCGTGTGTGTGTGCATCAGTGTCTGCATGTGTGTATATG
TGTGTATGTATGTGTGCGCGCGCATCTGTGTGTGTGCATGTGTGTATGTAT
GTGTGTGCATCTCTGTGTG 
GTGTGTCTGTGGGTCTGTGTGTGCATTTGTGTCTGTGCATGTGTGTATGCG
TGTGTATGTATGTGTGTGTGCATCTGTGTGCATCTGTATGTGTGTGTGTGC
GTCTGTCTGTGTGCATGTG 
TGTGCATGTGTGTATGTATGTGTGTGCATCTCTGTGTGTGCATGTGTGTAT
GTGTGTGTGCATCTGTGTGTGTGTGCATGTGTGCATGCGTGTGTATGTGTG
TGTGCGTGCGTGCATCTGT 
TMCO3 Frame shift (G→GGTTTT) 
(novel) 
Het GTCGTGGAAGTTCTCCGAATCCTGGTTTTGATTGGTCAGATTCTTTTTTCAC
TAGCGGCGGGTTTTTCTTTTATGTCTTGTTTTTCTTTTATGTCTTGTTATAAA
GAAGTATCTCATTGGACCCTATTATCGGAAGCTGC 
ZFP64 Frame shift (TA→T) 
(rs72411807) 
Het GTGAATTTTTAAATGCCGCTCCATGTCCTTCATGCCATAAGCAGTCTTGAAT
TGGCAACCTAAAAAAAAAAAGGAAAGATTAATTACAAAGGAAAACTTAGTAA
CTTTTAGCATGGAGAAA 
 
Table 6.3 Variants excluded during validation by Sanger sequencing, with wild type and variant alleles. Flanking regions of 60 base pairs (bp) 
upstream and downstream of the variant are shown, with the position of the variant underlined. Repetitive sequences are highlighted.  
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GOSR1 – Control and Patients 6 and 10 
(Control) No insertion 
 
(Patient 6) No insertion  
 
 
 
 
Figure 6.3 A false positive insertion (G→GT) in GOSR1 predicted during bioinformatic analysis. The arrow indicates the locus of the predicted 
variant allele. 
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these variants are shown in Figure 6.3. A high proportion (49/51; 96.1%) of 
these non-validated variants contained homopolymer runs and short tandem 
repeats (STRs) flanking within 100 bp upstream or downstream of the variant, 
potentially increasing the likelihood of false positive variant calling by the 
bioinformatics pipeline (Table 6.3). We observed ten predicted variants 
containing homopolymer runs of ≥8 guanine-thymine pairs (GTs) before or after 
the variant. Two variants in GOSR1 and TMCO3 contained a run of ≥6 thymine 
bases after the variant; one variant in KRI1 carried a run of 9 cytosine bases 
and one variant in ZFP64 carried a run of 11 adenine bases after the variant. 
Additionally, one variant in STXBP2 carried two STRs of ten bases in length 
(TGTGTGTGCA) after the variant (Table 6.3).  
6.3.5 Literature search of candidate genes associated with PNAO 
One variant in a single gene, PAPLN, was validated by Sanger 
sequencing, which identified PAPLN as a potential candidate gene for PNAO 
using our exome wide filtering Strategy 2. PAPLN has been cited in eight 
publications listed in PubMed since 1999, primarily in publications using GWAS 
of patients with depression to study suicide ideation. The majority of these 
publications concur that polymorphisms in PAPLN are linked to suicidal ideation 
in patients undergoing therapy for depression (Perroud, 2011; Brent et al. 2010; 
Laje et al. 2009; Laje et al. 2009*; Souslova et al. 2013). More recently, PAPLN 
was cited as one of four genes that encode extracellular matrix proteins that 
demonstrated substantial changes in expression after spinal cord injury in the 
neonatal South American grey short-tailed opossum (Monodelphis domestica; 
Saunders et al. 2014). PAPLN has also been associated with tooth 
development in mice (Pemberton et al. 2007). 
6.3.6 Alternative filtering strategies for identifying variants of 
interest  
The numbers of variants of interest for each strategy are depicted in 
Figure 6.4. There was considerable overlap in the genes listed for filtering 
Strategies 1-3, whilst the output for Strategy 4 largely overlapped with that of 
Strategy 2. The total numbers of variants for each filtering strategy ranged from 
59 to 220 variants. In order to reduce the total numbers of variants for molecular 
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analysis, we developed a bioinformatic approach to remove indels that were 
likely to be false-positive calls based on the results outlined in section 6.3.4.   
6.3.7 Removal of indels containing repetitive sequences in flanking 
regions  
 Removal of predicted indels with homopolymers and STRs present in 
their flanking regions resulted in an average of a 54.9% reduction in the total 
number of variants for molecular analysis (50.0% reduction in Strategy 1 output; 
31.9% reduction in Strategy 2 output; 100% reduction in Strategy 3 output; 
35.6% reduction in Strategy 4 output; 56.8% reduction in Strategy 5 output). A 
comparison of the numbers of variants before and after exclusion of indels with 
repetitive base sequences for each filtering strategy is given in Table 6.4. After 
removal of indels that met the selection criteria, the total numbers of variants 
listed for each filtering strategy ranged from 0 to 139 variants.  
We identified five genes (ANXA7, OR2T35, SMOC2, SPERT and 
TAF1D) that were common across strategies 1 and 2, whilst a further three 
genes (ASGR2, PAPLN and SLC17A5) were common across Strategies 1, 2 
and 5. We also observed overlap between Strategies 2, 4 and 5; seven genes 
were common across Strategies 2 and 4, whilst a further five genes were also 
present in Strategy 5. A schematic Venn diagram illustrating the overlap of 
genes identified via different filtering strategies is shown in Figure 6.4. All genes 
present in the exome resequencing output for each filtering strategy are listed in 
Table 6.5. 
6.4 Discussion 
6.4.1 False-positive variant calling of indels  
Validation of the variants predicted using filtering Strategy 1 by Sanger 
sequencing showed a high rate of false-positive variant calls (98.1%), all of 
which were indels. Of these false-positives, 96.1% contained repetitive base 
sequences in their flanking regions. These were primarily homopolymers and 
runs of consecutive guanine-thymine pairs (GTs), although one variant carried a 
short tandem repeat (STR) of eight bases in length. This suggested that the  
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(A) 
 
(B) 
 
Figure 6.4 Venn diagram of NGS output from each filtering strategy. (A) Venn 
diagram of numbers of variants (stop gains, truncating indels and nonsynonymous [Ns] 
variants) present for each filtering strategy. Variant numbers after exclusion of 
predicted indels containing homopolymers and STRs in their flanking regions and 
following exclusion of variants not present during validation are shown in brackets. (B) 
Enlarged view of central section of Venn diagram, showing genes present in 
overlapping regions of different filtering strategies. Of the genes listed here, only 
LRCC4 and MACF1 were not validated, since the variants called in these genes were 
false positives.
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 Strategy 1 Strategy 2 Strategy 3 Strategy 4 Strategy 5 
Initial 
data 
output 
After indel 
exclusion 
Initial 
data 
output 
After indel 
exclusion 
Initial 
data 
output 
After indel 
exclusion 
Initial 
data 
output 
After indel 
exclusion 
Initial 
data 
output 
After indel 
exclusion 
Total genes 20 8 145 99 2 0 18 12 39 18 
Total variants 74 20 204 117 15 0 59 33 220 83 
Stop gain variants 12 12 54 54 0 0 7 6 14 9 
Truncating indels 62 
 
8 150 63 5 0 17 9 43 15 
Nonsynonymous 
variants 
0 0 0 0 10 0 35 18 163 59 
 
Table 6.4 Summary of gene/variant numbers for each filtering strategy. Numbers of genes and variants are shown for each filtering strategy 
before and after bioinformatic analysis to exclude indels containing homopolymers or STRs in their flanking regions, and after exclusion of variants 
not present during validation.   
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Strategy 1 
(n=8) 
Strategy 2                                   
(n=99) 
Strategy 4 
(n=12) 
Strategy 5 
(n=18) 
ANXA7 
ASGR2 
OR2T35 
PAPLN 
SLC17A5 
SMOC2 
SPERT 
TAF1D 
 
ABCA7; ACADL; ADC; AFAP1L1; 
AF131215.4; AKNAD1; ALDH3A1; 
AL035460.3; AL355149.1; 
AL391421.1; ANGEL1; ANKRD46; 
ANXA7; AP001468.1; ASCL3; ASGR2; 
ATP6V1H; AQP7; BCLAF1; BGLAP; 
BTNL9; CCDC70; CCDC83; CCDC87  
CCDC108; CSTF2; CUZD1; CWH43; 
C5orf27; C9orf85; C11orf66; C12orf32; 
C15orf42; DCAKD; DNAH8; DSG4; 
ERCC4; ETNK2; EVPL; FAM109A; 
FAM5B; FAM53A; FES; FIBCD1; 
FRMD4A; FSTL5; GJA9; GPNMB; 
GRM3; KHNYN; KRT33B; KRT82; 
KRTAP19-4; LCE3C; LTK; MAN1B1; 
MRO; NBPF10; NDUFS7; NKIRAS1; 
NPIPL2; OR2T35; OR6F1; OR8K1; 
PABPC3; PAN2; PAPLN; PAX6; 
PCDHA11; PDE4DIP; PIK3R3; 
PP1R3A; QRICH2; RANBP10; RBMX; 
REG1B; RGS16; RNF212; RP11-
10G12.2-001; RP11-481A20.11; RP11-
867G23.8; SERPINA12; SLAMF8; 
SLC17A4; SLC17A5; SLC5A4; 
SMOC2; SMR3B; SNAPC1; SPERT; 
STOML3; TAF1D; TMEM159; 
TMEM54; TRIM16L; VRK2; ZNF135; 
ZNF354C; ZNF418; ZNF562.                                                                                                                 
ACADL 
AL035460.3 
AP001468.1 
BCLAF1 
C5orf27 
FES 
NDUFS7 
OR8K1 
PDE4DIP 
RNF212 
RP11-
481A20.11 
SLC5A4 
 
ABCA7 
AF131215.4 
AP001468.1 
ASGR2 
BCLAF1 
C5orf27 
DNAH8 
FES 
MAN1B1 
NDUFS7 
NPIPL2 
PABPC3 
PAPLN 
PDE4DIP 
PIK3R3 
RBMX 
SLC17A5 
ZNF135 
 
 
Table 6.5 Summary of genes listed for each filtering strategy. Genes present in the 
output for each filtering strategy after bioinformatic analysis to exclude indels 
containing homopolymer runs or STRs in their flanking regions and after exclusion of 
genes not present during validation. Genes highlighted in green are common across 
Strategies 1-2; genes highlighted in yellow are common across Strategies 1, 2 and 5.  
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presence of homopolymers and STRs reduced the accuracy of bioinformatic 
analysis when mapping the short read lengths to the correct sequence within 
these variants’ flanking regions, due to slippage of DNA polymerases at the 
repetitive site, resulting in false-positive calling of small indels.  
Identification of indels by NGS has been widely considered more 
challenging than SNP calling (Mullaney et al. 2010; Albers et al. 2011), in 
particular where sequencing errors and PCR enrichment bias is present (Fang 
et al. 2014). The majority of known indels range from 1-10bp in length (Zhang 
and Gerstein, 2003); however, within the human genome there are known 
indels that range up to 10,000bp in length (Mills et al. 2011). Detection of indels 
longer than 10bp provides a significant challenge for current NGS technologies, 
primarily due to the short read length used, making it difficult to accurately call 
indels that are longer than the short read length and increasing the likelihood of 
false-positive calls.  
However, here we have identified an issue with accurate variant calling 
of relatively small indels (2-15bp in length), which suggests that further 
optimisation of read mapping may be necessary when employing the use of 
NGS. Published data has reported previously that assembly based callers show 
a significantly higher sensitivity for detection of indels >5bp in length compared 
with alignment based callers (Fang et al. 2014). Therefore, the use of an 
alignment mapping tool for variant calling of our data could provide one 
explanation for the high incidence of false positive calls. 
The presence of homopolymers has been identified as an issue 
surrounding accurate indel calling by NGS previously (Koboldt et al. 2010; 
Krawitz et al. 2010; McElroy et al. 2012; De Beuf et al. 2012). A large scale 
validation experiment using 600 loci characterised by whole genome 
sequencing (WGS) and whole exome sequencing (WES) identified a low 
concordance (53%) in indel detection between WGS and WES of the same 
data, and a notably higher incidence of validated indels in WGS compared with 
WES data (84% vs. 57%, respectively; Fang et al. 2014), suggesting that WES 
may not be the most sensitive approach for large indel detection. Other issues 
have been reported including introduction of higher indel error rates following 
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poor PCR amplification and capture deficiency, in particular where 
homopolymers were present. Additionally, where homopolymers or STRs were 
located, the bioinformatic pipeline often called multiple variants at the same 
locus (Fang et al. 2014; Macalalad et al. 2012).  
There is much debate about whether to use WGS for personal exomes 
since it is free from exome capture deficiency issues and could potentially 
reveal structural variants (SVs) and maintain greater uniformity of coverage 
than that seen in WES (Metzker, 2010; Zhu et al. 2012). Of course, the cost of 
sequencing is considerably cheaper using WES, although prices continue to be 
reduced as new technology is developed (Cirulli and Goldstein, 2010).  
Another potential issue could be the level of coverage required to 
accurately call indels, which can vary depending on whether the variant is 
homozygous or heterozygous. The latter typically requires up to 60x coverage, 
which is significantly higher than the typical 30x coverage required for detection 
of homozygous variants (Fang et al. 2014; Li, 2011). Additionally, heterozygous 
indels are considerably more common than homozygous indels, indicating a 
need for higher coverage sequencing (Fang et al. 2014). Since 85.5% of the 
Strategy 1 output (53 of 62 indels) were heterozygous, this could provide an 
alternative explanation for such a high false-positive rate of indel calls.  
6.4.2 Alternative strategies for identifying genes that may cause 
PNAO 
Strategies 2 and 5 yielded large lists of variants, whilst Strategies 1-3 
provided more focussed lists of predicted variants for molecular analysis. For 
the latter strategies, we chose to select variants present in ≥2 patients with 
PNAO to account for de novo mutations that may arise in a single patient as a 
result of individual variation. A large proportion of variants listed for each 
strategy were truncating indels and therefore there was a high likelihood of 
false-positive variant predictions. In order to reduce the lists of genes, we 
removed indels that could be false-positive calls. 
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6.4.3 Reduction of candidate gene lists by indel exclusion 
We were unable to develop a bioinformatic pipeline to filter out predicted 
indels containing homopolymers and STRs in their flanking regions, due to the 
complexity required to account for differences in sequence length and base 
order of repetitive sequences. Therefore, any indels that met these criteria were 
removed manually.  
 Following removal of appropriate truncating indels and non-validated 
variants, a total of eight genes were identified that were common across 
multiple strategies (a combination of Strategies 1-2, 1-3 and 1, 2 and 5), 
suggesting that these might be implicated in PNAO. Of these eight genes, three 
were identified in Strategies 1, 2 and 5 (ASGR2, PAPLN and SLC17A5). 
PAPLN is discussed in section 6.4.4. SLC17A5 encodes the sialic acid 
cotransporter protein, or sialin, which is involved in trafficking of free sialic acid 
molecules around the cell following protein and fat degradation (Qin et al. 
2012). Mutations in SLC17A5 are associated with sialic acid storage diseases in 
which a defective proton-driven transport system results in abnormally high 
urinary sialic acid levels and accumulation of free sialic acid in fibroblasts. A 
common example is Salla disease (OMIM #604369; Verheijen et al. 1999), an 
autosomal recessive neurodegenerative disorder characterised by delayed 
psychomotor development, dysmorphic facial features and ataxia (Renlund et 
al. 1986). In contrast, ASGR2, which encodes the asiaglycoprotein receptor 2 
that functions to regulate serum glycoprotein homeostasis, has not been 
associated with neuron development or neuropathy (Veselkin et al. 2011). 
The remaining five genes were present in Strategies 1 and 2 only 
(ANXA7, OR2T35, SMOC2, SPERT and TAF1D); of these, two were associated 
with neuron development or neural stem cell differentiation in some way. 
SMOC2 encodes the SPARC related modular calcium binding 2 protein, which 
is primarily involved in extracellular matrix assembly and endothelial cell 
proliferation and migration (Bradshaw, 2012). LeDoux et al. (2006) reported a 
16-fold increase in SMOC2 expression in murine dorsal root ganglia (DRG) 
compared with spinal cord cells, whilst in drosophila, SMOC2 was identified as 
one of approx. 400 genes expressed in sympathetic neuronal cells during 
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development (Apostolova et al. 2007). However, despite these findings, no 
direct association with neuropathy in humans has yet been identified (Basciano 
et al. 2011). TAF1D encodes TATA box binding protein (TBP)-associated factor, 
RNA polymerase I, D, a protein essential for RNA polymerase I transcription 
(Gorski et al. 2007). TAF1D has been shown to be expressed in pluripotent 
stem cells and in the early stages of neural stem cell differentiation in mice 
(Guzman-Ayala et al. 2015; Wang et al. 2012). The apparent function of these 
genes in early neuron development and differentiation may increase the 
likelihood that they are implicated in PNAO.  
In contrast, the remaining three genes appear to play no role in neuron 
development or neuropathy; ANXA7 encodes the Annexin-A7 tumour 
suppressor, which functions as a voltage-dependent calcium channel and has 
been implicated in prostate cancer progression (Srivastava et al. 2001). 
Although not directly associated with neuropathy, splicing of an alternative exon 
within ANXA7 has been shown to promote tumour progression in glioblastoma 
cells (Ferrarese et al. 2014). OR2T35 encodes olfactory receptor, family 2, 
subfamily T, member 35, (Prasad et al. 2014), which has not been associated 
with neuron development. Finally, SPERT encodes spermatid-associated 
protein, which appears to be involved in spermatozoa formation, although its 
exact role remains elusive (Feige et al. 2002). There are currently no citations in 
PubMed that associate SPERT with neuron function or neuropathy.  
6.4.4 Identification of a candidate gene that may cause PNAO 
Validation of all variants identified using filtering Strategy 1 revealed that 
one variant in the PAPLN gene was genuine, whilst the second predicted indel 
was a false-positive call. Therefore, although we used the filtering criteria for 
Strategy 1, PAPLN is only applicable to filtering Strategy 2. 
PAPLN encodes the papilin proteoglycan-like sulfated glycoprotein 
(papilin), an extracellular matrix glycoprotein believed to influence cell 
rearrangement and migration, formation of basement membranes, and 
formation of the ectoderm, endoderm and mesoderm during embryogenesis. 
Papilin has been shown to be present in multiple basement membranes of the 
human eye (Kramerova et al. 2000; Uechi et al. 2014). The precise role of 
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papilin remains elusive, although PAPLN has been reported in a few high-
throughput studies. PAPLN was identified as one of 50 genes with upregulated 
expression and a hypomethylated promoter in neurally differentiated 
mesenchymal stem cells (MSC), suggesting that PAPLN may influence nervous 
system development (TacGhee et al. 2014). Additionally, variants in PAPLN 
have been reported to place patients with severe depression at increased risk of 
suicidal behaviour following treatment with citalopram, a commonly used anti-
depressant drug (Mann et al. 2009).  
Papilin shares a set of protein domains known as the ‘papilin cassette’ 
with a disintegrin-like and metalloprotease with thrombospondin type 1 motif 
(ADAMTS) superfamily of proteins. The ADAMTS family consists of 19 
ADAMTS zinc metalloproteases with ancillary domains and 7 ADAMTS-like 
(ADAMTSL) proteins, which resemble ADAMTS ancillary domains but lack 
proteolytic activity (Apte, 2009). An important paralog of PAPLN is the 
ADAMTSL4 gene, which is associated with nervous system development 
(Neuhann et al. 2011). Papilin has been shown to non-competitively bind to 
ADAMTS2 in vitro, demonstrating their markedly similar structures (Kramerova 
et al. 2000). 
Other paralogs of PAPLN include ADAMTS7, ADAMTS12, ADAMTS13, 
THSD4, ADAMTSL1, ADAMTSL2, ADAMTSL3 and ADAMTSL5 (GeneCards, 
2015). Although there is nothing in the literature to suggest that variants in 
PAPLN directly cause disease, several of PAPLN’s paralogs have been 
associated with human genetic diseases caused by impaired extracellular 
matrix function; variation at the ADAMTS7 locus has recently been associated 
with increased risk of inherited coronary artery disease (Schunkert et al. 2011). 
Additionally, missense variants in ADAMTS13 are responsible for the rare, life 
threatening disease, thrombotic thrombocytopenic purpura (TTP), characterised 
by thrombocytopenia and microangiopathic haemolytic anaemia (Lotta et al. 
2009). 
Additionally, variants in ADAMTS10, which shares homology with 
PAPLN, have been associated with Weill-Marchesani syndrome, an autosomal 
recessive disorder of connective tissue characterised by short stature, eye 
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abnormalities, bradydactyly and stiffness of the joints (Le Goff and Cormier-
Daire, 2011). Similarly, ADAMTS17 variants have been linked to Weill-
Marchesani-like syndrome, in which sufferers present with all typical symptoms 
with the exception of bradydactyly and decreased joint mobility (Spranger et al. 
1971).  
Finally, variants in the ADAMTSL2 and ADAMTSL4 genes have been 
reported to cause geleophysic dysplasia (GD) and autosomal recessive ectopia 
lentis (EL), respectively. GD is similar to Weill-Marchesani syndrome and is 
characterised by short stature, joint limitations, thick skin and progressive 
cardiac valvular thickening resulting in premature death (Le Goff et al. 2008). EL 
is a rare disorder characterised by partial or entire displacement of the ocular 
lens from its space, leading to marked loss of vision, which can progress to 
cataracts, glaucoma and entire retinal detachment (Ahram et al. 2009). 
6.4.5 Future directions 
All eight genes of interest (ANXA7, ASGR2, OR2T35, PAPLN, SLC17A5, 
SMOC2, SPERT and TAF1D) should be sequenced in a validation panel of 54 
further patients with PNAO to identify further stop gain mutations and 
nonsynonymous variants. These can then be assayed in a control cohort to look 
for variants that are over represented in patients with the PNAO phenotype.  
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Chapter Seven – General Discussion 
 
7.1 Optimisation of cell-based assays for analysis of XPF function 
 A large component of the experimental work in this thesis involved the 
optimisation of assays required to investigate cell function in mammalian cell 
lines and S. pombe strains. As mentioned previously, it has been reported that 
serum proteins can bind irreversibly to oxaliplatin and absorb UV light (Graham 
et al. 2000; Yue et al. 2009; Polet and Steinhardt, 1968), whilst complete 
removal of serum from tissue culture media containing mammalian cells can 
result in quiescence and adversely affect DNA repair and apoptotic pathways 
(Jia et al. 1997; Collier et al. 2006). This meant that the conditions for DNA 
damaging treatments required a delicate balance between ensuring damage 
took place and allowing cells to carry out their damage recognition and repair 
processes, without influencing the results. 
Additionally, the immunofluorescence and ELISA protocols involved 
multiple stages that required optimisation. It was particularly important to select 
an appropriate UV dose that would allow repair and ensure a high purity and 
yield of DNA from viable cells for ELISA. Alternatively, for immunofluorescence, 
it was essential to carefully optimise the fixation, permeabilisation and wash 
steps of the protocol, to allow sufficient entry of antibodies into cells without 
creating oversaturation of fluorescence or high background noise due to 
inadequate washing of cells.  
7.2 Assaying the effects of ERCC4 variants on mammalian cell function 
 In this thesis, we hoped to identify whether variants in ERCC4 directly 
affect viability, repair rate and localisation of ERCC1-XPF in mammalian cells in 
vitro. A summary of the key findings is outlined in Table 7.1. Previous research 
has indicated that altered expression of the ERCC1 and XPF subunits could 
affect side effects of and response to platinum therapy, most likely through 
impaired ability to repair damaged DNA (Section 1.5.1). Increased expression of 
one or both subunits is typically correlated with a worse prognosis due to 
increased resistance to therapy. Alternatively, decreased expression results in a  
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Result Assay and model used Chapter 
Negligible difference in viability 
after damage by either UV light or 
oxaliplatin between wild type and 
variant ERCC4 cell lines 
Viability measurement; 
mammalian cell lines 
Three 
Negligible difference in localisation 
of ERCC1/XPF complex after 
damage by oxaliplatin between 
wild type and variant ERCC4 cell 
lines 
Immunofluorescence; 
mammalian cell lines 
Four 
Negligible difference in localisation 
of rad16 after damage by 
oxaliplatin between wild type and 
variant rad16 strains 
Immunofluorescence;      
S. pombe strains 
Four 
Delayed repair in variant ERCC4 
cell lines compared with wild type 
cell lines after damage by UV light  
ELISA; mammalian cell 
lines 
Five 
Very similar repair rates in wild 
type and variant ERCC4 cell lines 
after oxaliplatin treatment 
ELISA; mammalian cell 
lines 
Five 
High proportion (>95%) of false 
positive indel calls by whole 
exome NGS technology 
NGS; DNA isolated from 
MRC COIN trial patients 
with PNAO 
Six 
Selection criteria established to 
remove predicted indels flanked by 
homopolymer runs or STRs  
Bioinformatic analysis of 
NGS data  
Six 
PAPLN identified as a gene that 
may cause PNAO 
NGS calling; validated 
by Sanger sequencing 
using DNA isolated from 
MRC COIN trial patients 
with PNAO 
Six 
 
Table 7.1 Summary of key findings in this thesis.  
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heightened sensitivity to treatment, which could improve response. However, 
this is likely to increase the severity of side effects due to reduced DNA repair, 
potentially resulting in an accumulation of adducts and increased apoptosis of 
healthy cells.  
 The mammalian cell lines were heterozygous for variants in ERCC4, 
suggesting that XPF expression was likely to be reduced, not absent. 
Therefore, we hypothesised that the presence of these variants would have a 
potentially subtle effect on viability, rate of DNA repair and cellular localisation 
of the repair complex.  
7.2.1 Viability 
Previously, embryonic fibroblasts isolated from homozygous XPF-
deficient mice have displayed hypersensitivity to UV and mitomycin C (MMC), 
indicated by markedly reduced viability in ERCC4-/- cells compared with wild 
type and heterozygous cell lines (Tian et al. 2004). This is consistent with the 
role of XPF in the incision of damaged DNA during NER, suggesting that 
defective NER as a consequence of ERCC4 variants results in eventual 
apoptosis. However, despite this, our data showed very similar trends in viability 
post treatment between wild type and variant cell groups, potentially as a result 
of haploinsufficiency of the variant cell lines due to their heterozygous nature, 
which may result in a subtle phenotype (Section 3.4.2).  
Previous work in our laboratory carried out by Dr Hannah West used 
haploid S. pombe strains with an incorporated novel stop gain truncating 
mutation and nonsynonymous variants (that mimicked the variants studied 
herein) in rad16 to investigate the effects of these variants on viability after 
damage. In contrast to the cell line data, this revealed a statistically significant 
decrease in viability (<20% compared with 100% in rad16WT cells) after both 
oxaliplatin and UV treatment in the fission yeast model carrying the novel stop 
gain mutation. In contrast, all strains carrying nonsynonymous rad16 variants 
displayed a smaller reduction in viability after damage (<60% viability compared 
with 100% in rad16WT cells) by both oxaliplatin and UV (West, 2013, Chapter 7).  
The significantly reduced viability of the rad16Ser585X strain following UV 
and oxaliplatin treatment suggested that the incorporation of Ser585X severely 
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disrupted the ability of rad16 to act normally in the repair of DNA damage, and 
was potentially as deleterious as removal of the entire gene. Additionally, the 
pattern of reduced viability in strains carrying nonsynonymous variants in rad16 
supported the hypothesis that rad16 variants contribute to an NER deficiency. 
The differences in viability data between the diploid mammalian cell lines and 
haploid S. pombe strains were most likely the result of a single mutated rad16 
allele in all S. pombe strains, meaning that potential haploinsufficiency of the 
variant strains was not an issue.  
 Other studies have shown reduced viability in cell lines carrying variants 
in NER genes; Schafer et al. (2013) reported reduced viability after UV-C 
treatment and decreased XPG mRNA expression in XPG-deficient fibroblast 
cell lines isolated from one homozygous and two compound heterozygous 
patients. This is consistent with the suggestion that variants that impair incision 
of the damaged DNA strand during NER also impair cell viability.  
It is commonly known that platinum compounds exert their cytotoxic 
effects by formation of lesions that inhibit transcription, resulting in impaired 
DNA repair and eventual apoptosis. This has been demonstrated in a number of 
in vitro cell-based assays and reconstituted systems (Mello et al. 1995; Jung 
and Lippard, 2007; Tremeau-Bravard et al. 2004; Tornaletti et al. 2003). More 
recently, Ang et al. (2010) demonstrated significant transcription inhibition in live 
mammalian cells using a site-specific platinated probe containing a single 
platinum-DNA adduct, followed by restoration of transcription following repair of 
adducts by NER. These findings were consistent with the hypothesis that 
platinum-DNA adducts form a physical barrier to block transcription by stalling 
RNA polymerase II. This results in cell cycle arrest in G2 phase because cells 
are unable to undergo mRNA synthesis in order to pass into mitosis, therefore 
implicating transcription inhibition as a critical determinant in the apoptotic 
pathway triggered by platinum drugs (Todd and Lippard, 2009). It is possible 
that DNA damage of our cell lines carrying heterozygous variants in ERCC4 
resulted in apoptosis of only a proportion of the cell population due to 
transcription stalling and cell cycle arrest. As such, the sensitivity of our assay 
may have not been sufficient to detect subtle differences in viability between 
wild type and variant cell lines.  
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7.2.2 ERCC1-XPF/Rad16 localisation 
 Previously, analysis of ERCC1 and XPF in cells isolated from XPE and 
XPF patients displayed cytoplasmic mislocalisation of both proteins, which 
could contribute to a reduced DNA repair capacity in these patients. Wild type 
cell lines showed ubiquitous expression of ERCC1 and XPF throughout the cell. 
Two cell lines from patients carrying one Pro379Ser allele in ERCC4 both 
demonstrated cytoplasmic mislocalisation of XPF without treatment (Ahmad et 
al. 2010).  
Despite this, our data showed similar localisation of ERCC1 and XPF in 
cell lines carrying Pro379Ser compared with wild type cell lines without 
treatment. In contrast, we observed a small trend of possible cytoplasmic 
mislocalisation in cell lines carrying Arg576Thr and marginally higher nuclear 
localisation of ERCC1 and XPF in cell lines carrying Glu875Gly. The localisation 
trends were very similar after treatment with oxaliplatin, with an overall trend 
showing small recruitment of ERCC1 and XPF into the nucleus after DNA 
damage in cell lines carrying Arg576Thr. Although the published results by 
Ahmad et al. (2010) differ from our data, it is possible that this is due to 
differences in method such as antibodies used or method of quantifying 
fluorescence. Our method involved analysis of fluorescent counts based on 
pixel number and intensity, whereas theirs involved manually observing cells 
and tallying the numbers of cells with exclusively nuclear, cytoplasmic and 
pancellular localisation of ERCC1 and XPF. It is therefore likely that our results 
are more accurate.  
Other diseases have revealed mislocalisation of cellular proteins as part 
of their aetiology, including mislocalisation of mutant forms of the cystic fibrosis 
transmembrane conductance regulator (CFTR) chloride channel to the 
endoplasmic reticulum, resulting in premature protein degradation (Koch and 
Hoiby, 1993). 
In order to address the potential issue of haploinsufficiency seen with 
heterozygous cell line models, we decided to mimic this experiment using a 
haploid model organism. As mentioned in section 7.2.1, viability studies using 
S. pombe strains carrying rad16 mutations revealed a clear pattern of reduced 
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viability following DNA damage in variant strains, which would imply a repair 
deficiency that resulted in apoptosis. However, despite these findings, we were 
unable to demonstrate cytoplasmic to nuclear recruitment of rad16 after 
damage by immunofluorescence, despite the haploid nature of the organism. 
We observed no recruitment in rad16Ser585X cells despite the presence of the 
novel stop gain mutation identified in Patient 8. This suggested that the stop 
gain mutation did not influence rad16 localisation after DNA damage by 
oxaliplatin.  
A number of studies have confirmed the presence of a novel UV repair 
pathway present in S. pombe, known as the UVER pathway (McCready et al. 
1993; McCready et al. 2000; Herrero et al. 2006). The presence of an additional 
damage repair pathway in S. pombe but not in other species of yeast suggests 
that there could be novel pathways that exist to repair chemical-induced 
damage by drugs including oxaliplatin. Additionally we had no way to introduce 
rad16 variants without the presence of Cre-loxP sites, meaning that it was not 
possible to determine whether the introduction of these constructs would affect 
the strain’s phenotype in terms of repair or localisation.  
Alternatively, there may be issues with damage recognition in the 
presence of NER variants. Research by Giannattasio et al. (2004) using 
Saccharomyces cerevisiae (S. cerevisiae) revealed that NER plays a role in 
DNA damage checkpoint function in the presence of UV-induced lesions via a 
physical interaction between Rad14 and Ddc1 (S. cerevisiae homologs of 
human XPA and PCNA, respectively). This physical interaction enables 
checkpoint complexes to identify DNA lesions, therefore suggesting that 
damage recognition relies on functioning NER factors. Similar checkpoint 
proteins become activated following UV damage in S. pombe, leading to cell 
cycle arrest via two distinct sub-pathways; a Chk1-dependent mitotic arrest 
pathway and a Cds1-dependent pathway resulting in maintenance of DNA 
damage during S phase of the cell cycle (Murray et al. 1997). Therefore, it is 
possible that, in the presence of mutated NER genes yielding ineffective 
proteins, the damage checkpoint may not be activated, resulting in ineffective 
damage recognition. If this were true of S. pombe in response to chemical 
damage by oxaliplatin, NER would not be initiated, which could therefore 
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account for the lack of Rad16 recruitment seen in the S. pombe strains. 
However, further work would be required to verify this.  
7.2.3 DNA repair rate  
Our data revealed a distinct lack of repair in cell lines carrying Pro379Ser 
and delayed repair in cell lines carrying Arg576Thr and Glu875Gly after UV 
treatment. This suggested that our variants in ERCC4 adversely affected 
function of the XPF protein in some way, perhaps by retarding the protein’s 
capacity to facilitate repair by NER. The major protein-protein interaction 
required for formation of the ERCC1-XPF complex is dimerisation of each 
protein’s hydrophobic C-terminal residues, which results in a stable heterodimer 
via the double helix-hairpin-helix regions of their HhH2 domains. It is believed 
that XPF acts as a scaffold protein for ERCC1 during folding, suggesting that in 
the absence of XPF, ERCC1 may be unable to fold correctly in vitro, resulting in 
impaired endonuclease activity (Tripsianes et al. 2005). Recently, the 
Glu875Gly variant was reported to reduce binding affinity between XPF and the 
damaged DNA strand, despite having no effect on the protein-protein interaction 
of the repair complex (Allione et al. 2013b). Additionally, the Pro379Ser variant 
has previously been identified as a pathogenic variant when present in 
combination with other ERCC4 mutations in a compound heterozygous state 
(Gregg et al. 2011), which may account for the most severe repair-deficient 
phenotype after UV damage in cells carrying this variant.  
There are other instances in the literature of delayed repair associated 
with NER disorders. Recently, primary fibroblasts isolated from patients with 
TTD-A, a mildly photosensitive form of TTD caused by variants in TFIIH, 
displayed retarded downstream binding of NER factors after damage by UV 
light, resulting in delayed NER by approximately 24 hours (Theil et al. 2011). 
Additionally, delayed repair of 6-4 PPs following UV damage was reported in 
human XPE cell lines carrying a compound heterozygous mutation in the p48 
gene, which indicated that binding of damage recognition proteins is retarded in 
these cells (Tang et al. 2000). 
Interestingly, despite the clear pattern of deficient DNA repair observed 
in variant cell groups compared with the wild type group following UV treatment, 
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in contrast this repair deficiency did not result in a reduction in viability of variant 
cell groups. This is surprising because we would expect a reduction in viability 
following an accumulation of UV-induced lesions, due to activation of apoptotic 
pathways in the absence of adequate DNA repair. As discussed previously, this 
may have been due to an issue regarding specificity of the assay used for 
viability measurements. Alternatively, there may be confounding due to cell 
proliferation during the 48 hour incubation period, which could have contributed 
to higher viability measurements at 24 and 48 hours, in addition to potentially 
lower levels of damage measured by ELISA. There is the additional 
consideration that the cell lines in question were EBV-transformed 
lymphoblastoid cell lines, and as such their ability to undergo apoptosis may 
have been compromised, which could account for the negligible differences in 
viability between wild type and variant cell groups.   
7.3 Involvement of NER in neuron function and PNAO  
 Since neurons are terminally differentiated, replication of the genome 
does not occur; however, the stability of neuronal DNA is essential for effective 
transcription. Maintenance of neuronal DNA is reportedly regulated by the 
various NER pathways, in particular TC-NER (Jaarsma et al. 2011). This is 
consistent with an association between reduced NER capacity and amplified 
adduct levels in the dorsal root ganglia (DRG) of XPA-/- and XPC-/- mice during 
cisplatin treatment (Dzagnidze et al. 2007). Oxaliplatin has been shown to 
produce fewer platinum adducts in the DRG than equimolar concentrations of 
cisplatin; however, both drugs still display their cytotoxic action via adduct 
formation and apoptosis of DRG cells (Ta et al. 2006). In addition, 20-30% of 
patients carrying mutations in multiple complementation groups of XP (XPA, 
XPD and XPG) exhibit neurological symptoms, including progressive mental 
deterioration, ataxia and peripheral neuropathy (Kraemar et al. 1987; Anttinen 
et al. 2008; Nakano et al. 2014). This suggests a role of NER in the 
development of peripheral neuropathy. 
 Overall, XPF patients have exhibited symptoms of a milder neurological 
phenotype (Gregg et al. 2011), with one patient presenting with late onset 
axonal polyneuropathy (Sijbers et al. 1998). Additionally, reduced expression of 
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the ERCC1-XPF complex has been shown in mice in an attempt to mimic the 
XFE syndrome that occurs as a result of functional disruption of ERCC1. This 
reduced expression resulted in a distinct phenotype associated with peripheral 
neuropathy, consisting of morphological loss of neurons and accelerated ageing 
related neuronal dysregulation (Goss et al. 2011). 
 PNAO has been reported previously to be a consequence of direct 
oxalate toxicity on neuronal cells via their influence on voltage-gated sodium 
channels (Grolleau et al. 2001; Jaggi and Singh, 2012). In contrast, previous 
work by Dr. Hannah West suggested that defects in DNA repair mechanisms 
could contribute to PNAO in the acute setting, which was demonstrated by an 
inability to repair oxaliplatin-induced damage in S. pombe. We hoped to 
demonstrate this using mammalian cell lines; however, the functional analyses 
we present here suggest that deficiencies in DNA repair mechanisms could 
contribute to accumulation of UV lesions, but not oxaliplatin adducts. A 
deficiency in the repair of DNA adducts following either UV or oxaliplatin 
treatment could theoretically increase the rate of neuronal apoptosis and 
therefore contribute to an elevated rate of onset or severity of PNAO. However, 
we would need to demonstrate deficient repair following oxaliplatin treatment in 
a mammalian model to suggest with any certainty that this is the case.  
7.4 NGS of patients with adverse reactions to chemotherapy  
 It is commonly known that genetic variation between individuals 
undergoing identical chemotherapy regimens can give rise to differences in the 
severity of adverse effects (Hertz and McLeod, 2013). Severe side effects 
associated with chemotherapeutic drugs often lead to treatment discontinuation 
or dose reduction, which could be detrimental to the treatment of the tumour. 
Improved understanding of the underlying genetics that influence cellular 
processing and efflux of drugs could significantly improve clinical decisions 
surrounding cancer treatment. This would potentially allow tailoring of treatment 
for individuals to maximise drug response with minimum toxicity.  
 The limitations of candidate gene approaches and their potential to 
overlook novel genes have been reported in several studies (Easton et al. 2007; 
Zanke et al. 2007; Gudmundsson et al. 2012). In contrast, GWAS offers the 
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ability to detect novel genes but may lack a large enough sample size to 
validate any association identified, particularly when rare variants are identified 
(Moen et al. 2012; Section 6.1).  
 The genomic work used to identify the nonsynonymous variants in 
ERCC4 utilised a pathway approach. We applied another comprehensive 
approach to identify causal alleles for PNAO via a ‘no prior hypothesis’ 
approach, using NGS data from ten patients with severe PNAO and a suitably 
sized cohort of ‘control’ patients without PNAO. The benefit of such an 
approach was the elimination of selection bias that is present during candidate 
gene or pathway analyses.  
 7.4.1 False positive calling of indels  
 The avoidance of false positive and false negative results owing to 
coverage issues is essential for analysis of whole exome NGS data. In this 
study, we failed to validate >95% of variants, and of these, a large proportion 
(96.1%) were indels with repetitive flanking sequences, including homopolymers 
or STRs. This revealed an issue with the bioinformatic pipeline with regard to 
accurate prediction of small indels, ranging 2-15bp in length. It is possible that 
the exome resequencing protocol may have required higher coverage, in 
particular for detection of heterozygous indels, as this has been reported as an 
issue previously (Fang et al. 2014; Li, 2011). Greater than 90% of all false-
positive indels in our data set were heterozygous in nature, which would support 
this hypothesis. Alternative explanations may lie with the bioinformatic pipeline, 
as has been discussed in section 6.4.1.  
Issues with indel calling by NGS have been highlighted in a number of 
studies previously (O’Rawe et al. 2013; Zook et al. 2014; Quail et al. 2012; Ley 
et al. 2008). Comparison of variant calls from validated data sets run on various 
SOLiD platforms revealed that >90% of variant calls were unique to only one 
platform. This was true for other NGS platforms also, with >20% of variant calls 
unique to only one Illumina variant caller, suggesting that consistent variant 
calling of indels between platforms from the same manufacturer remains an 
issue (Challis et al. 2012). Since indel calling is particularly challenging, it is 
necessary to perform multi-alignment for reads mapped to the same locus (Li 
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and Homer, 2010). However, even in cases where a sophisticated indel caller 
such as SAMtools was employed for read alignment, there remained a high rate 
of false-positive indel predictions (O’Rawe et al. 2013), which has been reported 
in other NGS studies (Albers et al. 2011; Challis et al. 2012; Yeo et al. 2012; 
Ding et al. 2010).  
 7.4.2 Different approaches to identify causal alleles for PNAO  
 The initial filtering strategy (Strategy 1) revealed an issue with high rates 
of false-positive indel calls; the only variant that was present upon validation 
was in the PAPLN gene (discussed in section 7.4.4). In order to broaden our 
search for additional novel genes that may be implicated in PNAO, we 
employed five filtering strategies to identify different combinations of novel and 
low frequency (<1%) truncating and nonsynonymous variants present in genes 
that were mutated in ≥1 of the 10 patients with PNAO. Verification of the 
presence of these variants was carried out using Sanger sequencing (Section 
6.3.6). 
 Similar exome wide, ‘no prior hypothesis’ approaches have been used 
for identification of novel genes associated with a certain phenotype. This 
approach has proven useful for the detection of causal Mendelian disease 
genes and is successful in approximately 60% of projects, depending on the 
availability of well-phenotyped patients and MAF of variants identified (Gilissen 
et al. 2012). Ng et al. (2010) employed a similar exome wide approach for 
manipulation of exome data from ten patients with a diagnosis of Kabuki 
syndrome (OMIM #147920), a monogenic disease characterised by short 
stature, skeletal abnormalities and delayed mental development. This revealed 
variants in MLL2 that were the primary cause of the disease, which had been 
previously overlooked during candidate approaches.  
 Exome wide approaches can also be applied to multigenic diseases 
associated with de novo mutations, in particular where family-based exome 
sequencing is possible. This would involve filtering out all inherited variants to 
identify only sporadic variants that could cause the disease phenotype (Gilissen 
et al. 2012). However, additional issues are associated with exome wide 
approaches irrespective of filtering strategy used, including instances of copy 
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number variations, translocations or inversions that overlap with SNPs. These 
variants often cause a disease phenotype but may be easily missed by NGS 
(Norton et al. 2011).   
 7.4.3 Removal of indels containing homopolymer runs 
 Work has begun in the laboratory to develop a bioinformatic pipeline 
capable of removing indels with repetitive flanking regions that are likely to be 
false-positive calls. The aim was to reduce the numbers of false variants 
identified for molecular analysis.  
 Despite the intention to remove indels containing repetitive flanking 
sequences using a bioinformatic approach, the reality was that this was not 
possible to develop quickly. Therefore, indels that met these criteria were 
removed manually. This resulted in an average reduction of 54.9%, which 
resulted in a more focussed list of genes for molecular analysis. Following indel 
exclusion, in addition to PAPLN, a further seven genes were identified (ASGR2, 
ANXA7, OR2T35, SLC17A5, SMOC2, SPERT and TAF1D), which could 
provide interesting candidate genes for future sequencing analyses to 
investigate PNAO pathogenesis.  
 7.4.4 Potential genes that may cause PNAO  
An initial filtering strategy (Strategy 1), followed by validation of predicted 
variants by Sanger sequencing, revealed one variant in the PAPLN gene, 
suggesting that this may be implicated in PNAO. Despite the fact that the 
second predicted variant was a false-positive call, therefore rendering the 
PAPLN gene a product of the filtering Strategy 2, it is possible that other 
polymorphisms in this gene could contribute to PNAO. This gene was not 
detected using previous candidate pathway approaches. Additionally, the 
presence of PAPLN across multiple filtering strategies after exclusion of 
variants with repetitive flanking regions would suggest that it may influence 
PNAO pathogenesis.   
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7.5 Future directions 
 7.5.1 Analysis of transcription recovery in human cell lines 
In chapter three, we revealed no apparent reduction in survival of cells 
carrying an ERCC4 variant. Despite this, in chapter five we observed deficient 
repair in variant cell lines following UV treatment only, with normal repair taking 
place following oxaliplatin treatment. Recent research in the field of defective 
DNA repair has identified a link between disorders of repair and impaired 
transcription. In response to DNA damage by UV light, local inhibition of 
transcription occurs via RNA polymerase II stalling; this DNA-damage induced 
transcription arrest is necessary to prevent production of aberrant RNA 
transcripts (Section 7.2.1; Svejstrup, 2010; Adam et al. 2013). Displacement of 
stalled RNA polymerase II results in completion of DNA repair and subsequent 
recovery of transcriptional activity (Gaillard and Aguilera, 2013).  
Therefore, it is desirable to identify whether the ERCC4 variants are 
exhibiting a functional effect following oxaliplatin treatment at the level of 
transcription as opposed to repair. It is possible that damage by oxaliplatin 
could adversely affect recovery of transcription, which could explain why we 
could not detect changes in repair rate or percentage survival in cell lines. This 
effect could be assayed for in vitro by examining mRNA synthesis following 
damage by real time quantitative PCR (qPCR) using both the mammalian cell 
lines and S. pombe strains as model organisms.  
 7.5.2 Sanger sequencing of PAPLN 
 In chapter six, we identified one candidate gene, PAPLN, which may be 
implicated in PNAO. PAPLN currently has no direct association with neuron 
development or function according to the literature, and has therefore not been 
identified previously using a pathway approach. It would be desirable to 
sequence all protein coding regions of this gene in a cohort of patients with 
PNAO to investigate the incidence of truncating variants in patients displaying 
the phenotype. This could then be compared with a suitably sized cohort of 
control patients without PNAO (Grade <1) to determine whether variants in 
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these genes are over represented in a population exhibiting the toxicity 
phenotype.  
7.5.3 Sanger sequencing of additional candidate genes 
In chapter six, a further seven candidate genes were identified by taking 
several exome wide approaches to filtering the NGS data and cross-referencing 
the output for each filtering strategy (Section 6.4.3). In addition to Sanger 
sequencing of PAPLN, it would also be desirable to sequence all protein coding 
regions of these seven genes using the same cohorts of patients with PNAO 
and controls for comparison. A proportion of these genes were associated with 
neuron development or neuropathy according to the literature. This could 
identify some interesting associations between novel genes not previously 
detected via pathway approaches and PNAO.  
 7.5.4 Improved optimisation of indel calling 
 Our findings suggested that accurate indel calling is an issue for both 
larger indels, as evident from scientific literature, and smaller indels. The small 
reads used and high error rates associated with NGS methodologies are 
partially responsible. In order to address this issue, the systematic errors that 
contribute to variant calling inaccuracies must be reduced to ensure that false-
positive and -negative rates are acceptable for sequencing-based association 
studies. Generally speaking, this would require simultaneous optimisation of 
library preparation, sequence alignment tools and base calling algorithms 
(Harismendy et al. 2009). However, with regard to this particular project, we 
could begin by optimising the base calling algorithms used to predict the 
presence of indels and revisit the exome sequencing data files in an attempt to 
reduce the false-positive call rate.  
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